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Abstract 
 
The human body is a complex piece of organic machinery, and as such, can be prone to 
faults and deterioration. There are many medical conditions that can be attributed to bone 
or cartilage deterioration and damage, like osteoporois and osteoparthritis. Regeneration of 
these tissues is an on-going challenge, which have been targeted in many different ways.  
 
MicroRNAs are short sequenced RNAs that are involved in the regulation of nearly 60 
percent of the genes in the body. This project aims to exploit their function to promote 
differentiation into different cell lineages. To do so, the implication of several microRNAs 
in osteogenesis, adipogenesis and chondrogenesis is investigated, and key microRNAs 
selected. Then, gold nanoparticles (GNPs) are used as a platform to deliver to the MSCs, 
anti-microRNAs (antagomirs) and microRNAs mimics, which are nucleotide sequences 
that can bind to the microRNA, preventing or promoting their function, respectively. The 
use of nanoparticles in medicine has picked up at a rapid rate, and its small size, non-
toxicity and multi-valency allows for a safer and customizable method of cargo delivery.  
 
In addition, the novel nanokicking technology, based on applying nanovibrations to the 
cells, which has been previously proven to induce osteogenesis, will be combined with the 
delivery of the miRNA-functionalised GNPs with the purpose of triggering a synergistic 
effect that enhances the osteogenic differentiation process. 
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Chapter 1: Introduction  
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1.1 Stem Cells 
 
The human body consists of cells that originated from stem cells. Stem cells are progenitor 
cells that can generate the specialised cells that form tissue and organs. Stem cells are also 
involved in the repair mechanisms of most multicellular organisms (Pittenger et al., 1999; 
Ullah, Subbarao and Rho, 2015).  The two main properties that define a stem cell are self-
renewal and multipotency. Self-renewal is the ability of a cell to replicate itself without 
losing any of its information i.e., forming a perfect copy of itself (Bianco and Robey, 2001). 
Multipotency is the capacity of the cell to transform into specific types. The two main types 
of stem cells are embryonic stem cells and adult stem cells (Bianco, 2014).  
Stem cell self-renewal occurs by two mechanisms. Obligatory asymmetric replication is 
when a cell divides into an undifferentiated mother cell, similar to its original state and a 
differentiated cell (Knoblich, 2008). Alternatively, stochastic differentiation is where the cell 
divides into either two undifferentiated or differentiated cells depending on the signals 
received (Sun and Komarova, 2015). Both methods of stem cell replication result in different 
cell pools, which are illustrated in fig. 1.1. 
 
Fig. 1. 1 MSC self-renewal. The different self-renewal pathways are illustrated. The S indicates 
undifferentiated stem cell, while P shows differentiated progeny. The cell divides by either 
symmetric self-renewal generating two stem cells (a) or by asymmetric self-renewal producing a 
differentiated cell and one stem cell (b). Over time, stem cells lose either their maintain stemness 
(c) or proliferate (d), leading to depletion of stem cell pool or differentiated cells (Fig. adapted 
from Molofsky, Pardal, & Morrison, 2004). 
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Potency is the property of the stem cell to differentiate in different cell types. Some cells are 
pluripotent, such as embryonic stem cells, and they differentiate into nearly all types, while 
other adult stem cells, such as, mesenchymal stem cells (MSCs), can only differentiate into 
a more limited number of cell types (Samsonraj et al., 2015).  
 
Embryonic stem cells are cells derived from the blastocyst phase of embryos. They are 
pluripotent and can differentiate into cells found in the three germ layers; endoderm, 
ectoderm and mesoderm (Odorico, Kaufman and Thomson, 2001). Through gene 
transcription, either from the body or manually (through chemical induction) in vitro, these 
cells have the capacity to differentiate into any cell type (Reubinoff et al., 2000). They are 
in high demand for use in regenerative therapy, but research is limited due to the ethical 
dilemmas brought about due to the procurement process of these cells (Avior, Sagi and 
Benvenisty, 2016). 
 
Adult stem cells can be classified into two types; haematopoietic stem cells (HSCs) and 
mesenchymal stem cells (MSCs) (Chamberlain et al., 2007; Vaidya and Kale, 2015). 
Mesenchymal stem/stromal cells or MSCs are found in different parts of the body such as 
bone marrow, adipose tissue and umbilical cord tissue (Mushahary et al., 2018). MSCs are 
known to differentiate into several key cell types, the prominent ones being osteoblasts 
(bone), adipocytes (fat) and chondrocytes (cartilage) (Phinney and Prockop, 2007). MSCs 
were initially used for supporting HSC cultures due to the limited knowledge of them 
(Eastment et al., 1982). Due to the arrival of recombinant growth factors and further 
understanding of their properties, bone-marrow derived MSCs are now routinely cultured 
and widely used in regenerative therapy, due to their comparative ease of procurement and 
differentiation profile (Richardson et al., 2010). 
 
1.1.1 Mesenchymal Stem Cells 
 
MSCs are fibroblastic cells that were first isolated from  guinea pig bone marrow 
(Friedenstein, Chailakhjan and Lalykina, 1970). Researchers were able to produce clonal 
colonies that could generate bone and reticular tissue. Further advancements and studies 
demonstrated that MSCs could also differentiate into other cells such as adipose and cartilage 
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cells. Their self-renewing nature and ability to differentiate into multiple cell types has 
allowed research into the capabilities of MSCs and showed the potential for regenerative 
medicine (Ding, 2011). 
 
MSCs are primarily located in the bone marrow, adipose tissue and umbilical cord, from 
where they can be isolated for research purposes.  The bone marrow stroma includes all the 
tissue within the bone marrow that are not involved in the function of haematopoiesis, the 
generation of new blood cells form HSCs.  Within the bone marrow, MSCs reside in what 
is termed a ‘niche’, existing as cells lining the compact bone (endosteal niche) and cells 
surrounding vascular areas (perivascular niche) (Friedenstein, Chailakhyan and Gerasimov, 
1987; Young et al., 1995; Cordeiro-Spinetti, Taichman and Balduino, 2015; Grayson et al., 
2015). 
 
There are many cellular markers that can be used to identify MSCs. The Mesenchymal and 
Tissue Stem Cell Committee of the International Society Cell & Gene Therapy (ISCT) 
defined the major markers that must be present to consider the cells as MSCs. The positive 
markers that must be present are CD73, CD90 and CD105, with the CD45 being a negative 
marker. Since MSCs exhibit several other markers which may or may not be present it all 
cells, it is extremely difficult to isolate a “pure” population of MSCs (Deans and Moseley, 
2000; Dominici et al., 2006). A mixed population is obtained and all the properties of each 
of these subtypes is yet to be understood. 
 
Typically, isolation of MSCs from bone marrow involves either the explant culture method 
or the enzymatic method. In case of the former, the source tissue is rinsed with buffer to 
exclude blood cells and cut into tiny pieces and cultured on a cell culture plate. In enzymatic 
isolation, the small pieces are incubated in an enzyme solution which degrades the 
extracellular matrix. This allows release of small cell aggregates which are plated. The cells 
are sorted using flow cytometry, which shows if the cells have the pertinent markers 
mentioned above. They can be further separated based on the different markers allowing for 
isolation of specific phenotypes from the mixed population (Li et al., 2016; Mushahary et 
al., 2018). 
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1.1.2 MSC Differentiation 
 
Mesenchymal stem cells are able to differentiate into multiple cell types (Dominici et al., 
2006; Ding, 2011; Bianco, 2014). When appropriate signals are received, the MSCs will 
drive toward a defined lineage (Bhaskar et al., 2014). MSCs can differentiate into 
osteoblasts, adipocytes, chondrocytes, myoblasts and even neuron-like cells (Augello and 
De Bari, 2010). Research has shown that through specific interactions, the MSCs can 
differentiate into other cell types similar to the ones mentioned (Ye et al., 2018; Leeman et 
al., 2019). The most widely studied lineages are osteogenesis, adipogenesis and 
chondrogenesis, due to their impact in regenerative medicine and potential for therapy 
(Wang, Qu and Zhao, 2012). 
 
Fig. 1.2: MSC differentiation in the Bone Marrow. The key differentiation pathways are 
illustrated with solid arrows indicating differentiation in vivo, while the dashed arrows show 
reported pathways of differentiation through in vitro research studies (Fig. adapted from Uccelli, 
Moretta, & Pistoia, 2008). 
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1.1.2.1 Osteogenesis 
 
Osteogenesis is defined as the differentiation of MSCs into osteoblasts or bone cells. This is 
a tiered process wherein the MSC becomes a pre-osteoblast and then into a mature 
osteoblast. During differentiation down the bone lineage, MSCs begin to synthesis and 
secrete an extracellular matrix consisting of fibronectin and type 1 collagen among other 
proteins. Indeed, osteoblast maturation can be characterised by the phases of proliferation, 
maturation, matrix synthesis and matrix mineralization (Neve, Corrado and Cantatore, 
2011). Once the bone matrix has mineralized, it can be realised as bone as shown in fig. 3. 
The osteoblasts trapped in their mineralization are known as osteocytes (Bonewald, 2007). 
These cells make up most of the cells in the bone tissue, being involved in the signalling and 
bone resorption (Metzger and Narayanan, 2019). 
Several signalling and transcription factors are involved in osteogenesis. The key 
transcription factor is the Runt-related transcription factor 2 (Runx2). Studies on Runx2 
knockout mice have shown a lack of bone formation due to insufficient osteoblasts (Bruderer 
et al., 2014). Other important bone matrix protein gene inducers are osterix and β-catenin. 
Immature and mature osteoblasts can be differentiated by the increased presence of either 
osteopontin (OPN) or osteocalcin (OCN) proteins respectively. The β-catenin dependent 
Wnt signalling pathway is an integral pathway, wherein β-catenin accumulates in the nucleus 
and heterodimerizes with lymphoid enhancer-binding factor/T-cell factor (Lin and 
Hankenson, 2011). This induces gene transcriptional activity leading to determination of 
MSC fate. Hedgehog signalling (HH) pathway is another important signalling pathway 
(Yang et al., 2015). Other important pathways for bone formation are the BMP pathway and 
NELL-1 signalling pathway (Lin and Hankenson, 2011; Hayrapetyan, Jansen and van den 
Beucken, 2014).  These pathways can collectively be visualised in fig. 1.3. 
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Fig. 1. 3: The key Signalling Pathways Involved in Osteogenesis. Adapted from (Burr, Bellido 
and White, 2015). 
 
1.1.2.2 Adipogenesis 
 
The maturation of MSCs to adipocytes is termed adipogenesis. This can be characterized by 
two phases; the determination phase and the terminal differentiation phase (Rosen and 
MacDougald, 2006). In the determination phase, MSCs commit to the adipocytic lineage 
and differentiate into pre-adipocytes. They have a fibroblastic structure and are thus 
indistinguishable from undifferentiated MSCs. In the terminal phase, the pre-adipocytes 
differentiate into adipocytes and become larger and rounder due to the presence of lipid 
vacuoles, where their functions include lipid synthesis and storage (Muruganandan, Roman 
and Sinal, 2009). 
 
Peroxisome proliferator-activated receptor gamma (PPARγ) is the main transcription factor 
for inducing adipogenic competence, and thus it is also known as the master regulator of 
adipogenesis(Masanobu, 2013). Loss of PPARγ function leads to absence of adipogenic 
capacity of MSCs (Kamon et al., 2003). Adipogenesis involves various sequential processes 
that converge at the PPARγ transcription level. . The other main proadipogenic transcription 
factor is the CCAAT/enhancer binding proteins (C/EBPs); PPARγ and C/EBPα induce gene 
expression for insulin sensitivity, lipogenesis and lipolysis (Darlington, Ross and 
MacDougald, 1998).  The Kruppel-like factor (KLF) family of proteins which function 
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cooperatively to trigger the appropriate genes and induce the differentiation into 
preadipocytes and eventually adipocytes (Darlington, Ross and MacDougald, 1998; 
Masanobu, 2013).  
 
Adipogenesis, has an inverse relationship with osteogenesis; the signals and pathways that 
promote adipogenesis inhibit the osteogenic lineage. The regulation of Wnt and HH 
signalling pathways are essential for adipogenesis (Fontaine et al., 2008; D’Alimonte et al., 
2013). The inhibition of these pathways prevents osteogenesis and thus direct the 
differentiation of MSCs toward adipocyte formation. Other proosteogenic pathways such as 
Notch signalling, and BMP pathways must be blocked for adipogenesis(James, 2013). 
 
Fig. 1. 4: Key signalling pathways in Adipogenesis: Adapted from (Christodoulides et al., 2009) 
 
1.1.2.3 Chondrogenesis 
 
Chondrogenesis is the differentiation of MSCs to chondrocytes, responsible for the 
development of cartilage in the body. MSCs need to be in a condensed form to be able for 
the change to occur. Extracellular matrix formation is vital, and the concentrated nature of 
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the cells is also essential for this. Mineralization is the next step, leading to the formation of 
calcified cartilage at a much later stage (Lefebvre and Smits, 2005). 
 
Chondrocyte formation is a comparatively lesser known differentiation pathway. Although 
some molecular signals have been identified, the processes that lead to chondrogenesis are 
still not completely understood. A member of the HH signalling family, sonic hedgehog 
(Shh), is integral in expression of Sox9, the master regulator of chondrogenesis (Akiyama, 
2008). Sox9, an early chondrogenic marker, is crucial for the differentiation and maturation 
of MSCs into chondrocytes as it leads of expression of Sox5 and Sox6, which together allow 
expression of type-II collagen, which is essential for chondrogenesis (Wuelling and 
Vortkamp, 2010). Sox9 is also integral in preventing hypertrophy of chondrocytes, although 
the exact mechanisms of which are not completely understood (Martinez-Sanchez, Dudek 
and Murphy, 2012). Runx2 is also involved, but only at the later stages to induce 
endochondral ossification (hypertrophy) (Liao et al., 2014). Similarly, BMP-2 is also a later 
stage transcription factor that also shift chondrogenesis towards hypertrophy (Michigami, 
2014). Cell-cell interactions are essential for development of cartilage, and although the 
exact mechanisms are still unknown, connexin-43 has been linked to osteoprogenitor 
chondrogenesis (Guillotin et al., 2004; Zhang et al., 2010). This may carry over to MSCs, 
but further study is required to be conclusive. 
 
Collagens II, IX and XI are expressed during extracellular matrix formation (Chen et al., 
2005). The process of chondrogenesis is regulated by several growth factors such as 
fibroblast growth factor (FGF), transforming growth factor beta (TGFβ), BMP and Wnt 
pathways (Mariani, Pulsatelli and Facchini, 2014).  The blocking of FGF and Wnt signalling 
pathways patently directs differentiation towards chondrocytes (Ito et al., 2008; Qu et al., 
2013), however the role of TGFβ pathway is less clear, as studies have shown it to help with 
chondrocyte formation in joints, but it does not seem to be involved in the lineage direction 
during the initial stages of chondrogenesis (van der Kraan et al., 2009). 
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Fig. 1. 5: Key signalling pathways in Chondrogenesis. Adapted from (Vinatier et al., 2009) 
 
1.1.3 Artificial MSC Differentiation 
 
The multipotent nature of MSCs has been exploited to artificially induce differentiation due 
to the potential for regenerative medicine. Chemical inducers were the primary method used 
to artificially trigger differentiation in vitro, due to their potency and relative ease of 
application (Lai et al., 2017). As these are potentially toxic and difficult to administer in 
vivo, other methods of differentiation have been discovered and studied.  Following the 
advent of micro- and nanotechnology, physical methods have also shown great promise. 
These methods can involve the use of physical forces to trigger certain mechanisms for 
differentiation, while others use proteins and other biological signals to induce 
differentiation (Li et al., 2011; Tsimbouri et al., 2014).  Indeed, due to their non-
intrusiveness, physical induction of differentiation is sought after for implants to be used in 
bone healing (Heydari Asl et al., 2018). 
 
1.1.3.1 Chemical Induction of MSC Differentiation 
 
The most commonly used method to induce differentiation in nearly all cell types is to use 
soluble chemical factors, or agonists, that can trigger the various pathways for 
differentiation. Chemical inducers are widely used in laboratory settings to study 
differentiation. 
25 
 
 
 For induction of osteogenesis, dexamethasone, ascorbic acid and β-glycerophosphate are 
the most commonly used supplements (Kuznetsov et al., 1997). Dexamethasone is an 
essential corticosteroid, whose increased concentration can induce osteogenesis, while 
decrease in its levels can induce adipogenesis of MSCs. Dexamethasone enhances Runx2 
expression (Viti et al., 2016). Ascorbic acid is required for increased collagen type I 
production and β-glycerophosphate provides the phosphates needed for mineralization 
(Langenbach and Handschel, 2013). 
 
Adipogenesis can be achieved by using dexamethasone, insulin and 3-isobutyl-1-
methylxanthine (IBMX) (Pittenger, 1998). Insulin mimics insulin-like growth factor (IGF), 
which is an important signal in adipogenesis. Dexamethasone, in tandem with IBMX, 
stimulates the master transcription factor PPARγ expression (Scott et al., 2011). 
 
With regard to chondrogenesis, dexamethasone, transforming growth factor beta (TGFβ) 
and insulin (along with certain supplements) are used (Yoo et al., 1998). Dexamethasone 
increase the collagen II levels with the cells and also the mRNA expression of aggrecan. 
Insulin, through the insulin receptor, acts as an inducer for chondrogenesis. TGFβ signalling 
pathways are essential for cartilage formation and maintenance (Zhang et al., 2010). 
 
There have been studies conducted to utilize proteins to trigger differentiation pathways of 
MSCs. An example includes the use of bone morphogenetic proteins (BMPs) such as BMP-
2, either in their native form or as mimics. By binding these to implant surfaces or within 
hydrogel matrices, osteogenic differentiation can be triggered (Noël et al., 2004; He et al., 
2014). 
 
1.1.3.2 Physical Induction of MSC Differentiation 
 
Over the past decade, research has shown the importance of physical cues and stimulation 
in cell behaviour (Higuchi et al., 2013). Mechanical stimuli are key regulators of cellular 
structure and function and cells respond to these cues and illicit responses that include 
26 
 
motility, differentiation and proliferation. These cues can also cascade along neighbouring 
cells causing wide scale changes within cells (Wang and Chen, 2013). By exploiting these 
mechanical factors, differentiation can be directed towards a preferred lineage allowing in 
vivo translation of these techniques (Guilak et al., 2009). 
 
1.1.3.3 Differentiation induced by the physico-chemical 
properties of the substrate 
 
The stiffness of substrates can be used to direct MSC fate. Engler et al. showed that MSCs 
are able to “feel” their environments and respond to the physical cues around them. Hard 
matrices cause the MSCs to be more secretory in terms of production of factors key for 
osteogenesis, while soft matrices are the opposite (Engler et al., 2006). This can be attributed 
to the motor appendages, such as myosin II, pulling the against the matrix, which causes the 
cellular mechano-transducers to release signals to cope with this stress (Pelham and Wang, 
1997). By inhibiting the action of the activities of myosin isoforms, the cells do not undergo 
the necessary stress changes to illicit a response (Kim et al., 2005). 
 
Several studies have shown that matrices of various stiffnesses can be used for multiple 
differentiations (Wen et al., 2014). Extracellular matrix (ECM) simulation using collagen, 
laminin or fibronectin proteins is well established (Lin et al., 2010; Llopis-Hernández et al., 
2015). A harder/stiffer substrate, preferably agarose or agarose blends, stimulates 
osteogenesis while a softer substrate can induce adipogenesis (Duarte Campos et al., 2014). 
Alginate gels have been widely used to trigger chondrogenic differentiation in MSCs 
(Kavalkovich et al., 2002). It has been theorised that non-muscle myosin (Nmm) II 
stimulation may be the cause of this, due to its presence in cell function (Parekh et al., 2011). 
 
 
1.1.3.4 Control of Cell Shape  
 
Another myosin related stimulation is the control of cell shape. By growing cells in specific 
shapes, actin-myosin generated tension leads to differentiation of MSCs. Electron-beam 
lithography (EBL) can be used to print structures on the nanoscale. By printing certain 
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patterns outlined by nanopillars or nanopits, mini-islands can be created that can keep the 
cell within its confines and fill out the specific shape. Studies using this technique have 
shown that flattening and spreading the cells can induce osteogenesis while rounding the 
cells triggers adipogenesis (Kilian et al., 2010; Duarte Campos et al., 2014). Using similar 
techniques, micro-channels can be created, aligning MSCs placed in them and directing them 
towards a chondrogenic lineage (Chou et al., 2013). By manipulating the 3D environment 
by encapsulating cells in gelatin or poly (lactic-co-glycolic acid) (PLGA) microfibers, cell 
stemness and viability were maintained for extended periods of time (Steele et al., 2012; 
Tamayol et al., 2013). 
 
In the above cases, the physical properties of integrin and integrin ligands are exploited to 
achieve differentiation, especially in the case of bone formation. Integrins link the 
extracellular matrix (ECM) and actin cytoskeleton across the plasma membrane (Rowlands, 
George and Cooper-White, 2008). The interaction between the integrins and ligands 
physically bind the cells with their cytoskeleton, and the signals from this enable the cell to 
react to the chemical and mechanical cues from their microenvironment (Chaudhuri and 
Mooney, 2012). By using this as a base, artificially created structures can be used to achieve 
the same effect. A commonly used ligand is the arginine-glycine-aspartic acid (RGD) 
sequence, which are present in many ECM glycoproteins such as fibronectin, vitronectin and 
osteopontin (X. Wang et al., 2013). By controlling cell adhesion using this concept, the 
appropriate signalling pathways are triggered, allowing us to mediate the direction of cell 
differentiation. Thus, cytoskeleton manipulation can have a great impact on differentiation. 
 
Studies using nanotopographies have also shown the importance of integrin interactions in 
cell function. By causing actin and vinculin stresses due to reaching around nanopits and 
nanopillars, osteogenesis can be stimulated. Strain on adhesion proteins may also be the 
reason for these changes (Dalby et al., 2007; McNamara et al., 2010). 
 
1.1.3.5 Mechanical stimulation of MSCs 
 
Biomechanical stimulation is essential for development of cartilage and skeletal 
development. Paralysis of chick embryos showed the inhibition of progenitor 
chondrogenesis and even joint cavity formation (Hall, 1979). Dynamic forces act on 
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cartilage, with shear and hydrostastic stresses regulating ossification of the cartilage (Carter 
et al., 1987). Shear stresses have been shown to direct migration of MSCs in vitro and 
mechanical loading stress has shown to improve angiogenic capacity of MSCs and also their 
proliferation (Kasper et al., 2007; Yuan et al., 2013; Wang et al., 2015). As such, observing 
the MSC secretome due to mechanical stresses is a developing frontier. 
An exciting and novel form of stimulating differentiation is the use of vibrations at the nano-
scale. Using nanovibrations, Dalby’s group was able to trigger osteogenesis in hMSCs 
(Nikukar et al., 2013). These vibrations act on the actin-myosin of the cell, causing 
contractions. These contractions trigger the Rho-kinase activated (ROCK) pathway 
(Robertson et al., 2018). SMAD proteins, such as SMAD1 and SMAD4 are activated and 
dimerize, which then translocates to the nucleus initiating the SMAD activated BMP/TGFβ 
pathway (Attisano and Wrana, 2002). This stimulates the osteogenesis of the cells leading 
to the formation of osteoblasts. The use of nanovibrations to stimulate osteogenesis has been 
coined ‘nanokicking’. A special bioreactor containing piezoelectric conductors is used to 
induce the vibrations and cell cultures can be placed on top of the bioreactor, making it an 
easy and useful tool for bone-related research. 
 
 
1.1.3.6 The Role of microRNAs in MSC Differentiation 
 
MicroRNAs (miRNAs) are small non-coding RNAs of around 22 nucleotides in length that 
have been shown to be involved in around 60% of all gene functions. They function by post-
transcriptionally inhibiting or degrading target mRNAs, thus promoting or inhibiting certain 
pathways (Bartel, 2009; Wahid et al., 2010). As such, there is a new-found interest in 
studying the effects of miRNAs in the differentiation of MSCs and if this function of 
miRNAs can be exploited for regenerative medicine. 
 
1.1.4 MicroRNAs and MSC Differentiation 
 
Recently, miRNAs have been shown to be active in nearly every step of the different paths 
of differentiation of MSCs (Clark et al., 2014). Multiple miRNAs work in tandem to inhibit 
multiple steps in a pathway, causing great impact in cell function. Although the exact 
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mechanisms of miRNA regulation are not fully understood, significant progress has been 
made in understanding their targets and methods of action. By using prediction methods, 
initial targets can be identified and studied to understand their role in differentiation (Lai et 
al., 2003; Baglìo et al., 2013). 
A plethora of studies have been conducted to discover the role of specific miRNAs in each 
differentiation process. A few important studies can be seen in table 1. The main problem in 
exploiting these miRNAs is their fragile nature due to their small size and the fact that they 
are RNAs. The need for protection is essential in this case. The use of transfection molecules, 
dendrimers and nanoparticles to act as a delivery platform can be used to mitigate this (Ebert 
and Sharp, 2010). Due to the nature of miRNAs, off-target effects need to be studied to 
prevent side-effects such as immunotoxicity and even degradation. MiRNAs functions 
through binding of the ribosome induced silencing complex (RISC) with the target sequence 
(Chendrimada et al., 2005). Addition of these extrinsic miRNA sequences through 
therapeutics may compete with the intrinsic miRNAs, leading to the decreased expression 
of the therapeutics (Formstecher et al., 2006). Such problems need to be dealt with in vitro 
to confirm the required dosage for eliciting the required changes. Different delivery platform 
can mitigate some issues and this will be elucidated further on. 
 
miRNA Effect in MSC MSC source Target (s) Ref. 
let‐7 Inhibits adipogenesis and 
migration of cell lines 
h‐BM IL6 (T. Sun et al., 
2009) 
miR‐21 Promotes osteogenesis h‐BM SPRY1/2 (Trohatou et 
al., 2014) 
miR‐
23a 
Promotes chondrogenesis h‐BM PRKACB (Hassan et al., 
2010; Kang et 
al., 2016) 
 
Inhibits osteogenesis m‐cell line SATB2  
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miRNA Effect in MSC MSC source Target (s) Ref. 
miR‐
26a 
Inhibits adipogenesis h‐AT, m‐cell 
line 
Fbxl19 (Acharya et 
al., 2019) 
miR‐
27a 
Promotes immune 
regulation 
r‐AT SDF‐1α  
 
Promotes osteogenesis h‐BM DKK1, 
KREMEN2, 
SFRP2 
 
miR‐
27b 
Promotes adipogenesis h‐AT RUNX2 (Karbiener et 
al., 2009) 
 
Inhibits osteogenesis m‐BM SMAD1  
miR‐
29a 
Inhibits osteogenesis h‐BM Ostrerix, 
n.d. 
(Kapinas, 
Kessler and 
Delany, 2009) 
miR‐30 Inhibits osteogenesis h‐AT BMPR2 (Gao et al., 
2011) 
 
Inhibits proliferation h‐BM n.d.  
miR‐31 Inhibits osteogenesis and 
proliferation 
h‐BM SATB2 (Xie et al., 
2014) 
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miRNA Effect in MSC MSC source Target (s) Ref. 
miR‐
126 
Promotes proliferation r‐BM n.d. (Dorrance et 
al., 2015) 
 Inhibits osteogenesis m‐cell line SMAD5 
miR‐
130a 
Inhibits adipogenesis h‐AT EID1 (Wei et al., 
2017) 
miR‐
133 
Promotes chondrogenesis h‐BM, m‐
BM, m‐cell 
line 
ADAMTS‐
5, HDAC4 
(Y. Zhang et 
al., 2011; 
Liao et al., 
2013)  
Inhibits osteogenesis m‐cell line DLX5 
miR‐
138 
Promotes osteogenesis h‐cell line APC (Ye et al., 
2012; Viti et 
al., 2016)  
Inhibits chondrogenesis m‐BM SOX9 
miR‐
140 
Inhibits immune 
regulation 
m‐BM PTGES2 (Miyaki et al., 
2010) 
miR‐
143 
Inhibits/promotes 
adipogenesis 
h‐cell line MAPK5 (Chen et al., 
2014) 
miR‐
145 
Inhibits chondrogenesis h-BM Sox9 (B. Yang et 
al., 2011) 
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miRNA Effect in MSC MSC source Target (s) Ref. 
miR‐
194 
Promote myogenesis m‐cell line CX43 (Wang et al., 
2019) 
miR‐
199a* 
Inhibits adipogenesis h‐cell line n.d. (E. A. Lin et 
al., 2009) 
 
Table 1.1: Various microRNAs involved in differentiation and maintenance of MSCs along 
with the studied cell line and identified targets. Adapted from (Clark et al., 2014). 
 
1.2 MicroRNAs: 
 
MicroRNAs (miRNAs) are single stranded sequences, of roughly 22 nucleotides in length, 
that base pair with mRNA and thus post-transcriptionally repress gene expression. Their 
genes are present located in independent transcription units, with a quarter of all miRNA 
genes present in the introns (Ramalingam et al., 2014). They are found endogenously and 
are only partially complementary to the messenger RNA (mRNA). miRNAs are transcribed 
from endogenous transcripts that can form a local hairpin structures, which are processed in 
such a way that a single miRNA molecule accumulates from one arm of a hairpin precursor 
molecule (Bartel, 2004). Although miRNAs are mostly involved in repression, there have 
been situations where they upregulate the expression of certain genes, such as the 
upregulation of hepatitis C virus (HCV) RNA by miR-122 (Vasudevan, 2012). 
 
1.2.1 Biogenesis of miRNAs 
 
In animals, RNA Polymerase II (Pol II) transcribes the gene encoding the miRNA, leading 
to the formation of the primary miRNA (pri-miRNA) (Axtell, Westholm and Lai, 2011). 
This primary transcript contains the miRNA sequences, which are present in its hairpin 
structure. The hairpin structure consists of a stem that is 33-35 base pairs (bp) long, a 
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terminal loop and single stranded RNA segments at both the 5’ and 3’ end. This pri-miRNA 
gets cleaved to form hairpin structures called precursor-RNA (pre-RNA). The 
Microprocessor complex achieves this (Ha and Kim, 2014). This complex consists of the 
DiGeorge Syndrome Critical Region 8 (DGSCR8) associated with the enzyme Drosha. The 
DGSCR8 orients the RNAse III region of the Drosha, which in turn facilitates cleavage 
(Landthaler, Yalcin and Tuschl, 2004). The pre-miRNA is then exported from the nucleus 
by the Exportin-5 protein (Bohnsack et al. 2004). 
 
After exporting the pre-miRNA to the cytoplasm, another RNAse III enzyme, Dicer, cleaves 
it near the terminal loop (Abrahante et al., 2003). This leads to the formation of the miRNA 
duplex, indicated by miRNA:miRNA* (Knight and Bass, 2001). miRNA* is the passenger 
strand, which is biologically less active than the other ‘guide’ strand (Ha and Kim, 2014). 
Although the guide strand is more commonly observed in the silencing process, the 
passenger strand has also been seen in certain situations. One such example is that mir-142-
3p, is found frequently in embryo tissue samples, compared to mir-142-5p, found in ovaries, 
testes and brain (Wu et al., 2009). 
 
The miRNA duplex then loads on to the Argonaute (AGO) protein to form RNA induced 
silencing complex (RISC) (Wahid et al., 2010).  This effector complex is how the miRNA 
induces downregulation of genes. AGO is the catalytic engine of the RISC (Chendrimada et 
al., 2005). After the duplex loads, the unwinding of the miRNA begins. The N domain of 
the AGO protein unwinds the duplex, which leads to the guide strand being stably 
incorporated. The passenger strand is usually discarded, while the guide strand remains in 
the protein. The endonuclease C3PO is involved in the removal of the passenger strand 
(Kwak and Tomari, 2012). Certain AGO proteins can cleave the duplex in some situations, 
but as the duplex contains mismatches, unwinding without cleavage is preferred. This 
complex is known as the micro-ribonucleoprotein (miRNP) (Valinezhad Orang, 
Safaralizadeh and Kazemzadeh-Bavili, 2014). 
 
The miRNP that is obtained is involved in the downregulation process. This is done by either 
posttranscriptional repression or by cleavage of the mRNA. The posttranscriptional 
repression occurs when the miRNA does not completely bind to the mRNA. It has been 
established recently that the most commonly seen method of downregulation is mRNA 
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degradation (Wahid et al., 2010). This is achieved by cleavage of the mRNA, which has 
been guided to by the miRNA, by the AGO protein. This occurs when the miRNA 
completely binds to the complementary mRNA. The silencing of mRNA, by its binding to 
the miRNA, is a phenomenon that has not been completely explored. Although there is a 
large amount of information on the molecular aspect of the process, the mechanism is not 
clearly understood (Jonas and Izaurralde, 2015). It has been shown that in the case of 
Arabidopsis, the mRNA silencing may in fact take place at the initiation of translation, and 
not at the posttranslational period (Djuranovic, Nahvi and Green, 2012). Further work needs 
to be done on multiple species to establish the mode of action. 
 
 
 
Fig. 1. 6: Biogenesis of miRNA occurs by transcription of intronal sequences by RNA polymerase 
II which produces either pri-miRNA or pre-miRNA. In the case of pri-miRNA, it is cleaved by 
Drosha to form pre-miRNA. The pre-miRNA is then cleaved by Dicer and forms a complex with the 
RISC, which binds to the mRNA, repressing it. 
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1.2.2 Functions of miRNAs: 
 
As previously mentioned, miRNAs control the translation of proteins by binding to the 
mRNAs. This can be a broad statement and studies have shown this to be quite true. It has 
been noted that miRNAs are involved in around 60% of all genetic pathways (Jonas and 
Izaurralde, 2015). It has also been suggested by the Functional Annotation of the Mammalian 
Genome (FANTOM5) that for a specific cell type, nearly 50% of the miRNA pool is 
represented by the top five expressed miRNAs (de Rie et al., 2017). This may suggest that 
miRNAs might mostly be involved in regulating expressional noise, indicated by the high 
mRNA to protein ratio observed during most experiments. 
 
There has been a surge in miRNA studies over the last decade due to its large and varied 
functions. Over 2000 miRNAs have been discovered, but finding its exact role is a challenge 
(Friedman et al., 2009). Computational target prediction is the initial practise to understand 
potential targets for miRNA action (Riffo-Campos, Riquelme and Brebi-Mieville, 2016). 
Once the targets have been identified, there efficacy is tested by amplifying and blocking 
the miRNAs. Potentially powerful ones are even taken to in vivo studies to understand its 
effects on development of relevant pathways.  
 
The importance of miRNAs were first confirmed by mice models with the Dicer or DGCR8 
deficiency (Kanellopoulou et al., 2005; Wang et al., 2007). Loss of either had shown 
embryonic lethality, indicating the importance of these to miRNA biogenesis, which in turn 
showed the impact in the growth of the embryo. Loss of specific miRNAs did not show 
complete loss of function, as in the case of miR-208. It was shown to be a vital component 
in cardiac tissue, but the mice with miR-208 knocked out still grew a heart. What was 
important to note was the role of the miRNA in homeostasis, as loss of miR-208 resulted in 
cardiac hypertrophy and defects in stress responses (Callis et al., 2009).  
 
The main reason for the increase in the attention to miRNAs was its role in cancer. Increase 
in certain miRNA families for different cancer types showed it role in cell differentiation 
state. Promoting or inhibiting these miRNAs during functional studies supported their role 
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in controlling cancer development (Hayes, Peruzzi and Lawler, 2014; Peng and Croce, 
2016). miR-21 and miR-17-92 clusters were showed to be upregulated in cancer tissue, while 
others such as let-7 and miR-34 were downregulated (Pan, Wang and Wang, 2010; 
Concepcion, Bonetti and Ventura, 2012). This has also led to the use of miRNAs as markers 
for cancer. 
 
1.2.3 MicroRNAs in MSCs 
 
With their importance in cell state regulation, studies were conducted to see their effects on 
multiple cell types, including MSCs. Microarray studies provide a list of miRNAs that 
change their expression in MSCs. Most miRNAs discovered in this case tend to be from the 
let-7 family and miR-23-24-27 clusters, along with other families including, miR-10miR-
29, miR-30 etc (Lim et al., 2005; Thomson, Parker and Hammond, 2007). Since a large 
number of miRNAs from the same family share the same seed sequence, it has been 
hypothesised that co-expression of the different members may add to the robustness of their 
functions (Alberti and Cochella, 2017). 
 
MSCs are mainly characterized by their ability to differentiate into osteoblasts, adipocytes 
and chondrocytes. While regular transcription factors are responsible for differentiation, it 
is emerging from the literature that miRNAs also play a major role in these pathways. Indeed, 
many miRNAs and their families have been discovered to be active during differentiation 
(Clark et al., 2014).  
 
In periodontal ligament tissue-derived MSCs, miR-17 was shown to target Smad ubiquitin 
regulatory factor-1 (SMURF1), promoting osteogenesis (Liu et al., 2011). By targeting 
Osterix, miR-31 downregulates osteogenesis in human bone-marrow MSCs (Xie et al., 
2014). Certain families such as miR-30 and miR-24 families repress osteogenesis, and thus 
help in promoting adipogenesis (F. Sun et al., 2009; Gao et al., 2011).  The miR-27 family 
targets PPARγ and C/EBPa, crucial to adipogenesis, inhibiting this pathway(Q. Lin et al., 
2009). Sox9 is targeted by miR-145 and SMAD1 is targeted by miR-199* (E. A. Lin et al., 
2009; B. Yang et al., 2011). Both these genes are essential for chondrogenesis and inhibiting 
the translation of these stunt the chondrogenic development. There are a large number of 
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miRNAs that regulate the expression of important genes in MSC differentiation and a lot of 
studies are still being conducted to confirm their efficacy and potential therapeutic usage. 
 
1.2.4 MicroRNA mimics and antagomiRs 
 
MicroRNA based therapeutics can be classified into miRNA mimics and miRNA inhibitors. 
The more widely studied method is the inhibition using anti-sense oligonucleotides (ASOs), 
which can be used to directly target the miRNAs. These sequences are called anti-miRs or 
antagomiRs (Krutzfeldt et al., 2005). By binding to the miRNAs, the antagomiRs prevent its 
translation, thus inhibiting it. Like antagomiRs, miRNA mimics are also used (Younger and 
Corey, 2011). These focus on copying miRNAs that have been shown to positively regulate 
important pathways. 
 
 Both these types of oligonucleotides need to be protected from enzymatic degradation, 
immune system, as well as requiring transport to the target location. Over the past few years, 
a lot of progress has been made to increase the affinity, stability and effects of these 
sequences. They can be made to be highly complementary to the target miRNA or match the 
sequence, but an efficient delivery method needed to be created.  
 
The first miRNA based therapeutic experiments consisted of injecting miRNA mimics 
encoded in viral vectors directly at the target sites. This led to poor results due to degradation 
of the sequences, as well as poor target specificity (van Rooij and Olson, 2012). By 
modifying the sequences, they can be protected from the various nucleases in the body. 2’-
O-methyl (2’-OMe) modifications to the sequences have been shown to provide increased 
resistance against nucleases and also improving the binding efficacy to the miRNA (Lamond 
and Sproat, 1993; Verma and Eckstein, 1998). Even with the improved resistance, the serum 
exonucleases can still affect the antagomiRs. This can be mediated by adding 
phosphorothioate bonds in place of the phosphate backbone (Krutzfeldt et al., 2005). 
Replacing the non-bridging oxygen atoms with sulphur atoms can do this.  This method 
requires that the replacement occur at specific intervals, as this modification lowers the 
binding affinity of the antagomiRs. Another modification that has been successful is the 
incorporation of 2’-O-methyoxymethyl (2’-MOE) group. This modification has shown 
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greater affinity and binding that is comparable to the phosphorothioate modifications 
(Manoharan, 1999). The advantage is that it is much easier to create, as only one 
modification is made to each strand. It was seen that these modifications were well tolerated 
at the 3’ end, compared to the 5’ end. This was due to the importance of molecular 
asymmetry and that the 5’ end being important for its interference activity (Chiu and Rana, 
2003). There are several other modifications that can be done, and the one to pick would 
depend on the target and the required effect, i.e. better binding or better stability. 
 
1.2.5 Delivery of mimics and antagomiRs 
 
Significant work has been done to increase the affinity and stability of the antagomiRs. But 
without a carrier, the oligonucleotide will not be able to reach its intended target. This could 
also potentially prevent the early excretion of the antagomiRs.  This would allow for delivery 
in vivo without loss of the sequences. 
 
The earliest foray into miRNA therapeutics were the use of viral vectors. Modified 
adenoviruses, lentiviruses and retroviruses were used with constructed vectors onto which 
the miRNA sequences were added on. They are then deployed in cells, so the miRNA is 
integrated into the cell’s genomic DNA. This method showed promise as miR-138 induced 
a 1,000-fold expression increase, enhancing the production of pluripotent stem cells (Ye et 
al., 2012). Another study showed a 2,500-fold increase in miR-143 expression in corneal 
epithelial cells (Lee et al., 2011). Although the rewards are great, it carries the usual risks 
involved in viral vector use such as potential toxin production, immunological responses and 
mutations. 
 
To go around this, non-viral methods were used next. Gene gun, electroporation, ultrasound 
and laser-based systems do not pose the same risks as viral-vectors, but their low transfection 
rate and relatively high apoptotic rate for cells may be a hinderance in developing this 
method (Nayerossadat, Maedeh and Ali, 2012). Lipid-based systems using a liposome 
covered cargo do not have any of the above issues, but their low half-life led to problems 
due to binding to non-specific serum proteins. By conjugating it with other compounds such 
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a polyethylene glycol (PEG) or cholesterol derivatives alleviate these issues (Vickers and 
Remaley, 2012). 
 
A newer and safer delivery was achieved by using miRNA ‘sponges’ or by small molecules 
and oligonucleotides. MicroRNA sponges use vectors, such as with multiple binding sites, 
acting as a decoy or sponge for the miRNAs.  The vectors express several sequences that 
allow binding of miRNAs that are antisense to them. This prevents the miRNA from being 
able to bind to the mRNA, allowing the mRNA to express itself (Ebert, Neilson and Sharp, 
2007). This method has only been introduced in transgenic animals, where the target tissues 
overexpress the vectors, and as such are not a big focus in therapies (Ebert and Sharp, 2010). 
Small molecules have also shown to have an inhibitory effect on miRNAs, by disrupting its 
transcription. But due to its high EC50 (effector concentration for half-maximum response) 
and lack of knowledge on direct targets, this method has not been explored fully (Li and 
Rana, 2014). 
 
Conjugation based methods were explored as a means of delivery. Cholesterol based 
conjugation was initially developed and it showed improved inhibition of microRNA action 
as well as being able to transport the antagomiRs mostly to the liver and also to the gut, 
kidney and steroidogenic organs to some extent (Krutzfeldt et al., 2005; Wolfrum et al., 
2007). Liposome based delivery was also seen to show success. In this case, the antagomiRs 
were conjugated with lipids and this could also be modified to have high affinity for liver 
(Morrissey et al., 2005; Akinc et al., 2010). They can also be used for localized delivery as 
in the case where it was vaginally introduced in mice, and this prevented contraction of 
herpes simplex 2 for up to 9 days (Palliser et al., 2006). Another approach consists of the 
use of the Fab domain of an antibody and conjugating it with the antagomiR. This confers it 
the ability to target specific locations, which are complementary to the antibody (Li and 
Rana, 2014). 
 
There are several other methods available to transport antagomiRs, each having their benefits 
in terms of stability, specificity and effectiveness in general. The most promising mode 
seems to be the use of nanoparticles. These are widely recognized as the go to method for 
the future due to its high functionalization capabilities, allowing us to modify and choose 
the effect and properties we desire. They can be coated to shield against nucleases or bypass 
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the body’s defences, have high loading capacity and be controlled during synthesis to obtain 
specific sizes and shapes, allowing for the required levels of biodistribution, cytotoxicity, 
imaging and excretion properties (Dreaden, Alkilany, et al., 2012; Berry, 2013; Ding et al., 
2014). 
 
The particles can be covalently or non-covalently conjugated to attain desired properties. 
The most commonly used conjugation is the covalently bound thiol conjugation, in the case 
of gold nanoparticles. The sulphur-gold interaction is a strong bond consisting of a partially 
covalent bond and mostly electrostatic bond (Roca and Haes, 2008). The antagomiRs can 
contain thiol modifications, and this can be used to form a bond with the nanoparticle, 
allowing for functionalization of the particle (Seferos et al., 2009). Non-covalent methods 
can be used, but this applies only to unmodified oligonucleotides (Ding et al., 2014). This 
principle requires that the GNPs be functionalized with cations, so as to bind with the 
negatively charged nucleic acids (McIntosh et al., 2001). The covalent method is preferred 
as the oligonucleotides are synthetic and can be modified to include the thiol modification. 
 
Once in the cells, this thiol modification helps in the release of the cargo, i.e. the mimic or 
antagomiR. The cell cytoplasm contains glutathione, a tripeptide antioxidant, that is essential 
for prevention of oxidation by reactive oxygen species in the cell (Pizzorno, 2014). They are 
essential in cargo release due to the binding of the cargo to the nanoparticle by a disulphide 
bond. The dithiol-disulphide exchange, catalysed by glutathione, cleaves the disulphide 
bond attaching the cargo, thus releasing it into the cell (Neves, Fernandes and Ramos, 2017). 
The chemical modifications mentioned above protect the cargo and allows it to bind to the 
mRNA, preventing its translation and thus promoting or inhibiting the targeted pathways. A 
study conducted with dye loaded nanoparticles showed its efficacy in both in vitro and cell 
cultures, showing the possibility of its use in therapeutics (Kumar, Meenan and Dixon, 
2012). 
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1.3 Nanoparticles 
 
Nanoparticles are organic or inorganic particles that usually have a size between the ranges 
of 1 and 100 nm in diameter (Sperling and Parak, 2010). Due to their extreme size, the 
properties they possess are distinct, compared to those of a larger scale. Nanoparticles that 
fall in the size range of biomolecules have attracted a lot of attention due to their unique 
properties and are widely studied for their use in biomedical applications.  
 
There are many varieties of nanoparticles that are widely used. They are separated based on 
their constitution. Organic nanoparticles can be subdivided into liposomes, dendrimers, 
organic polymers and carbon nanomaterials (Romero and Moya, 2012). Inorganic 
nanoparticles consist of elemental metals, metal oxides, salts, alloys and quantum dots 
(Giner-Casares et al., 2016). Each type brings a new property with it allowing for a diverse 
range of applications. Depending on whether imaging, delivery, biotoxicity, 
functionalization, etc. is the focus, multiple types are available, leading to a surge in studies 
of finding the optimal type for utilization in a specific area of research (Khan et al., 2018).  
 
The most commonly used inorganic nanoparticle is made from gold. Gold nanoparticles 
(GNPs) are widely used due to their relative ease of manufacture, non-toxic nature, 
photophysical and surface properties and inertness, among other desirable qualities (Ghosh 
et al., 2008; Daraee et al., 2016). These various properties have led to a surge in the use of 
GNPs in different fields, over the past few decades.  Although various industrial applications 
have been the main destination for GNPs, its medical applications have been a very 
promising and attractive. 
 
1.3.1 Optical properties of GNPs 
 
Among its properties, GNPs exhibit enhanced radiative properties due to its surface plasmon 
resonance (SPR). This can be defined as the resonant oscillations of the free electrons on the 
nanoparticle surface caused by specific wavelengths of light. The condition of SPR is met 
when the frequency of incoming radiation matches the plasma frequency (oscillation of 
conduction electron due to a certain oscillation frequency). At this stage, the optical field is 
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highly localised and enhanced at the surface of the nanoparticle. This can be modified by 
changing the size of the nanoparticle, where an increase in the radius of the particle 
corresponds to an increase in the wavelength of the SPR peak (the colour exhibited) (Nilesh 
Kumar Pathak, Alok Ji, 2014). 
The scattering cross-sections of GNPs has been seen to be around 105-106 times stronger 
than that of the emissions of a fluorescent dye molecule (Yguerabide and Yguerabide, 1998). 
As such, there is a large interest in its use as an imaging medium. Using a simple optical 
microscope, these GNPs can be visualised and thus allows easy tracking and localisation of 
the particles. Another important aspect is the virtually indefinite nature of its photostability, 
allowing less constraints on time and environment of experiments (Dreaden, Alkilany, et al., 
2012). 
 
Due to their size, GNPs tend to preferentially accumulate in tumour cells. Tumour cells 
require more nutrients than regular cells, which in turn leads to formation of new vasculature, 
to supply more blood. Highly disordered endothelium and damaged lymphatic systems lead 
to preferential penetration of the nanoparticles and reduced elimination of the nanoparticles 
(Dreaden et al., 2011). The photothermal properties of GNPs are very interesting as they 
have high absorption efficiency of light in the near-infrared (NIR) region. This allows photo-
ablation of tumour cells, destroying them. Studies have shown the efficacy of GNPs and its 
various nanostructures in use for photothermal therapy and shows great future due to the 
accumulation of these particles in certain tumour sites (Loo et al., 2004, 2005). 
 
1.3.2 Biological application of GNPs 
 
In regard to their biological application, GNPs have been found to have relatively low 
toxicity and good affinity for cellular uptake thanks to their inert nature. Due to their small 
size, GNPs are easily taken into the cell by several different internalization processes which 
are standard for the cells. These processes are necessary due to the size of the GNPs. 
 
 Endocytosis is the process by which cells internalize various macromolecules into the cell. 
This includes molecules that are not small enough to be diffused through the cell membrane.  
The two types of endocytosis are phagocytosis and pinocytosis (Dykman and Khlebtsov, 
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2014). Phagocytosis is the process in which the cell actin engulfs the molecule of a size 
above 500 nm, trapping it in a phagosome. The phagosome undergoes several pathways, 
which ends in the molecule being enzymatically degraded in the lysosome. Pinocytosis 
occurs when the cell uptakes molecules smaller than 500 nm. In this case the cell ‘drinks’ 
the molecule, thus taking in a small number of unwanted molecules. There are two types of 
pinocytosis, i.e., clathrin dependent and clathrin independent pinocytosis, with clathrin bring 
the protein that would coat membranes, eventually separating it off as vesicles, allowing for 
trafficking of particles (Royle, 2006). Macropinocytosis is another type, wherein the cell 
takes in a bulk amount and this type of endocytosis is receptor independent. This method of 
internalization is non-specific and so takes in foreign bodies too (Kafshgari, Harding and 
Voelcker, 2015). 
 
The cell usually stores the foreign molecules in endosomal vesicles, which eventually get 
degraded in the lysosome, except in the case of macropinocytosis. This is not ideal as the 
cargo or ligands attached to the nanoparticles would also get destroyed. By using certain 
compounds (e.g. chlorpromazine and Dynasore) in tandem with the nanoparticle, we can 
promote the preferred endocytosis pathway, which would allow targeting of specific areas 
of the cell (Macia et al., 2006).  Blockage of a particular pathway usually entails the 
prevention of the formation of invaginations of the cell by attacking the pathways leading to 
it (Kafshgari, Harding and Voelcker, 2015). 
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Fig. 1. 7: The different methods by which the cell intakes nanoparticles of different 
sizes. Adapted from (Kamaly and Miller, 2010) 
 
 There is a constant struggle to escape the vesicle and prevent transport to the lysosome. This 
can be remedied by using two methods, i.e. by either using specific coatings to facilitate 
escape, or adding other molecules in tandem with the particles to facilitate escape or target 
specific endocytosis pathways that would be detrimental to the nanoparticle or its cargo. 
Endosomal vesicle escape would allow the nanoparticle to leave its confines and deliver its 
cargo. This can be achieved by coating the nanoparticle with a cationic polymer or 
complexing the cargo with a liposome or a virus fusion protein. These work by damaging 
the vesicle causing the release of the nanoparticles. If the nanoparticle needs to target the 
nucleus, a nuclear localization signal can be conjugated with its coating, allowing transport 
into the nucleus. 
 
The low toxicity of GNPs allows their accumulation up to a certain concentration without 
any ill effects. Several studies have been conducted to understand the pharmacological 
interactions of GNPs with cells and organs. A recent study showed the effect of nanoparticle 
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size and shape on toxicity. A concentration of up to 30 µM showed very little cell death and 
seemed to agree with conventionally accepted levels of GNP administration (Yang et al., 
2016).  Another study showed no significant cell toxicity and organ changes in rabbit studies 
with administration after 24-hours (Park et al., 2010). After an initial weight loss, dogs were 
shown to completely recover within 37 days without any signs of abnormalities (Abdoon et 
al., 2016). GNPs have been shown to circulate in the blood stream for around 7 days, ending 
up in the liver. Due to the high surface area-to-mass ratio of the nanoparticles, care must be 
taken in these studies. This property allows for higher biological activity, which may lead to 
toxicity issues if not carefully followed. 
 
1.3.3 Synthesis of gold nanoparticles: 
 
There are various processes by which nanoparticles are synthesized, but the inherent concept 
for is same for all, i.e. the top-down technique. This involves obtaining smaller particles 
from a larger source (Dreaden, Alkilany, et al., 2012). Chemical synthesis of nanoparticles 
is the most widely used technique. It usually involves the citrate reduction of chloroauric 
acid (H[AuCl4]) using a reducing agent.  This causes the reduction of Au3+ ions to Au+ ions. 
Further reactions lead to the formation of Au0 ions, which acts as the centre of nucleation 
(Jörg Polte et al., 2010). At this stage, other chemicals must be added to prevent growth or 
agglomeration of the particle. A capping or stabilizing agent, like glutathione, prevents 
aggregation of the nanoparticles, but it can lead to the increase of particle size (Zhou et al., 
2011). A surfactant can be used instead, which would provide a charge to the particle, 
thereby repelling other particles and again, preventing aggregation. This does not increase 
particle size, which is essential for biological studies. Some chemicals, such as a citrate, can 
act as both the reducing and stabilizing agent (Dreaden et al., 2011). Depending on the 
structure and dimension of the nanoparticle desired, the above method can be altered by 
changing the reducing and stabilizing agent and also the ratio of the gold ions to the agents 
(Dreaden, Alkilany, et al., 2012). This is the most commonly used method as it allows 
monodispertion of the GNPs preventing aggregation, essential for biological applications. 
The size can be controlled by adjusting the pH of the reactants in the process (Ji et al., 2007). 
 
Laser ablation of the bulk metal in solution is also used to form GNPs. The nanoparticles are 
formed due to the condensation of the plasma plume of the metal (Amendola and 
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Meneghetti, 2009). Other physical methods such as sono-chemical, microwave irradiation, 
ultra-violet radiation, etc., can also be used (Khan, Vishakante and Siddaramaiah, 2013), but 
the laser ablation is preferred over other physical methods. A relatively newer method 
involves using supercritical fluid technology; gold can be micro-ionized and then 
precipitated, which would lead to the formation of nanoparticles (Thote and Gupta, 2005). 
Another method involves the use of ‘green technology’, i.e., using bacteria, fungi or plants, 
and their extracts, to produce nanoparticles. This involves the use of benign solvents or the 
microbe itself, and as such would be much safer and easier to dispose (Kharissova et al., 
2013; Hulkoti and Taranath, 2014). Although plenty of methods are available to synthesize 
nanoparticles, the citrate reduction method is preferred due to a larger output and greater 
control of the reaction process, and thus the formed nanoparticles. 
 
1.3.4 Functionalization of nanoparticles: 
 
 The large surface area-to-mass ratio also allows functionalization of the GNPs. This is 
required to impart certain functions or load biological molecules onto the particles. It can 
also be used to passivate the GNPs against the immune responses of the cells. To load other 
molecules, ligand attachment is necessary, as it allows the attachment of the required cargo. 
It also allows the nanoparticles to target specific diseased areas and promotes selective 
interaction with cells or biological molecules. Although the tumour tissue allows preferential 
localization of the nanoparticles, the nanoparticles get localized in the liver and spleen due 
to the body’s excretory mechanisms (Khlebtsov and Dykman, 2011). As such, it is always 
desired that the particles have specificity for problem regions. It also removes the toxic or 
undesired agents on the nanoparticle; for example, cetrimonium bromide (CTAB) is used as 
a surfactant during synthesis, but is harmful to cells or tissues (Alkilany and Murphy, 2010). 
By using a thiol-containing polyethylene glycol (PEG), the CTAB on the surface can be 
replaced by an inert and biologically advantageous compound (W. Wang et al., 2013). 
 
For the replacement to occur, the new ligand must have an affinity equal to or stronger than 
that of the ligand it is replacing. Another factor to consider would be the ligand structure and 
size in relation to the geometry of the nanoparticle, as this would indicate the density of the 
ligand around the particle, which would in turn affect the stability of the particle (Sperling 
and Parak, 2010). 
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The most commonly used ligand is the thiolated PEG (PEG-SH), as its hydrophobicity 
allows the dispersion of gold nanoparticles attached with a wide range of lipophilic 
molecules, along with increasing the circulatory half-life (Manson et al., 2011). Thiolated 
nanoparticles can stay stably adsorbed for nearly 35 days under physiologic conditions. New 
research has shown that branched PEG has added benefits when conjugated with carbon 
nanotubes. This may be applied to gold nanoparticles in the future, providing better 
functionalization (W. Wang et al., 2013). 
 
1.3.5 Delivery of nucleic acids: 
 
Nanoparticles can be used to deliver various cargos to a desired location.  For the cargo to 
have the intended effect, it must reach the site of action intact. In the case of nucleic acids, 
they must be protected from enzymes such as nucleases.  There are two ways of binding the 
load to the nanoparticles so as to protect them. These are the covalent and non-covalent 
conjugation to nanoparticles (Kafshgari, Harding and Voelcker, 2015). 
 
Covalent conjugation is ideal when dealing with modified biological or synthetic compounds 
such as siRNAs. This bonding involves the anchorage of the cargo to the particle using a 
strong metal to sulphur bond (the cargo is thiolated to facilitate this). Protection from 
nucleases is a concern in this method, but recent advances have mitigated this issue by 
coating the conjugated nanoparticle with a copolymer. This coating was also shown to 
enhance cell internalization (Ding et al., 2014). 
 
Non-covalent conjugation is used to bind unmodified nucleic acids such as DNA or RNA to 
the nanoparticle. It uses different biotin binding proteins to conjugate the cargo to the surface 
of the nanoparticle. In DNA-GNP conjugates, the DNA is bent around the nanoparticle, 
which protects it from DNases (Ding et al., 2014). The coated nanoparticles can be 
administered to cells using a gene gun, but a less invasive method would be to use the cellular 
uptake to transport the nanoparticles into the cell (Berry, 2013). 
 
48 
 
1.4 Aims and Objectives 
 
Mesenchymal stem cells (MSCs) are multipotent and capable of differentiation into bone, 
cartilage and fat cells and therefore have great potential for regenerative medicine. 
MicroRNAs (miRNAs) are known to regulate differentiation, with key microRNAs being 
identified in this regard over the past 5-10 years. The aim of this project is to select and 
verify microRNA targets in MSC differentiation and to exploit their mechanism by delivery 
of miRNA and/or their antagomiRs to promote the differentiation process. The hypothesis 
is that by enhancing or repressing miRNA function, we can influence MSC differentiation. 
The specific objectives of this project are explained below: 
 
• Confirm chemical induction via conditioned media (standard positive control for 
differentiation). Culture both commercially available Promocells and in-house 
isolated MSCs, obtained from the bone marrow of patients, in either DMEM or 
osteogenic / chondrogenic / adipogenic conditioned media for 21 days. Verify MSC 
differentiation.  
 
• Complete a literature search to generate a catalog of established miRNAs that are 
expressed during MSC differentiation, in particular during osteogenesis (bone 
formation) and chondrogenesis (cartilage formation), but also adipogenesis (fat 
formation). This will inform on likely candidates for this study. 
 
• Assess miRNA candidate expression in our differentiating MSCs. Both sources of 
MSCs will be cultured for 21 days in osteogenic / chondrogenic / adipogenic 
conditioned media. Isolate RNA and assess the expression levels of the candidate 
miRNAs using Fluidigm dynamic PCR. 
 
 
• Confirm any strong candidates from the Fluidigm study in standard qPCR (which 
allows for higher cycling).  
 
• Create oligonucleotides for several key miRNAs identified during Fluidigm and their 
antagomiRs (repression of miRNAs). Gold nanoparticles (GNPs) will be synthesized 
and functionalized with the sequences to deliver miRNA mimics/antagomiRs.  
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• Obtain the best combination of mimic/antagomiR to induce maximum shift towards 
differentiation with regards to osteogenesis, adipogenesis and chondrogenesis. 
 
• In the final section of my PhD a dual osteogenic stimuli, both in comparison and in 
combination, will be used on MSCs to promote enhanced osteogenic stimulation.  To 
do this, the miRNA approach of using antagomiR-31 treatment will be combined and 
compared with nanokicking, using within an established bioreactor in our laboratory.  
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Chapter 2: Materials and Methods 
  
51 
 
2.1 Cell Culture general protocol: 
 
All experiments were conducted using human mesenchymal stem cells (hMSCs) obtained 
either from PromoCell® GmBH or Stro-1 selected MSCs donated graciously by Prof. 
Richard Oreffo and group (University of Southampton). 
The MSCs were cultured in T75 flasks and maintained in growth media (13 ml) (section 
2.1.2) at 37°C with 5% CO2. Media was replaced every 3 days. Once nearing confluency, 
the media was removed and the cells were washed with HEPES solution (10 ml). The cells 
were detached using trypsin/versine solution (5 ml) at 37°C for around 5 minutes until cell 
detachment was seen. Fresh media was added to the cells to neutralize the trypsin/versine 
and the whole suspension was transferred to a universal tube and centrifuged at 1400 rpm 
for 4 minutes. A pellet was seen at the bottom of the flask and the supernatant was removed. 
The MSCs were resuspended in fresh media (1 ml) and transferred to new T75 flasks for 
subculturing or plated on well plates for experiments. 
Before plating, 1 µl of the cell suspension was transferred to a haemocytometer with a 
coverslip on top to count the number of cells to maintain the initial seeding density across 
most experiments (excluding micromass cultures). 
 
2.1.2 Growth Media: 
 
Both the Promocell MSCs and the STRO-1 MSCs were cultured in a culture medium 
comprising of Dulbecco’s modified Eagles media (DMEM, 430 ml), foetal bovine serum 
(FBS, 50 ml), antibiotics (Ab, 10 ml), sodium pyruvate (5 ml) and non-essential amino acids 
(NEAA, 5 ml). This DMEM is the standard culture media used throughout my project, unless 
otherwise stated. 
The trypsin/versene solution used consisted of 1 ml trypsin in 20 ml of versene. 
 
2.1.3 Conditioned Media for Differentiation: 
 
For induction of differentiation, the base culture media described was used with added 
supplements, depending on the desired lineage, as follows: 
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 (i) Osteogenesis (OM): 
Dexamethasone (10 nM) 
Ascorbic acid (100 μM) 
β-glycerophosphate (20 mM) 
 (ii) Chondrogenesis (CM): 
Ascorbate-2-phosphate (1 mM) 
Transforming growth factor beta 1 (TGFβ1, 10 ng/ ml) 
Dexamethasone (100 nM) 
Insulin (6.25 μg/ ml) 
 (iii) Adipogenesis (AM): 
Indomethacin (100 μM) 
3-isobutyl-1-methylxanthine (IBMX, 500 μM) 
Insulin (10 μg/ ml) 
Dexamethasone (1 μM) 
 
2.2 Micromass cultures of MSCs: 
 
To enable differentiation of MSCs to chondrocytes, micromass cultures were required, as 
the high density of cells enables the release of essential factors for differentiation. This 
process is similar to the passaging of cells, up until the cell counting stage. After the cells 
were counted, the required number of cells, along with some media, were transferred to an 
Eppendorf. It was then centrifuged to obtain a pellet. The supernatant was discarded, and 
enough fresh media was added such that 10μl of the suspension would contain 100,000 cells. 
The cells were then plated by placing a 10μl drop in the middle of the well and left to attach 
for 2-4 hours. After the required time had passed, fresh media was added the cover the cells. 
After a couple of days, formation of spheroid like shapes indicated successful micromass 
culture. 
 
2.3 MiRNA Extraction for Fluidigm and RT-qPCR: 
 
MSCs were grown in DMEM, OM, AM and CM conditions for 3, 7 and 21 days of culture 
for both the Fluidigm study and the succeeding qPCR study. The total RNA was extracted 
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using the MagMAXTM -96 for Microarrays kit. The cells were detached and lysed using TRI 
Reagent, which was subsequently spun at 12,000g for 10 minutes. The aqueous phase at the 
top of the samples was collected and plated on to the processing plate. 100% Isopropanol 
was added and placed on a shaker for 1 minute. RNA binding beads were added and the 
plates were shaken again for 3 minutes. The beads were collected to the bottom with the help 
of magnets and the supernatant was discarded. This process was repeated twice using a Wash 
Solution. It was then left to dry on the shaker. Finally, the Elution Buffer was added and 
placed on the shaker for 2 minutes and the supernatant containing the Total RNA was 
quantified using a UV spectrophotometer and was stored for Reverse Transcription. 
 
2.4 RNA Extraction for RT-qPCR: 
 
The MSCs were grown in DMEM and OM conditions for 7, 14 and 28 days of culture. The 
total RNA was extracted using the Qiagen RNeasy Mini Kit. The cells were harvested using 
RLT Buffer. The resulting solution was mixed with an equal volume of 70% ethanol and 
subsequently added onto a RNeasy MiniElute spin column, on a collection tube. This was 
then centrifuged at max speed for 1 minute. The flow-through was discarded and the samples 
were washed with Buffer RW1 by spinning at max speed for 1 minute. To remove any DNA 
present, the sample was incubated with DNase incubation mix for 15 minutes at room 
temperature. Buffer RW1 was added again and the samples were spun at max speed. Buffer 
RPE was added to the columns and spun at max speed. The columns were washed with 80% 
ethanol and spun again. The last remnants of liquid in the column were completely removed 
and dried by spinning again at max speed for 5 minutes. The spin column was moved to a 
fresh collection tube and RNase-free water was added. This was then spun at max speed for 
a minute to collect the elute where the RNA was present. The concentration was obtained 
using a UV spectrophotometer and was stored at -80°C for Reverse Transcription. 
 
2.5 Extraction of protein and RNA for micromasses: 
 
Due to the high number of cells required to test chondrogenesis, an Ambion® PARIS™ kit 
was used to extract protein and RNA from the same samples. The company suggested 
protocol was followed. Commercial Promocell MSCs were grown under DMEM and CM 
conditions for 7, 14 and 28 days. At each time point, the cells were harvested. The media 
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was removed, and the cells were washed with PBS. The cells were trypsinised and collected 
in an Eppendorf tube and washed again with PBS. Ice-cold Cell Disruption Buffer was added 
to lyse the cells. A plastic pestle was used to crush the micromasses as the addition of GNPs 
required an amount of force to break down the cultures. A portion of this lysate was stored, 
to use for protein analysis. 
To obtain RNA, the remainder of the lysate was mixed with an equal volume of 2X 
Lysis/Binding Solution. A volume of absolute ethanol, equal to the initial amount of lysate, 
was added and the solution was mixed. This was then transferred to a filter cartridge 
assembled in a collection tube and centrifuged for one minute at 13,000 rpm. The flow-
through was discarded and Wash Solution 1 was added and centrifuged at the same speed 
and time. It was then washed twice with Wash Solution 2/3. The filter cartridge was then 
transferred onto a fresh collection tube and Elution Buffer (preheated to 95-100°C) was 
added to the filter in sequential aliquots. The concentration was obtained using a UV 
spectrophotometer and was stored at -80°C for Reverse Transcription. 
 
2.6 Reverse Transcription of Total RNA to cDNA: 
 
The samples were reverse-transcribed using QuantiTect Reverse Transcription kit. The 
samples were aliquoted to obtain desired RNA concentration. Genomic DNA was eliminated 
from the sample by incubating with gDNA Wipeout Buffer for 2 minutes at 42°C. A master 
mix was made using the components provided, which included Reverse Transcriptase, RT 
Buffer and the RT primer mix. The master mix was added to the samples and finally loaded 
onto a thermal cycler. The parameters were as shown in table 1. The samples were stored at 
-20°C until further use. 
 
Step Time Temperature 
Hold 15 minutes 42°C 
Hold 3 minutes 95°C 
 
Table 2. 1: Parameter values used to program the thermal cycler. 
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2.7 qPCR of cDNA: 
 
The cDNA obtained from the reverse transcription was also used in a standard qPCR. A 
master mix for each primer was made using SYBR Green, primers and RNase free water 
from the Quantitect SYBR Green PCR kit. This was pipetted into different wells along with 
their respective sample cDNA products. The plate was sealed and transferred onto the 7500 
Sequence Detection System to obtain Ct values of the samples. Sequence Detection System 
to obtain Ct values of the samples. Quantification was done using the standard method. The 
endogenous controls used for the experiment were GAPDH. The machine was run as shown 
in table 2: 
 
Step Time Temperature 
Hold 2 minutes 50°C 
Hold 10 minutes 95°C 
Melt Step 1 15 seconds 95°C 
Melt Step 2 1 minute 60°C 
Melt Step 3 30 second 95°C 
Melt Step 4 15 seconds 60°C 
 
Table 2. 2: Parameter values used to program the 7500 Sequence Detection System. 
 
2.8 Fluidigm Digital PCR: 
 
Digital PCR using a microfluidics chip allows for a sensitive and time-saving PCR 
experiments. In this experiment, the 48.48 Dynamic ArrayTM integrated fluidic circuit (IFC) 
was used, which conducted reactions for 48 samples along with 48 primers.  
The digital PCR involved 3 major steps; Specific Target Amplification (STA), Exonuclease 
I (Exo I) Treatment and PCR. 
In a DNA-free hood, the STA reaction solution was made using the TaqMan PreAmp Master 
Mix, pooled primers and DNase free water. This was equally transferred to a small volume 
of the samples and placed in a thermal cycler with the protocol as shown in Table 3: 
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Step Time Temperature 
Hold 10 minutes 95°C 
10-14 cycles 
15 seconds 95°C 
4 minutes 60°C 
Hold ∞ 4°C 
 
Table 2. 3: Time of one cycle and its respective temperature for Preamplification of sample 
cDNA. 
The samples were cleaned up using Exo I treatment by adding Exonuclease I Reaction 
Buffer, Exonuclease I and water to each sample and ran in the thermal cycler as per Table 
4: 
 
Step Time Temperature 
Digest 30 minutes 37°C 
Inactivate 15 minutes 80°C 
Hold ∞ 4°C 
 
Table 2. 4: Time of one cycle and its respective temperature for Exonuclease treatment of 
amplified sample cDNA. 
The final products were diluted with TE Buffer, if required, and then carried over for the 
final PCR. SsoFast EvaGreen Supermix with Low ROX and DNA Binding Dye Sample 
were aliquoted to each sample. The primers were mixed with Assay Loading Reagent and 
Suspension Buffer to create the Assay Mix solution. 
The IFC was fed with the control line fluid to lubricate the channels. The chip was primed 
in the IFC controller MX for the correct chip size and the samples and primers were pipetted 
onto their respective inlets on the chip. The chip was loaded back onto the controller which 
allowed the samples and assays to load into the chip. The IFC was finally placed in the 
Biomark HD PCR machine and the following program was run as per Table 5: 
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Segment Step Time (secs) Temperature BioMark HD Ramp Rate 
1 Hot Start 60 95°C 2°C/s 
2 PCR (30 cycles) 5 96°C 2°C/s 
  20 60°C 2°C/s 
3 Melting Curve 3 60°C 1°C/s 
   60°C-95°C 1°C/3s 
 
Table 2. 5: Time of one cycle and its respective temperature for the Digital PCR. 
 
From the above run, a heat map was obtained, providing a quick look at the Ct values of 
each sample-primer combination. The endogenous controls used for the experiment were 
miR-191 ad U6 snRNA. 
 
2.9 In-cell western assay:  
 
To determine MSC differentiation, certain protein markers were assessed via in cell western. 
The protocol was followed according to the manufacturer’s instructions. 
The fixed cells were permeabilised with permease buffer at 4°C for 4 minutes. The buffer 
was then removed and blocking buffer (1% BSA) was added and shaken on a plate shaker 
for 1.5 hours. The blocker was then removed and the primary antibodies (diluted according 
to manufacturer’s instructions) were added and incubated for 2.5 hours. The antibodies were 
removed and the wells were washed five times, for 5 minutes each, with wash buffer on a 
shaker. The secondary antibodies (1:500), for the respective animal, as well as the LICOR 
Cell Tag 700 (cell normalisation control) were added and incubated for 1 hour on a shaker. 
The previous wash step was repeated and subsequently wrapped in foil and stored at 4°C. 
The samples were imaged once dry using a LI-COR Odyssey® Sa. 
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2.10 Light Microscopy Staining (Histology) 
 
To confirm the success of the differentiation media used, cells were grown on 24 well plates 
and stained appropriately. The MSCs were seeded on 24-well plates, at a cell density of 5000 
cells per well (500 μl of DMEM per well). The cells were left to adhere for 24 hours and the 
media was replaced with the appropriate differentiation media (OM, CM and AM). Control 
groups of cells in DMEM were also included. 
After 28 days culture, the cells were fixed in 4% formaldehyde (10 ml formaldehyde in 90 
ml PBS with 2 g sucrose) and stained to assess differentiation. Von Kossa stain was used for 
osteogenesis, Safranin O stain for chondrogenesis and Oil Red O stain for adipogenesis. All 
these protocols were followed according to the manufacturer’s instructions. 
 
2.10.1 Von Kossa staining 
 
The fixed cells were covered with 5% silver nitrate solution and exposed to Ultraviolet 
radiation using a U.V lamp, for 30 minutes. The wells were subsequently rinsed with 
deionised water and covered with 5% sodium thiosulphate solution for nearly 10 minutes. 
The cells were washed under tepid running tap water to clear and counterstained with nuclear 
fast red solution for 10 minutes. The wells were then rinsed with deionised water and 70% 
ethanol, ready to be viewed. 
 
2.10.2 Oil Red O 
 
The fixed cells were washed with distilled water and 60% isopropanol was added such that 
it covers the cells. After incubating for 5 minutes, the isopropanol was aspirated and the cells 
were covered with Oil Red O staining solution and incubated for 15 minutes. The solution 
was removed and the cells were washed with distilled water several times until the water 
was clear. After the water was removed completely, the wells were half-filled with PBS and 
then viewed. 
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2.10.3 Safranin O 
 
The fixed cells were washed with distilled water and stained with Wiegert’s iron 
haematoxylin solution for 10 minutes. It was then washed under running water for 10 
minutes and subsequently stained with fast green solution for 5 minutes. It was then rinsed 
with 1% acetic acid solution for 10-15 seconds and then stained with 0.1% safranin O 
solution for 5 minutes. It was then dehydrated with 95% ethyl alcohol, absolute ethyl alcohol 
and xylene for 2 minutes each with 2 changes for each solution. Resinous solution was added 
and the plate was viewed.  
 
2.11 Immunostaining for different markers of 
differentiation: 
 
In addition to the histological staining, immunostaining was conducted to further confirm 
differentiation of the MSCs. All antibodies used in this protocol were diluted in 
PBS/1%BSA. The cells were plated and fixed similar to histological staining. The fixed cells 
were permeabilized for 5 minutes at 4°C using perm buffer. The cells were then incubated 
with PBS/1%BSA for 5 minutes at 37°C. The required primary antibody, along with 
phalloidin (actin stain) were added. The plate was covered in foil and incubated at 37°C for 
an hour. The antibody was removed and subsequently washed with PBS/0.5%Tween 20 
thrice for 5 minutes each on a plate shaker. The secondary antibody, complementary to the 
species of the primary antibody, was added and incubated again at 37°C for an hour. It was 
removed and the plates were washed again. Streptavidin-FITC was added and incubated for 
30 mins at 4°C. A final wash was done and a small drop of vectorshield-DAPI was placed 
on the cells. The cells were viewed under the microscope and then imaged. 
 
2.12 Synthesis of gold nanoconjugates 
 
Gold nanoparticles, with an average diameter of 13.7 ±2nm, were synthesized by the citrate 
reduction method (Jorg Polte et al., 2010). Briefly, 250 ml of 1 mM  hydrogen 
tetrachloroaureate (III) hydrate (Sigma) (98.46 mg) dissolved in 500 ml of distilled water 
were heated to reflux while stirring. Then, 25 ml of 38.8 mM  sodium citrate dihydrate 
(285.28 mg) were added and refluxed for additional 30 minutes with vigorous stirring and 
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protected from light. The resulting red solution was cooled down and kept protected from 
light. Citrate capped GNPs were characterized by transmission electron microscopy (TEM) 
and UV-Vis spectroscopy (see Fig. 2). 
These GNP were then functionalized with poly (ethylene glycol) (PEG). Briefly, 10 nM of 
the GNP solution were mixed with 0.003 mg/ ml of a commercial hetero-functional poly 
(ethylene glycol) (PEG) [O- (2-Mercaptoethyl)-O’-methyl-hexa (ethylene glycol), 
C15H32O7S, 356.48 Da, Sigma] in an aqueous solution of SDS (0.028%). Excess PEG was 
removed by centrifugation (14000g, 45min, 4ºC) and discarding the supernatant. This was 
repeated three times. 
Four sets of NP-antagomiRs were prepared using modified 2’-ACE (2-bis (2-acetoxyethoxy) 
methyl) protected RNA oligonucleotides (Horizon Discovery Ltd). Briefly, the thiolated 
RNA oligonucleotides were suspended in 1 ml of 0.1M dithiothreitol (DTT), extracted three 
times with ethyl acetate and further purified through a desalting NAP-5 column (GE 
Healthcare) using 10 mM phosphate buffer (pH 8) as eluent. Following oligonucleotide 
quantification via UV/Vis spectroscopy, each RNA oligonucleotide was added to the 
GNP@PEG in a 100:1 ratio. AGE I solution (2% (w/v) SDS, 10 mM  phosphate buffer (pH 
8)) was added to the mixture to a final concentration of 10 mM  phosphate buffer (pH 8), 
0.01% (w/v) SDS, sonicated for 10 seconds using an ultrasound bath and incubated at room 
temperature for 20 minutes. Afterwards, the ionic strength of the solution was increased 
sequentially in 50 mM  NaCl increments by adding the required volume of AGE II solution 
(1.5M NaCl, 0.01% (w/v) SDS, 10 mM  phosphate buffer (pH 8)) up to a final concentration 
of 10 mM  phosphate buffer (pH 8), 0.3M NaCl, 0.01% (w/v) SDS. After each increment, 
the solution was sonicated for 10 seconds and incubated at room temperature for 20 minutes. 
The solution was allowed to rest for additional 16 hours at room temperature, with mild 
agitation. Then, the functionalized NP-antagomiRs were centrifuged for 45 minutes at 
14,000g, the oily precipitate washed three times with DEPC-treated H2O, and redispersed in 
the same buffer. 
The resulting NP-antagomiRs, were stored in the dark at 4 °C until further use. 
Physical characterization of the NP-antagomiRs was performed by dynamic light scattering 
(Nanopartica SZ-100, Horiba), zeta potential (Nanopartica SZ-100,Horiba), UV/Vis 
spectroscopy and transmission electron microscopy. 
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2.13 Nanokicking Bioreactor setup: 
 
The bioreactor surface area holds two standard 6-well plates. The design consists of an array 
of piezos sandwiched between an aluminium base block and a bimetallic top plate. The top 
plate of the platform used magnetic attachment to secure the 24-well plates using magnetic 
sheets stuck to the bottom of the plate. The static magnetic field produced has not been found 
to affect cellular function. However, these magnets, being halbach arrays, are only magnetic 
on the side facing the bioreactor and away from the cell culture, therefore any stray magnetic 
fields would be far smaller. A signal generator (GW Instek, New Taipei City, Taiwan) was 
used, which is capable of providing 10 Vpk–pk. The sine wave modulation of the amplifier 
output was provided by a signal generator (AD9833, Analog Devices, Massachusetts, USA). 
The frequency used was 1,000 Hz, controlled through a computer device connected to the 
bioreactors with a displacement amplitude of 30 nm (Campsie et al., 2019). 
 
2.14 Analysis of PCR data and statistics: 
 
All PCR data was analysed using the standard Delta-Delta-Ct (DDCt) algorithm. Expression 
fold change (EFC) was calculated using the formula 2-DDCt. 
Statistical analysis of PCR was conducted using the GraphPad Prism software. A Kruskal-
Wallis one-way ANOVA was used to compare samples. In all figs, * = p<0.05. Two-way 
ANOVA was conducted using the RStudio software for ICW. 
Graphs were generated using Microsoft Excel for PCR and RStudio for ICW. 
2.15 Western Blot: 
 
After protein extraction, a Pierce™ BCA Protein Assay Kit was used to calculate protein 
concentration, following the protocol provided. A set of standards was created using 
supplied bovine serum albumin (BSA) with concentrations ranging from 2,000 µg to 25 µg. 
The standards were diluted with 1x PBS. Reagent A was mixed with Reagent B at a ratio of 
50:1 to obtain a working reagent. On a 96-well microplate, 25 µl of sample or standard was 
added to each well and 200 µl of working reagent was added after. The plate was covered 
with aluminium foil and incubated at 37°C for 30 minutes. The plate was then cooled to RT 
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and was read on a Thermo Scientific™ Multiskan™ FC Microplate Photometer. A standard 
curve was displayed on the machine providing the final concentrations of all samples. 
After calculating the concentrations of proteins, a volume containing 10 µg of protein was 
transferred to a new Eppendorf tube and 20 µl of 4x NuPAGE LDS sample loading buffer 
and 8 µl of 10x reducing agent (Invitrogen NP0004) was added. Finally, dH2O was added to 
bring the final volume up to 80 µl. The samples were vortexed and boiled at 70°C for 10 
minutes, after which they were ready to be loaded. 
An Invitrogen Bolt gel (Bis Tris 4-12% NW04120) was loaded on to the gel cassette and 
assembled with Invitrogen Mini Gel Tank (A25977) to form the apparatus used for the 
western blot. 1x MES buffer was added and the tank was filled enough to just submerge the 
gel. The samples, along with a pre-stained marker (SeeBlue Plus 2 Prestained Marker), was 
loaded on to the wells. The samples were run at 150 V until the samples reached the near 
bottom of the gel. 
Once the run is finished, a gel blot sandwich was made as shown in fig. 2.1. The filter paper 
and sponge were pre-soaked in transfer buffer and sandwiched with the rest of the apparatus, 
making sure no bubbles were present. The apparatus was then transferred on to the tank and 
transfer buffer was added to the brim of the core and run at 100V for 1 hour. 
 
 
 
 
 
 
 
 
 
Fig. 2.1: Assembly order of the protein transfer apparatus. The membrane used is the 
nitrocellulose membrane, which would bind the proteins transferred from the gel. 
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Once the transfer step is completed, the apparatus was disassembled and the nitrocellulose 
membrane (containing the transferred proteins) was placed in a container. Blocking buffer 
(PBS with 5% milk powder) was added and transferred to a plate shaker for 1 hour at RT to 
allow blocking. Primary antibodies were added to blocking buffer at a concentration 
recommended by the manufacturers. Strips of the nitrocellulose membrane was cut in line 
with the size of studied proteins and placed inside 50 ml falcon tubes. The primary antibody 
solution was added, and the falcon tube was placed on a roller to allow binding of primary 
antibodies to the protein. The samples were left to bind at 4°C overnight.  
The samples were then washed with washing buffer and secondary antibodies were added. 
The secondaries were diluted in the same process as the primary antibodies. The samples 
were placed on a roller again for 1 hour at RT. The samples were again washed and placed 
on saran wraps. ECL HRP substrate mix was added to the blots and taken to Thermo 
Scientific MYECL imager to develop the blot and obtain the images. 
 
 
2.16 Materials List: 
 
Materials/Reagents Supplier 
Cell culture 
Dulbecco’s modified eagle medium (DMEM) Sigma-Aldrich, UK 
Foetal Bovine Serum (FBS) Sigma-Aldrich, UK 
Penicillin-streptomycin Sigma-Aldrich, UK 
Non-essential amino acids (NEAA) Sigma-Aldrich, UK 
L-glutamine Invitrogen, UK 
Sodium pyruvate Life Technologies, UK 
Dexamethasone Sigma-Aldrich, UK 
β-glycerophosphate Sigma-Aldrich, UK 
Ascorbic acid Sigma-Aldrich, UK 
Insulin Sigma-Aldrich, UK 
Ascorbate-2-phosphate Sigma-Aldrich, UK 
Transforming growth factor beta 1 (TGFβ1) PeproTech, UK 
Indomethacin Sigma-Aldrich, UK 
3-isobutyl-1-methylxanthine Sigma-Aldrich, UK 
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Trypsin Transforming growth factor beta 1 
Versene In-house 
HEPES Fisher Scientific, UK 
Bovine Serum Albumin (BSA) Sigma-Aldrich, UK 
General Reagents 
Phosphate Buffer Solution (PBS) In-house 
Ethanol VWR Chemicals, UK 
Methanol VWR Chemicals, UK 
Acetic acid VWR Chemicals, UK 
Isopropanol VWR Chemicals, UK 
Hydrochloric acid (HCL) VWR Chemicals, UK 
Sodium Hydroxide (NaOH) VWR Chemicals, UK 
Formaldehyde VWR Chemicals, UK 
Sucrose Fisher Scientific, UK 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, UK 
Histology and Immunofluorescence 
Sodium Chloride VWR Chemicals, UK 
Magnesium chloride hexahydrate (MgCl2) VWR Chemicals, UK 
Triton X-100 Sigma-Aldrich, UK 
Tween 20 Sigma-Aldrich, UK 
Rhodamine Phalloidin Invitrogen, UK 
Primary antibodies Abcam, UK 
Santa Cruz Biotechnology, USA 
Biotinylated anti-mouse secondary Vector Laboratories, UK 
Biotinylated anti-goat secondary Vector Laboratories, UK 
Biotinylated anti-rabbit secondary Vector Laboratories, UK 
Streptavidin-FITC Vector Laboratories, UK 
DAPI Vector Laboratories, UK 
Silver nitrate Sigma-Aldrich, UK 
Sodium thiosulphate VWR Chemicals, UK 
Nuclear Fast red Sigma-Aldrich, UK 
Oil Red O Sigma-Aldrich, UK 
Wiegert’s iron haematoxylin solution Sigma-Aldrich, UK 
Safranin O Sigma-Aldrich, UK 
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Xylene VWR Chemicals, UK 
In-cell western 
Donkey anti-mouse IR Dye 800 LI-COR Biosciences, UK 
Donkey anti-rabbit IR Dye 800 LI-COR Biosciences, UK 
Donkey anti-goat IR Dye 800 LI-COR Biosciences, UK 
Cell Tag 700 LI-COR Biosciences, UK 
Western Blotting 
Pierce™ BCA Protein Assay Kit Thermo Fisher Scientific, UK 
NuPAGE™ MES SDS Running Buffer (20X) Thermo Fisher Scientific, UK 
4x NuPAGE LDS Thermo Fisher Scientific, UK 
NuPAGE™ Sample Reducing Agent (10X) Thermo Fisher Scientific, UK 
Bolt™ 4-12% Bis-Tris Plus Gels, 10-well Thermo Fisher Scientific, UK 
SeeBlue™ Plus2 Pre-stained Protein Standard Thermo Fisher Scientific, UK 
Primary antibodies Abcam, UK 
NuPAGE™ Transfer Buffer (20X) Thermo Fisher Scientific, UK 
Goat anti-Mouse IgG (H+L) Secondary Antibody, 
HRP 
Thermo Fisher Scientific, UK 
Pierce™ ECL Plus Western Blotting Substrate Thermo Fisher Scientific, UK 
Quantitative Real-Time qPCR (PCR)  
RNeasyTM Micro Kit Qiagen, UK 
RNase-free water Qiagen, UK 
QuantiTectTM Reverse Transcription Kit Qiagen, UK 
Primers and Probes Eurofins MWG Operon, UK 
Thermo Fisher Scientific, UK 
QuantiTectTM SYBR Green PCR kit Qiagen, UK 
Protein Extraction for micromasses  
PARIS kit Thermo Fisher Scientific, UK 
Fluidigm   
MagMAXTM -96 for Microarrays kit Thermo Fisher Scientific, UK 
48.48 Dynamic ArrayTM integrated fluidic circuit 
(IFC) 
Fluidigm, UK 
12.12 Dynamic ArrayTM integrated fluidic circuit 
(IFC) 
Fluidigm, UK 
SsoFast EvaGreen Supermix Bio-Rad, UK 
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TaqManTM PreAmp Master Mix Fisher Scientific, UK 
Primers and probes Fisher Scientific, UK 
 
Table 2. 6: List of materials used and their supplier 
 
The primers used for the Fluidigm study of microRNAs were purchased from Fisher 
Scientific, UK, and are proprietary. Primers used in the qPCR are listed below: 
 
Primer Sequence (5’-3’) 
GAPDH 
(endogenous 
control) 
TCAAGGCTGAGAACGGGAA - Forward 
TGGGTGGCAGTGATGGCA- Reverse 
Runx2 GGTCAGATGCAGGCGGCCC - Forward 
TACGTGTGGTAGCGCGTGGC- Reverse 
ALP ATGAAGGAAAAGCCAAGCAG - Forward 
CCACCAAATGTGAAGACGTG- Reverse 
OCN CAGCGAGGTAGTGAAGAGACC - Forward 
TCTGGAGTTTATTTGGGAGCAG- Reverse 
PPARγ CTATGGAGTTCATGCTTGTG - Forward 
GTACTGACATTTATTT- Reverse 
GLUT4 GTATCATCTCTCAGTGGCTTGG - Forward 
ATAGGAGGCAGCAGCATTG- Reverse 
AdipoQ TATGATGGCTCCACTGGTA - Forward 
GAGCATAGCCTTGTCCTTCT- Reverse 
Sox9 GCTCTGGAGACTTCTGAA - Forward 
GGTACTTGTAATCCGGGTG- Reverse 
ACAN GGCTTCCACCAGTGTGAC - Forward 
GTGTCTCGGATGCCATACG- Reverse 
Col10 TGCCCACAGGCATAAAAGGCCC - Forward 
TGGTGGTCCAGAAGGACCTGGG - Reverse 
 
Table 2. 7: List of primers used and their forward and reverse sequences 
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Chapter 3: Pilot study to identify potential 
miRNA targets  
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3.1 Introduction 
 
3.1.1 Mesenchymal Stem Cell Differentiation 
 
All the cells in the body are derived from undifferentiated stem cells that transform into other 
cell types as required (Bianco, 2014). In this regard, mesenchymal stem cells (MSCs) carry 
out repair and regeneration of bone, fat and cartilage. MSCs are primed to do this either by 
receiving external signals from other cells, or from the cell’s internal gene regulatory 
systems.  The differentiation process of MSCs is of great interest due to its potential in 
regenerative medicine (Bianco and Robey, 2001; Grayson et al., 2015).  
 
Osteogenesis is the process by which MSCs differentiate into mature osteoblasts. These 
osteoblasts are essential in replacing resorbed bone (by osteoclasts) in a process known as 
bone remodeling. Osteogenesis is controlled by key transcription factors such as Runx2 and 
Osterix (Zhang et al., 2006; Vimalraj et al., 2015). Controlling osteogenesis, allowing 
regulation of bone remodeling, has great therapeutic potential for the treatment of disease 
conditions such as osteoporosis and osteoarthritis, as well as bone difficulties including 
skeletal fracture healing (Dawson et al., 2014). 
 
Adipogenesis is the process by which MSCs differentiate into adipocytes. Adipocytes store 
energy in the form of free fatty acids during energy excess and this can be accessed later by 
the body when required (Gupta, 2014). It is mainly regulated by PPARγ, the master regulator 
of adipogenesis, as well as C/EBP alpha (Lefterova et al., 2008). MSC commitment towards 
either osteoblasts or adipocytes is reciprocally regulated; both master transcriptional 
regulators, Runx2 (for osteoblasts) and PPARγ (for adipocytes) are present in low levels in 
undifferentiated MSCs and differentiation towards one lineage completely suppresses the 
genes associated with the other lineage [Pino, Biol Res, 4 (2012)]. The inverse relationship 
between adipogenesis and osteogenesis is a widely known interaction. By controlling 
adipogenesis, the direction of MSC differentiation can be shifted towards bone formation, 
which is more relevant in therapeutic studies.  
 
 
Chondrogenesis is the process by which MSCs differentiate into chondrocytes. Cartilage 
tissue does not regenerate due to it being avascular and aneural (Akkiraju and Nohe, 2015). 
This causes it to be in a low metabolic state and requires nutrients through diffusion from 
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the articular surface (Simon and Jackson, 2018). Therefore, cartilage repair therapies are 
becoming commonplace, in particular for sporting injuries (Benthien and Behrens, 2010). 
Sox9 is the major transcription factor involved in the differentiation of MSCs to 
chondrocytes (Herlofsen et al., 2011). Chondrocytes only make up about 1 -5% of the total 
cartilage mass, the remainder comprising the extracellular matrix (ECM) of collagen, 
proteoglycans and glycoproteins (Akkiraju and Nohe, 2015). A key research goal in 
controlling chondrogenesis is to achieve differentiation without hypertrophy, i.e., when the 
cells undergo endochondral ossification. As of yet, there is no clear method of achieving this 
and any development in this area would provide a major advance (Magne et al., 2005). 
 
 
3.1.2 MicroRNAs: 
 
MicroRNAs are a recently discovered class of small RNAs that regulate gene expression 
post-transcriptionally , by either blocking mRNA translation or mRNA degradation (Chen 
and Rajewsky, 2007).. Recently, microRNAs have been shown to play a major role in MSC 
differentiation (Baglìo et al., 2013). Emerging evidence now shows that microRNAs are 
crucial for bone development and osteogenesis as post-transcriptional regulators of Runx2 
and PPARγ (e.g. miR-31, miR-34, miR-335, miR-26) with several exclusively identified in 
bone diseases such as osteoporosis (e.g. miR-705, miR-3077) [Liao, Cell Death Dis, 4 
(2013)]. Thus, the control of microRNAs may prove a very powerful avenue of investigation 
for potential skeletal therapies.  
 
Knock-out studies have been conducted on mice utilizing gene-editing techniques, which 
demonstrated the impact and importance of miRNAs in osteogenesis (E. A. Lin et al., 2009; 
Yu et al., 2010). MicroRNAs both positively and negatively regulate osteogenesis, targeting 
transcription factors and established pathways such as Runx2, Osterix, Wnt pathway and 
Hedgehog pathways. The main challenge, as with most miRNA studies, is the safe and 
targeted delivery of miRNAs and their antagomiRs. 
 
Similarly, chondrogenic and adipogenic focused miRNAs have also been identified. As with 
osteogenesis, the main targets are transcription factors and key signaling pathways.  For 
example, in chondrocytes miR-145 showed an inverse relationship with Sox9 expression, 
while miR-140 had a positive relationship (Miyaki et al., 2010; B. Yang et al., 2011). MiR-
199a was also seen as a potent inhibitor by targeting SMAD1(E. A. Lin et al., 2009). For 
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adipogenesis, miR-143 targeted ERK5, promoting adipogenesis and miR-138 was found to 
be a negative regulator(Esau et al., 2004; Ye et al., 2012).  
 
In addition to the three main differentiation pathways, miRNAs are also involved with other 
differentiation processes such as myogenesis and neurogenesis in MSCs, as well as MSC 
self-renewal and proliferation (Peng and Croce, 2016). The let-7 family showed a possible 
influence on this process, but further work needs to be done to confirm its effects (Koh et 
al., 2010). Fig. 3.1 illustrates the key miRNAs identified to date and their regulatory effects 
on MSC differentiation pathways. 
 
 
Fig. 3. 1: Differentiation pathways of MSCs and the miRNAs that target them. As research is 
continuously being conducted, further miRNAs are being discovered that may influence different 
pathways. Adapted from (Collino et al., 2011). 
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3.2 Aims and Objectives: 
 
The aim of this chapter is to identify miRNAs that target a specific differentiation 
transcription factor for each of the three main lineages. To achieve this, we must initially 
establish the multipotency of the two MSC populations, Stro-1 and Promocells, by 
confirming their ability to differentiate into osteoblasts, adipocytes and chondrocytes. Once 
this has been established, candidate miRNAs were selected following a literature review.  
Their expression levels were then determined during Stro-1 and Promocell MSC 
differentiation, confirming a final miRNA target for each differentiation lineage.  
 
These aims were achieved by the following objectives: 
 
• Confirming the potential of MSCs to differentiate via chemical induction using 
conditioned media. Two populations of MSCs are used in order to ascertain any 
differences between cell source; patient bone-marrow derived Stro-1 selected and 
commercially available Promocell® MSCs. The cells were cultured with either basal 
DMEM or osteogenic/ adipogenic/chondrogenic media. Differentiation was 
assessed via fluorescent staining and histology for appropriate markers.  
• Completing a literature search to generate a catalog of miRNA candidates that are 
expressed during MSC differentiation, in particular during osteogenesis (bone 
formation), chondrogenesis (cartilage formation) and adipogenesis (fat formation). 
This will inform on likely candidates for our studies. 
• Assessing miRNA candidate expression in our differentiating MSC populations. 
Using the conditioned media conditions and culturing MSCs for 21 days, we can 
isolate RNA and identify the candidate miRNAs using Fluidigm PCR, confirming 
their expression using RT-PCR. 
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3.3 Materials and Methods 
 
3.2.1 Cell Culture 
 
Two MSC populations were employed in this chapter. Both patient derived Stro-1 selected 
cells and commercial Promocells were cultured in T75 flasks in basal DMEM medium 
grown in an incubator at 37oC at a CO2 concentration of 5% (see section 2.1.1). All cells 
were expanded until approximately 80% confluent and used at passage 3. 
 
For all experiments, the cells were seeded (5,000 cells per well) into appropriate cell plates, 
allowed to adhere to the bottom of the well plates over 24 hours whereupon the media was 
changed every 3 days to reflect the experiment conditions (see section 2.1.1). To trigger 
chondrogenic differentiation, it was necessary to coalesce the MSCs into a spheroid-like 
shape called a micromass for the duration of culture.  The cells were cultured for 3, 7, 14, 
21 or 28 days according to the experiment requirements.  
 
3.3.2 Immunofluorescence microscopy 
 
Both Stro-1 and Promocell MSCs were cultured in 24 well plates and allowed to grow for 
28 days in basal DMEM, osteogenic, adipogenic and chondrogenic media, depending on the 
experiment conditions. The media was changed twice a week and at the end point, the cells 
were processed for immunofluorescence microscopy (section 2.11). The proteins of interest 
were osteocalcin (OCN, osteogenesis), fatty acid-binding protein (FABP, adipogenesis) and 
Sox9 (chondrogenesis). The images were then taken with a Zeiss Axiovert 200M fluorescent 
microscope and processed using the ImageJ software. 
 
3.3.3 Histology (Light microscopy) 
 
As above, both MSC populations were cultured on 24 well plates for 28 days, under 
appropriate conditions, at which point the cells were processed for histological staining. Von 
Kossa staining was conducted for osteogenesis, Oil Red O for adipogenesis and Safranin O 
staining for chondrogenesis, the protocols of which can be found in section 2.10 (1-3). 
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3.3.4 Fluidigm PCR for testing candidate miRNA expression 
during differentiation 
 
Following a literature review to verify 3/4 miRNA targets per lineage pathway, the 
expression levels of each miRNA was assessed for both MSC populations upon 
differentiation. Both MSC populations were cultured within the appropriate media in 24 well 
plates for 3, 7 and 21 days. At the selected time points, the media was removed and the cells 
were washed. Using the MagMAX-96 kit, the cells were lysed and the RNA was extracted 
as described in section 2.4.  
 
The concentration of the obtained RNA was initially measured using a UV 
spectrophotometer and then reverse transcribed with proprietary primers purchased from 
Thermo Fisher Scientific. The miRNAs tested are listed in table 3.1. A TaqMan MicroRNA 
Reverse Transcription kit was used for the reverse transcription (section 2.3) and the 
obtained cDNA was then amplified using a TaqMan PreAmp kit (see section 2.8). The 
samples were then loaded onto either a 12.12 Dynamic Array or 48.48 Dynamic Array 
integrated fluidic circuit (IFC) chip. The endogenous controls used were U6 snRNA and 
miR-191. 
 
Section 2.8 describes the processes involved in the loading of the chip, where the chip was 
placed in a Biomark HD PCR machine and the program for the Fluidigm was run according 
to table 2.5. A heatmap was used to illustrate expression level changes and their Ct values 
(cycle threshold) were provided by the machine. Using the Ct values expression fold change 
(EFC) was calculated using the delta delta Ct method (section 2.13). 
 
3.3.5 qPCR for confirming selected miRNA expression during 
differentiation 
 
Based on their expression levels from the Fluidigm assessment, the miRNA candidates were 
short listed to 1/2 per differentiation pathway.  As miRNA levels are transient and small, due 
to the restrictive nature (30 cycles) of the Fluidigm PCR, these sequences were further 
verified in both MSC populations using qPCR.  Both types of MSCs were cultured on 24 
well plates for 3 and 7 days in appropriate media, as published studies have indicated that 
miRNAs were most active during this early time period.  
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At the time points, the media was removed and the cells were washed with PBS. The cells 
were then lysed and the RNA was extracted using the MagMAX-96 kit, as described in 
section 2.3. The RNA was measured using a UV spectrophotometer and stored for reverse 
transcription.  
 
The samples were reverse transcribed using a TaqMan MicroRNA Reverse Transcription 
Kit as detailed in section 2.6. The primers used were those previously used for the Fluidigm 
study. The cDNA was then processed using Qiagen SYBR Green qPCR kit (see section 2.7) 
and plated on to 96 well qPCR plates. The plate was then transferred onto the 7500 Sequence 
Detection System to obtain the Ct values of the samples. The endogenous control used was 
U6 snRNA. The results were calculated to obtain the EFC of each sample. 
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3.3 Results: 
 
3.3.1 Confirmation of Stro-1 and Promocell MSC 
Differentiation 
 
Treating the cells with different conditioned media and subsequently assessing appropriate 
markers at day 28 via immunofluorescence and histology confirmed Stro-1 and Promocell 
MSC multipotency.  
3.3.1.1 Osteogenic Differentiation.  
 
Osteogenic differentiation was noted in Stro-1 and Promocell MSCs cultured in osteogenic 
media. Positive Von Kossa staining of black deposits, indicating presence of silver 
phosphate (replacing calcium in calcium phosphate) (Fig. 3.2), whilst immunostaining 
demonstrated osteocalcin staining (late stage osteogenic marker), both supporting MSC 
differentiation down the osteogenic lineage (Fig. 3.3).  
Fig. 3. 2 Von Kossa osteogenic staining of MSCs. Von Kossa staining after 28 days of culture 
within osteogenic media of (A) Stro-1 selected MSCs cultured in basal media, (B) Stro-1 selected 
MSCs cultured in osteogenic media, (C) Promocell MSCs cultured in basal media and (D) of 
Promocell MSCs cultured in osteogenic media. Arrowheads denote positive Von Kossa staining. 
Scale bar – 100 µm 
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Fig. 3. 3 Fluorescence osteogenic staining of MSCs at day 28. Immunofluorescence staining of 
actin (red), OCN (green) and nuclei (blue) in (A) Stro-1 selected MSCs cultured in basal media, (B) 
Stro-1 selected MSCs cultured in osteogenic media, (C) Promocell MSCs cultured in basal media 
and (D) Promocell MSCs cultured in osteogenic media. Arrowheads denote positive OCN staining. 
Scale bar – A & B 50 µm; C & D 100 µm. 
 
3.3.1.2 Adipogenic Differentiation 
 
 Adipogenic differentiation was observed in both MSC populations cultured in adipogenic 
media. Under light microscopy, fatty droplets were noted seen, whilst Oil Red O staining 
confirmed fatty acid deposits (Fig. 3.4) and immunostaining highlighted fatty acid binding 
proteins within cells cultured in adipogenic media (Fig. 3.5). 
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Fig. 3. 4 Oil Red O adipogenic staining of MSCs. Oil Red O staining after 28 days of culture within 
osteogenic media of (A) Stro-1 selected MSCs cultured in basal media, (B) Stro-1 selected MSCs 
cultured in adipogenic media, (C) Promocell MSCs cultured in basal media, (B) Promocell MSCs 
cultured in adipogenic media. Arrows denote fatty droplets within the cell. Scale bar -100 µm 
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Fig. 3. 5 Fluorescence adipogenic staining at day 28 of FABP MSCs. Immunofluorescence 
staining of actin (red), FABP (green) and nuclei (blue) in (A) Stro-1 selected MSCs cultured in basal 
media, (B) Stro-1 selected MSCs cultured in adipogenic media, (C) Promocell MSCs cultured in 
basal media and (D) Promocell MSCs cultured in adipogenic media. 
 
3.3.1.3 Chondrogenic Differentiation.   
 
Chondrogenesis was also noted in both MSC populations when cultured with chondrogenic 
media. Safranin O staining was unsuccessful with Promocell MSCs, but was evident with 
Stro-1 selected MSCs (Fig. 3.6). The immunostaining process highlighted Sox9 
(transcription factor) around the micromass, indicating chondrogenic lineage, shown in Fig. 
3.7. 
 
                DMEM                                                            AM 
   
   
   
   
   
   
   
Pr
om
oc
el
ls 
   
   
   
   
   
   
   
   
   
   
   
 S
tr
o-
1 
79 
 
 
Fig. 3. 6 Safranin O chondrogenic staining of MSCs. Safranin O purple/red staining after 28 days 
of culture within chondrogenic media of (A) Stro-1 selected MSCs cultured in basal media, (B) Stro-
1 selected MSCs. cultured in chondrogenic media. Arrows denote positive Safranin O staining. 
 
 
Fig. 3. 7 Fluorescence chondrogenic staining at day 28 of Sox9 in MSCs. Immunofluorescence 
staining of actin (red), sox9 (green) and nuclei (blue) in (A) Stro-1 selected MSCs cultured in 
adipogenic media, (B) Stro-1 selected MSCs cultured in basal media, (C) Promocell MSCs cultured 
in adipogenic media and (D) Promocell MSCs cultured in basal media. 
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3.3.2 MicroRNA Candidates Identification using Fluidigm PCR 
 
To obtain an initial list of miRNA candidates involved in MSC differentiation, an extensive 
literature review was conducted. This included studies based on knockout and 
overexpression of miRNAs under osteogenesis, adipogenesis, chondrogenesis and also 
studies using standard growth media. From this, several key miRNA candidates, shown in 
table 3.1, were selected for expression studies within the two MSC populations via Fluidigm 
PCR.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. 1: The miRNAs selected form a literature review for further Stro-1 and Promocell 
MSC expression studies by Fluidigm study. Those highlighted in bold were additionally selected 
for individual qPCR analysis.  
 
MiR Mechanism Lineage References 
miR-31 SATB2 Osteo (-) (Xie et al., 2014) 
miR-205 Runx2 Osteo (-) (Hu et al., 2015) 
miR-133a Runx2 Osteo (-) (Liao et al., 2013) 
miR-135b SMAD5 Osteo (-) (Schaap-Oziemlak et al., 2010) 
miR27b PPARγ Adipo (-) (Karbiener et al., 2009) 
miR-143 ERK Adipo (+) (Esau et al., 2004) 
miR-138 EID1 Adipo (-) (Z. Yang et al., 2011) 
miR-145 Sox9 Chondro (-) (B. Yang et al., 2011) 
miR-199a* Smad1 Chondro (-) (E. A. Lin et al., 2009) 
miR-140 Adamts-5 Chondro (+) (Miyaki et al., 2010) 
miR-21 TGFβR2 Stem (+) (Pan, Wang and Wang, 2010) 
miR-30e Ubc9 Stem (+) (Yu et al., 2010) 
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Both patient derived Stro-1 and commercial Promocell MSCs were cultured in 24-well plates 
in similar conditions as section 3.2.1. The cells were lysed at three time points; at day 7, day 
14 and day 21. The RNA was extracted and reverse transcribed to obtain cDNA. This was 
then pre-amplified and plated onto a 12:12 (for Promocells) and a 48.48 (for Stro-1) 
Dynamic Array™ integrated fluidic circuit (IFC) plate which holds 12/48 samples:12/48 
primers (Please note that the larger 48:48 array was planned for use for the Stro-1 cells as 
our collaborator who gifts the cells was interested in a wider pool of miRNAs). 
 
3.3.3 Promocell MSC Fluidigm PCR for candidate miRNAs 
 
The microRNA candidates for expression during differentiation were all assessed in 
Promocell MSCs, cultured for 3, 7 and 21 days under basal and appropriate differentiation 
conditions. The cell samples were loaded onto the Fluidigm microfluidic chip and the PCR 
was run as explained in section 2.9 After running the Fluidigm PCR, a heatmap was obtained 
that illustrates an initial scan of the samples, allowing identification of successfully run 
samples and also potential data trends. Fig. 3.8 shows the Promocells 12:12 heatmap, where 
the colours indicate approximate Ct values (cycle threshold). Unfortunately, due to possible 
contamination, too low expression or low amplification, not all time points were successfully 
run (as indicated by black boxes in the heatmap). 
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Fig. 3. 8 Promocell heatmap of a 12:12 Fluidigm chip assessing miRNA expression. The left 
column shows the miRNA primers used. The top row shows the samples denoted by media 
type/replicate number/time point in days (AM: adipogenic media; CM: chondrogenic media and OM: 
osteogenic media).  The left column lists the miRNA sequences assessed and the right column shows 
the colours, which reflect the number of cycles required to provide a value, which is the cycle 
threshold or the Ct value.  
 
From the Ct values obtained by Fluidigm, the expression fold change (EFC) for MSCs 
cultured under differentiation conditions normalised to cells cultured in basal DMEM was 
calculated and depicted in fig. 3.9. Only successful samples can be graphed, hence several 
are missing. Four selected miRNA expressions are shown below, other successful run 
samples can be found in the Appendix.  
The expression of both osteogenic miRNAs (miR-31 and miR-205) was decreased with time 
in osteogenic media culture (Fig. 3.9 A,B), reflecting the literature, where both miRNAs are 
reported as being decreased during osteogenesis (Xie et al., 2014; Hu et al., 2015). 
MiR-145 is reported as being decreased during chondrogenesis (B. Yang et al., 2011). Here, 
miR-145 expression is massively reduced with time in chondrogenic culture, supporting the 
literature (Fig. 3.9 C).  
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Finally, miR-143 is reported as being increased during adipogenesis (Esau et al., 2004). 
Here, miR-143 is clearly increased with time in adipogenic culture (Fig. 3.9 D).  
       
 
Fig. 3. 9 Expression fold change (EFC) of Promocell MSC miRNA sequences in differentiation 
media. (A) and (B) show the EFC of miR-31 and miR-205 respectively for Promocells cultured in 
osteogenic media. (C) is the EFC of miR-145 in chondrogenic conditions. (D) is the EFC of miR-
143 in adipogenic media. (n=2; error bars indicate SD; p<0.05). 
 
3.3.4 Stro-1 MSC Fluidigm PCR for candidate miRNAs 
 
Stro-1 selected MSCs were cultured for 3, 7 and 21 days under basal and appropriate 
differentiation conditions. Fluidigm PCR for Stro-1 MSCs generated a heat map indicating 
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all the miRNA sequences (and several additional ones as requested by out collaborator), at 
time points days 3, 7 and 21, under appropriate differentiation conditions (Fig. 3.10)  
Unfortunately, due to the transient nature of the miRNAs and the potentially low expression 
levels, many samples were undetected (as indicated by black boxes in the heat map).  
 
 
Fig. 3. 10 Stro-1 heatmap of a 48:48 Fluidigm chip assessing miRNA expression. The left column 
shows the miRNA primers used. The top row shows the samples denoted by media type/replicate 
number/time point in days (AM: adipogenic media; CM: chondrogenic media and OM: osteogenic 
media).  The left column lists the miRNA sequences assessed and the right column shows the colours, 
which reflect the number of cycles required to provide a value, which is the cycle threshold or the Ct 
value.  
 
Where sufficient readouts from the Fluidigm allowed, graphs were generated to indicate 
miRNA expression levels over time for MSCs cultured under differentiation conditions 
normalised to cells cultured in basal DMEM.  
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The expression of miR-31 was decreased with time in osteogenic media culture (Fig. 3.11 
A), reflecting the literature.  Unfortunately, whilst miR-205 is clearly expressed, only a 
single time point was identified, so timeline comparisons were not possible (Fig. 3.11 B). 
Both miR-145 (chondrogenesis) and miR-143 (adipogenesis) are both expressed, but again 
only a single time point, thus no timeline comparisons were available (Fig. 3.11 C,D). 
 
     
Fig. 3. 11 Expression fold change (EFC) of miRNA in differentiation media for Stro-1 selected 
MSCs. Due to the limited values obtained from the Fluidigm study, only few data points were 
obtained. (A) and (B) represent the EFC of miR-31 (n=4) and miR-205 (n=2) respectively for cells 
cultured in osteogenic media, (C) represents the EFC of miR-145 (n=2) in chondrogenic conditions, 
whilst (D) represents the EFC of miR-143 (n=3) in adipogenic media (error bars indicate SD; 
p<0.05). 
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3.3.5 Verification of final candidates MicroRNA expression via 
qPCR 
 
Following on from the Fluidigm study, a final list of single candidate miRNAs per lineage 
were identified; these were further verified in Promocells and Stro-1 by qPCR. Two time 
points were assessed, days 3 and 7, as studies have shown that miRNAs are most active 
during the early time periods (Moreau et al., 2013; Freiesleben et al., 2016). The expression 
levels were calculated using the double delta Ct analysis. 
3.3.5.1 MiRNA Expression in Promocell MSCs 
 
The osteogenic miRNA expression levels, miR-31 and miR-205, are shown in figs 3.12. The 
expression of miR-31 decreases over time for Promocell MSCs cultured in osteogenic media, 
supporting the Fluidigm data and the literature. However, there was a surprisingly large 
significant increase in the expression of miR-205 from day 3 to day 7 (unlike the Fluidigm 
data and the literature).  
 
   
Fig. 3. 12 Expression fold change (EFC) of miRNA in Promocell MSCs cultured in osteogenic 
media. (A) miR-31 expression at days 3 and 7, and (B) miR-205 expression at days 3 and 7 (n=4, 
error bars indicate SD, p<0.05). 
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The chondrogenic expression levels for miR-145, are shown in fig.3.13 (A). There is a trend 
of decreasing expression with time, supporting the Fluidigm data and the literature (B. Yang 
et al., 2011). 
The adipogenic expression levels of miR-143 are shown in fig. 3.13 (B). Here, a significant 
increase in miRNA expression with time in adipogenic culture was noted, supporting the 
Fluidigm data and the literature stating that miR-143 is a promoter of adipogenesis (Esau et 
al., 2004). 
 
   
Fig. 3. 13 Expression fold change (EFC) of miRNA in Promocell MSCs cultured in 
chondrogenic or adipogenic media. (A) miR-145 under chondrogenic conditions, and (B) miR-143 
in adipogenic media (n=4, error bars indicate SD, p<0.05). 
 
3.3.5.2 MiRNA Expression in Stro-1 MSCs 
 
The osteogenic miRNA expression levels, miR-31 and miR-205, are shown in figs 3.14. In 
both cases, the trend was for a decrease in miRNA expression with time in osteogenic 
culture. This mirrored the Fluidigm data and the literature, where both miR-31 and miR-205 
are decreased during osteogenesis (bone formation), demonstrating that both may be 
considered inhibitors of osteogenesis (Xie et al., 2014; Hu et al., 2015). 
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Fig. 3. 14 Expression fold change (EFC) of miRNA in Stro-1 cultured in osteogenic media. (A) 
miR-31 expression at days 3 and 7, and (B) miR-205 expression at days 3 and 7 (n=4, error bars 
indicate SD, p<0.05).  
 
The miR-145 expression levels are shown in fig. 3.15. Here, the trend was for a decrease in 
miRNA expression with time in chondrogenic culture (Fig. 3.13 (A)), as expected from the 
literature, where miR-145 is decreased during chondrogenesis (cartilage formation) (B. 
Yang et al., 2011). 
The miR-143 expression levels are shown in fig. 3.15 and supported the Fluidigm data, with 
a significant increase in miRNA expression with time in adipogenic culture (Fig. 3.13 (B)). 
Again, this reflected the literature, where miR-143 is increased during adipogenesis (fat 
formation) (Esau et al., 2004). 
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Fig. 3. 15 Expression fold change (EFC) of miRNA in Stro-1 cultured in adipogenic media and 
chondrogenic media. (A) shows miR-145 cultured in chondrogenic media while (B) is miR-143 in 
adipogenic media (n=4, error bars indicate SD, p<0.05). 
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3.4 Discussion: 
 
MSCs are known for their ability to self-renew, as well as differentiate into other cell types 
(Pittenger et al., 1999). There is a bulk of recent evidence supporting the role of miRNAs in 
the differentiation process (Oskowitz et al., 2008; McGregor and Choi, 2011; Y. Zhang et 
al., 2011). Within this chapter the aim was to employ two MSC populations and verify their 
capability to differentiate down the osteogenic, adipogenic and chondrogenic lineage. 
Subsequently, following a literature review of miRNAs and MSC differentiation, the 
expression of several highlighted miRNAs were assessed within our MSC populations over 
time during differentiation, with a view towards finalising a miRNA candidate for further 
study. 
 
3.4.1 Confirmation of Stro-1 and Promocell multipotency  
 
Two MSC populations were employed, an in-house bone marrow isolated population Stro-
1 and the commercially available Promocells. MSCs are usually extracted from bone marrow 
(mostly from femoral heads from hip replacement surgeries) using density gradient 
centrifugation before mononuclear fraction and marker selection (Bieback et al., 2008). This 
is a commonly used procedure and allows for selection of plastic adherent MSCs and also 
haematopoietic stem cells (HSCs), if needed. Commercially available MSCs, such as 
Promocell MSCs, are obtained through proprietary techniques. Although in-house derived 
cells, such as the Stro-1 cells used in this chapter, represent a true osteoprogenitor population 
depending on the isolation technique used, expansion culture is time-consuming and patient 
samples cannot be reliably obtained when required. In this chapter, by comparing both in-
house derived and commercially available cells, it was demonstrated that both MSC 
populations have similar differentiation capacity and miRNA expression profiles and as 
such, be used interchangeably. In some instances, there were higher expression of markers 
in Stro-1 cells, but due to the benefits of Promocells, the latter was used for research. 
To assess differentiation potential in vitro, the most widely established method utilises of 
chemical supplements added to standard growth media (Liu et al., 2016). Depending on the 
chemicals used and their concentrations, we can direct their lineage towards the required 
direction. Chemical induction is widely used to differentiate different cell types under in 
vitro conditions. They cannot be easily directed to the required location (to prevent off-target 
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reactions) and can also cause toxicity. So whilst the chemicals cannot be used in vivo, it has 
proved to be an essential tool in research as it is a relatively reliable method of differentiating 
cells (Hwang et al., 2008). The timeline of in vitro differentiation closely matches that of the 
body, as it takes around 4-weeks for cells to differentiate, which is close to the time it takes 
for bone fractures to heal (Funk et al., 2000).  
With regard to osteogenesis, both MSC populations clearly express calcium phosphate, as 
indicated by the black areas in the Von Kossa staining (Fig. 3.2). The black spots around the 
cells show silver phosphate, resulting from the exchange of calcium with silver present in 
the solution used during the staining protocol. Calcium phosphate is an essential component 
in bone formation. During this process, osteoblasts deposit mainly hydroxyapatite (insoluble 
salt of calcium and phosphorous) in the bone matrix. Other minerals such as magnesium and 
sodium are also deposited. Nearly 70% of the mineralization occurs within the first few days 
while complete mineralization can take up to five weeks (Funk et al., 2000). In support of 
this is positive staining for osteocalcin (Fig. 3.2 (B&D)), which is a late stage osteogenic 
marker (Yang et al., 2014). The image also shows a cluster of cells (9 using a nuclei count), 
which is necessary for differentiation as adhesion proteins like focal adhesion kinase (FAK) 
are involved in this process (Wrobel, Leszczynska and Brzoska, 2016). Collectively, this 
confirms the induction of osteogenesis by the differentiation media. 
 
With regard to adipogenesis, again both MSC populations exhibit fatty acid deposits in their 
cytoplasm, as stained by Oil Red O (Fig. 3.4). The diazo dye works by staining neutral 
triglycerides and lipids in the cells (Mehlem et al., 2013). Further evidence is shown with 
positive fatty acid binding protein (FABP) staining around the fatty deposits (Fig. 3.4 
(B&D)). Both positive stains confirm the induction of adipogenesis. 
 
Finally, chondrogenic differentiation was assessed in micromass cell culture. Micromass cell 
culture involves the culture of a high density of cells confined to a small area. This leads to 
the formation of a spheroid like structure. Micromass culture is necessary as the high cell to 
cell interactions are a required component for chondrogenic differentiation (Zhang et al., 
2010). Positive staining of Sox9, a master regulator of chondrogenesis was noted (Fig. 3.7 
B&D) (Akiyama, 2008).  
In summary, both cell populations are capable of differentiation down the three main 
lineages, with little difference noted between cell types. 
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3.4.2 Expression of key miRNAs within differentiating MSC 
populations 
 
Over a thousand papers were published within the last two decades detailing the involvement 
of various miRNAs in MSC differentiation. Though this has not translated into any FDA 
approved research for miRNAs, companies and laboratories are involved in efforts to finalise 
phase 1 and phase 2 trials. Patisiran, a small-interfering RNA (siRNA) drug was granted 
FDA approval in 2018, paving the way for small RNA to be used in medical trials (Adams 
et al., 2018). The promising field of miRNAs in therapeutics is an exciting endeavour and 
has large untapped potential in regenerative medicine and even cancer. 
In order to develop a system whereby we can use a single miRNA to influence MSC 
differentiation, an initial screen of the expression of several miRNA candidates within both 
MSC populations was needed. Next generation sequencing (NGS) would be an excellent 
approach (Galván et al., 2014; Manning et al., 2015). NGS technology or high-throughput 
sequencing is a term used for a wide variety of modern techniques that are used to sequence 
either DNA or RNA. Although the term suggests NGS involves only sequencing, any next-
generation techniques used to resolve multiple genetic loci can be considered as NGS. 
However, due to the cost restrictions, here the Fluidigm BioMark HD system was employed. 
Fluidigm allows for the use of an integrated fluidic circuit (IFC) to conduct a high-
throughput PCR. Several different sizes of microfluidic chips are available, allowing the 
calculation of up to 96 samples with 96 primers. As such, a large number of samples can be 
analysed, allowing for high-throughput experiments. Microfluidics is the science of 
controlling small volumes of fluids using channels in the size range of microns and has a 
wide range of applications. Due to the nature of microfluidics, only a small volume of sample 
and reaction mixes are required, allowing for cost and sample efficiency. The Fluidigm 
device used in this chapter also touts single-cell analysis, improving the range of experiments 
that can be conducted. For example, Wechsler et al. compared the effects of alternating 
current on differentiation of MSCs at the cell level using the above technique (Wechsler, 
Hermann and Bizios, 2016). After loading the samples onto the chip, automated systems 
control the rest of the process, allowing for better time management. All these benefits lower 
the workload of analysing single gene expressions in cells considerably, whilst providing 
accurate results. 
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By using the literature as a base, several miRNA candidates were selected that were 
identified in osteogenesis, adipogenesis, chondrogenesis and MSC ‘stemness’ retention. 
Both MSC populations were cultured for 7, 14 and 21 days under appropriate differentiation 
media conditions and the change in miRNA expression was assessed. Initially the data was 
presented as a heat map (Fig. 3.8 and Fig. 3.10). Heat maps are a form of representing data 
wherein the colours represent a value or its approximation from a given data set. Heatmaps 
are used as a preliminary form of analysis where the data is summarised simply and 
effectively, and as such has been used in several studies (Fu et al., 2013; Kumar et al., 2014). 
The endogenous control used was U6 snRNA, a widely used control in miRNA studies (Lou 
et al., 2015; Masè et al., 2017).  
 
3.4.2.1 Osteogenic miRNA gene expression 
 
The Promocell data from the 12:12 Fluidigm chip is shown in fig. 3.9 and the Stro-1 chip in 
fig. 3.10. There were several samples that did not yield values, but on the whole, the chip 
generated useful data that allowed the observation of the gene expression fold changes over 
time. The changes observed were mostly as expected and mirrored the literature. 
 
 In particular we were interested in miR-31 and miR-205, as both were referenced recently 
in the literature as being involved in osteogenesis (Deng et al., 2014; Qiao, Chen and Zhang, 
2014; Xie et al., 2014; Hu et al., 2015). In addition, two other relevant miRNAs, miR-133a 
and miR-135b, were also assessed (Schaap-Oziemlak et al., 2010; Liao et al., 2013). All four 
miRNAs assessed have been reported as negatively influencing osteogenesis (i.e. their 
expression is decreased during osteogenesis), as indicated in fig. 3.16. Both miR-31 and 
miR-133 directly inhibit osteogenesis via inhibiting Runx2 expression whilst miR-31 also 
inhibits osterix (Osx). 
Both miR-31 and miR-205 were clearly expressed in Promocell MSCs and mirrored the 
literature, whilst only miR-31 was expressed in Stro-1 cells. However while miR-133a 
showed a decrease in expression, miR-135b showed an increase over time in Promocells 
(Appendix Fig. 3.18), whilst no data was generated for Stro-1 cells.  As such, miR-31 and -
205 were selected as inhibitors of osteogenesis for further study in subsequent chapters.  
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. 
Fig. 3. 16:  Schematic summary of the individual miRNAs involved in osteogenesis. The 
progression of osteogenesis from an MSC through to an osteocyte is illustrated, with miRNAs 
indicated in purple, relative to their targets in yellow. Both miR-31 and miR-133 are circled in red 
(adapted from (Jing et al., 2015)). 
 
3.4.2.2 Adipogenic miRNA gene expression 
 
The main miRNAs stated in the literature as being involved in adipogenesis are miR-143, 
miR-138 and miR-27b (fig. 3.17). Both miR-138 and miR-27b were shown to be negative 
regulators of adipogenesis, while miR-143 being the positive regulator (Esau et al., 2004; 
Karbiener et al., 2009; Z. Yang et al., 2011).  
In these studies, miR-143 supported the literature and demonstrated a large, significant, 
increase in expression during adipogenesis (Fig. 3.13 D & 3.15 D) in both MSC populations. 
The other two adipogenic miRNAs are graphed in the appendix; only miR-27b showed a 
response for both Promocells and Stro-1 selected cells, with a slight increase noted. 
Therefore, miR-143 was selected for further study.  
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Fig. 3. 17:  Schematic summary of the individual miRNAs involved in adipogenesis. The 
progression of adipogenesis from an MSC through to a mature adipocyte is shown, with positive 
miRNAs influencers in the upper panel and negative miRNA influencers in the middle panel; relative 
to their targets on the right-hand side panels. MiR-27a/b, miR-138 and miR-143 are circled in red 
(adapted from (Arner and Kulyté, 2015)). 
 
3.4.2.3 Chondrogenic miRNA gene expression 
 
For chondrogenesis, the main miRNAs studied to date are miR-145, miR-199a* and miR-
138. Both miR-145 and miR-199a* decrease in expression over chondrogenesis, while miR-
140 is a positive regulator (E. A. Lin et al., 2009; Miyaki et al., 2010; B. Yang et al., 2011). 
Neither miR-140 or miR-199a* elicited a sufficient response in the Stro-1 selected cells but 
did show a response in Promocells as seen in the appendix fig. However, miR-145 clearly 
decreased in expression over time under chondrogenic conditions as expected.  
 
 
 
 
 
96 
 
3.4.2.4 The issues with using Fluidigm to analyse gene 
expression 
 
The main problem with the Fluidigm technique is that it restricts itself to 30 cycles. This, 
along with the low levels of miRNAs (mostly being repressed), often cannot provide a 
suitable platform to obtain the expression levels. It did, however, allow the generation of an 
initial candidate list, verifying their expression where possible. Any miRNAs with a 
considerably high Ct value (>30) had to be neglected. 
The formation of primer dimers is also a major concern, as the primers are not much larger 
than the miRNAs themselves. This can lead to problems with the interpretation of data, but 
by analysing the melting curves, this can be mitigated. There may be other reasons such as 
purity of the RNA or low reverse transcription rate that may cause the high Ct values. 
Perhaps there may also have been degradation of samples occurring. Due to the relatively 
new nature of this technique, troubleshooting was difficult. The technique was repeated, but 
most of the results remained the same.  
 
Summary – using the data from both Fluidigm studies, a single target per lineage was 
selected for further study; osteogenic miR-205, adipogenic miR-143 and chondrogenic 
miR-145. 
 
3.4.3 Confirmation of expression of single miRNA targets for 
osteogenesis, adipogenesis and chondrogenesis by qPCR 
 
Following on from the Fluidigm data, real-time qPCR was carried out on the single selected 
miRNA target from each lineage.  Real-time qPCR has the benefit of reaching up to 40 
cycles, thus is better for amplifying small quantities of mRNA, however it can be prone to 
errors, due to the high number of samples and replicates involved.  
 
3.4.3.1 Osteogenic study 
 
MiR-205 was selected as the main target for osteogenesis. Expression levels of miR-205 
were low in Stro-1 cells, but very high in Promocell MSCs, in particular at day 7 (nearly an 
8-fold change increase compared to control).   Mir-205 is involved in the ERK and p38 
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MAPK pathways, affecting Runx2 and leading to the negative regulation of osteogenesis; a 
study by Zhang et al. highlighted this reverse relationship between miR-205 expression and 
Runx2 (Y. Zhang et al., 2011). Furthermore, Hu et al. confirmed that controlling the 
expression of miR-205 during osteogenesis influences the phosphorylation of ERK and p38 
(Hu et al., 2015). Both ERK and p38 phosphorylate several osteogenic factors such as Runx2 
and even DLX5. DLX5 transactivates Osterix which is also essential for osteogenesis 
(Rodríguez-Carballo, Gámez and Ventura, 2016). ERK is involved in the proliferation, 
differentiation and apoptosis of cells. Inhibition of the ERK pathway promoted 
mineralization of cells, essential for bone formation (Doan et al., 2012). Other studies also 
showed the importance of miR-205 in osteogenesis, thus miR-205 was selected as an 
osteogenic miRNA for further study in subsequent chapters (Tabruyn et al., 2013; Qiao, 
Chen and Zhang, 2014; Zhao et al., 2014; Hu et al., 2015). 
 
3.4.3.2 Adipogenic study 
 
The expression of miR-143 in Promocells and Stro-1 MSCs increased significantly during 
adipogenesis (Figs. 3.13 D & 3.15 D). Unlike the other miRNA targets studied, miR-143 has 
a positive relationship in adipogenesis. An early study conducted by Esau et al. discovered 
the role of miR-143 in adipogenesis (Esau et al., 2004). They showed that miR-143 
expression increased during the differentiation and repressing its activity inhibited 
adipogenesis. It was further discovered that by targeting the MAPK and ERK, miR-143 
promotes adipogenesis. As mentioned previously, these two pathways are also essential for 
osteogenesis. By taking into account the inverse relationship of these two differentiation 
paths, miR-143 can be seen to be an important factor in adipogenesis. MAPK is involved in 
the proliferation and differentiation of cells. In the early stages of adipogenesis, this pathway 
promoted the clonal expansion of cells. Although at the later stages, overexpression of miR-
143 has been shown to limit adipogenesis, the ERK mediated phosphorylation of PPARγ 
due to miR-143 counteracts the mentioned effect, positively regulating adipogenesis (Chen 
et al., 2014; An et al., 2016). Thus, miR-143 was selected as an adipogenic miRNA for 
further study in subsequent chapters.  
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3.4.3.3 Chondrogenic study 
 
The expression of miR-145 was decreased over time for both Promocell and Stro-1 MSCs 
(Fig. 3.13 C & 3.15 C). The expression levels did not show the same level of change across 
the two cell types, but this could be attributed to genetic variation between sources. The most 
essential transcription factor for chondrogenesis, Sox9, is targeted by miR-145; this was first 
reported by Yang B. et al.  MiR-145 has also been reported to cause decreased collagen II 
and aggrecan protein expression, which are key constituents of the cartilage matrix (B. Yang 
et al., 2011). As the master regulator of chondrogenesis, Sox9 is essential for 
chondrogenesis, triggering expression of genes such as Sox5 and Sox6, which along with 
Sox9, are often referred to as the chondrogenic trio (Akiyama et al., 2002). Furthermore, 
miR-143 also prevents ossification of chondrocytes helping to maintain their cartilage state 
(Dy et al., 2012). Although several transcription factors including TGFβ control the 
expression of miR-145, it has been shown in studies that inhibiting it also showed promising 
results (Kenyon et al., 2019). Thus, miR-143 was selected as a chondrogenic miRNA for 
further study in subsequent chapters (Martinez-Sanchez, Dudek and Murphy, 2012). 
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3.5 Conclusion 
 
The aim of this chapter was twofold; (1) to verify multipotency in two MSC populations and 
(2) to assess the expression of miRNAs during differentiation, with a view towards 
manipulating miRNA levels in MSCs to influence differentiation. A list of potential miRNA 
candidates was identified form the literature and their expression levels were established in 
both MSC populations during differentiation. 
 
Both the in-house derived Stro-1 cells and commercially available Promocells were capable 
of differentiation down the three main lineages; osteogenesis, adipogenesis and 
chondrogenesis, thus verifying that both MSC populations used are multipotent.   Due to the 
easily available nature of the commercial Promocell MSCs and the similarity of results 
between the two sample types, we will be using these cells for all further experiments. 
 
Following an extensive literature review, a list of candidate miRNAs was obtained. To 
identify whether these miRNAs are present in the two cell types, a multiplex PCR was 
conducted. Using the Fluidigm BioMark HD system, we were able to conduct a large 
experiment of multiple samples and primers. Although it had its limitations, the ability to 
obtain a high throughput allowed us to screen several miRNA candidates. 
 
A final miRNA target for each differentiation pathway was identified for further 
confirmation via qPCR in both MSC populations. Changes in expression of miRNAs were 
verified during differentiation. Both Stro-1 and Promocell MSCs showed similar changes in 
the levels of miRNA expression, further showing that either cell types were suitable for 
further experiments. The miRNAs chosen to be used in further stages were miR-31, miR-
205, miR-145 and miR-143.  
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3.6 Appendix 
 
A.1 Expression fold change of excluded miRNAs from the Promocell Fluidigm study: 
 
A1.1 Osteogenesis. The Promocell Fluidigm study also included miR-133a and miR-135b, 
negative regulators of osteogenesis. MiR-135b showed a decrease in its expression overtime 
during osteogenesis as expected according to literature, however miR-133a demonstrated a 
significant increase over time in culture. Due to none or very little response for the same 
miRNAs in the Stro-1 study, these miRNAs were not taken for further experiments. As of 
yet, no studies have shown the expression of miR-135b till such a late time point, so it may 
have an unidentified interaction, which might be essential for cell development 
 
   
Fig. 3. 18: Promocell expression fold change (EFC) of miRNA cultured in osteogenic media. 
(A) miR-133a, and (B) miR-135b (n=3, error bars indicate SD, p<0.05). 
 
A1.2 chondrogenesis. MiR-140 and miR-199a* expression was assessed in Promocells over 
time in chondrogenic culture. Being a negative regulator, miR-199a* showed a decrease in 
its expression from the earliest time point to the final. Although miR-140 is a positive 
regulator of chondrogenesis, it also showed a decrease in its expression. Both graphs 
indicated high variation, which, coupled with the opposing data trend for miR-199a in the 
literature, removed these miRNAs from further study. 
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Fig. 3. 19: Promocell expression fold change (EFC) of miRNA cultured in chondrogenic media. 
(A) miR-140, and (B) miR-199a* (n=3, error bars indicate SD, p<0.05). 
 
A1.3 adipogenesis.  MiR-27b is a reported negative regulator of adipogenesis; the data 
supported this, with expression clearly decreased in Promocells over time in adipogenic 
culture (fig. 3.20). However, miR-143 showed large, significant increases in expression in 
both Promocell and Strol-1 MSCs, therefore it was selected for further study. 
 
 
Fig. 3. 20: Promocell expression fold change (EFC) of miRNA cultured in adipogenic media.  
MiR-27b expression under adipogenic conditions (n=4, error bars indicate SD, p<0.05). 
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A.2 Expression fold change of excluded miRNAs from the Stro-1 Fluidigm study: 
 
A2.1 Osteogenesis. 
 The Fluidigm study of Stro-1 selected cells did not show many positive results, as the 
heatmap illustrated. Only miR-27b, a negative regulator of adipogenesis, showed a response 
which can be visualised in fig. 3.21. Due to this, Promocells were selected for further study 
in subsequent chapters.  
 
 
Fig. 3. 21: Stro-1 expression fold change (EFC) of miRNA cultured in adipogenic media. MiR-
143 in adipogenic media (n=3, error bars indicate SD, p<0.05). 
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Chapter 4: Using miRNA 
antagomiRs/mimics to stimulate 
differentiation of MSCs  
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4.1 Introduction 
 
4.1.1 MicroRNA and Mesenchymal Stem Cell Differentiation 
 
MicroRNAs (miRNAs) are short RNA sequences of around 22 nucleotides in length. Their 
function is to regulate the expression of mRNAs through silencing or degradation through 
perfect or imperfect complementarity, respectively (Ha and Kim, 2014). Being found 
endogenously, they are formed through the transcription of endogenous transcripts forming 
a structure that is looped on one end and single stranded segments at the other end. This is 
called the primary miRNA (pri-miRNA). This structure is then cleaved by a microprocessor 
complex leading to precursor miRNA (pre-miRNA) with its loop intact, forming a hairpin 
structure. The Dicer enzyme cleaves the loop and forming miRNA:miRNA*, where the 
miRNA is the guide strand and miRNA* is the passenger strand (Ruby et al., 2007). In most 
cases the guide strand functions more effectively and usually has the nomenclature of miR-
X-5p, where X is an arbitrary number identifying the miRNA. This guide strand binds to the 
Argonaute protein which leads to a complex that can bind to mRNAs within the cell and 
regulate its expression (Meister et al., 2004). 
 
By repressing the function of mRNAs, the miRNAs can regulate many different pathways 
within the cell, with appropriate signaling leading to the repression of the required mRNA. 
MSC differentiation is of great importance due to their ability to differentiate mainly into 
osteoblasts, adipocytes and chondrocytes. This process has a multitude of chemical and 
physical pathways required to function (Bianco, 2014). One such process is the regulation 
by miRNAs. Recent studies have shown the importance of miRNAs in differentiation (Gao 
et al., 2011; Baglìo et al., 2013). Through over and under expression studies, an increasing 
number of miRNAs have been discovered that target various transcription factors for during 
mesenchymal stem cell differentiation. One can therefore assume that by manipulating the 
levels of miRNAs, the lineage of the cell can be directed towards a particular direction.  
 
To identify the miRNA candidates, an extensive literature study was conducted. The ideal 
miRNA would have non-conflicting targets of action and be modestly studied for relevance 
of function. The previous chapter used the Fluidigm and qPCR studies to confirm the levels 
of initial candidate miRNAs during different time points of MSC differentiation. 
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4.1.2 MicroRNAs and Osteogenesis 
 
Osteogenesis is the formation of osteoblasts and osteoclasts from MSCs, and they have 
important functions for bone formation and resorption, respectively (James, 2013). As 
osteogenesis is vital for skeletal development, understanding it is essential for the 
development of treatments for skeletal dysfunctions. MiRNAs control osteogenesis by 
interacting with its positive and negative regulators such as the main transcription factors 
Runx2 and Osterix. Multiple studies have identified targets of miRNA action at various 
stages of osteogenesis. MiRNAs such as miR-135 and miR-138 can act at the early stages, 
while miR-29 and let-7 can act at the later stages of osteoclast formation (Koh et al., 2010; 
Y. Zhang et al., 2011). It is necessary to understand the time of action and select the right 
candidates for potential therapeutic use. MiR-205 is an important candidate for osteogenesis. 
It acts on the master transcription factor, Runx2, and represses its function. Hu et al. showed 
the decrease of alkaline phosphatase (ALP) and bone sialoprotein (BSP) when miR-205 was 
overexpressed in MSCs (Hu et al., 2015).  A recent cancer study also showed miR-205 
affecting Runx2 expression, inhibiting the progression of pancreatic cancer (Zhuang et al., 
2019). Targeting this microRNA, through the use of antagomiRs (anti-sense miRNAs) could 
lead to the repression of this miRNA, allowing unhindered functionality of Runx2. This 
could lead to increased osteogenesis in MSCs. 
 
4.1.3 MicroRNAs and Adipogenesis 
 
Adipogenesis is also influenced by miRNAs. The formation of adipocytes is essential for the 
eventual deposition of lipids to be used as a source of energy (Rosen and MacDougald, 
2006). As adipogenesis and osteogenesis are inversely related, any insights into this process 
can be used to fortify osteogenesis. Esau et al. conducted a high throughput study of several 
miRNAs during adipocyte formation (Esau et al., 2004). One of these miRNAs was miR-
143. They continued their study into this miRNA and discovered its role as an adipogenesis 
promoter. Targeting the ERK pathway, by introducing antagomiRs of miR-143 they 
observed lower expression of adipogenic genes and also lowered triglyceride accumulation. 
By introducing mimics, we can potentially increase the rate of adipogenesis and control 
MSC fate. 
 
4.1.4 MicroRNAs and Chondrogenesis 
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The formation of cartilage is also of great importance due to its role in the skeletal system. 
Injuries or diseases to the cartilage can lead to drastic quality of life changes (Herlofsen et 
al., 2011).  MiRNAs such as miR-140 and miR-145 positively and negatively regulate 
chondrogenesis (Wuelling and Vortkamp, 2010). MiR-145 was shown to target Sox9 
expression through the use of plasmid reporter vectors with a Luciferase reporter. They 
showed the inverse relationship between miR-145 and Sox9. By creating antagomiRs to 
miR-145, chondrogenesis may be promoted, leading to quicker cartilage formation. (B. Yang 
et al., 2011) 
 
4.1.5 In-house MSCs vs commercial Promocell MSCs 
 
MSC populations can be obtained from multiple sources such as bone-marrow and adipose 
tissue. These populations can exhibit differences in stemness, proliferation and 
differentiation properties, and as such, it is essential to identify the ideal phenotype of MSCs 
for research to translate it for medical use. In-house Stro-1 selected MSCs are patient 
derived, and as such are biologically relevant. Stro-1 is a common MSC marker and cells 
selected for this antigen are used for studies (Stewart et al., 1999). There has been contention 
on its use due to the marker being prevalent in MSCs found in bone marrow and adipose 
tissue, but not in the endothelium of blood vessels. A certain section of these MSCs also do 
not show presence of essential MSC markers such as CD34 (Lin et al., 2011). Commercially 
Promocell MSCs have been selected to show the recommended ISCT (International Society 
Cell & Gene Therapy) markers and are also commonly used for in vitro studies (Samsonraj 
et al., 2015). Due to their ease of availability and meeting the criteria for MSCs, they are an 
ideal source for this work. 
 
The previous chapter compared the differentiation potential and the presence of miRNAs in 
both cell types. The similarity in the results in most cases showed the possibility of using 
either cell types for clinical relevance. Due to the widely used nature and availability of 
Promocell MSCs in scientific studies, this study chose to use this cell types for future 
experiments. 
 
4.1.6 Chapter Aims 
 
We aim to deliver the miRNA antagomiRs/mimics to stimulate differentiation of MSCs. The 
main issue is the delivery of these sequences safely to the target. Several delivery vehicles 
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have been used in studies to deliver oligonucleotides to specific locations. Most in vitro 
studies conducted use transfection agents to deliver the sequences (Lee et al., 2011; Jensen, 
Anderson and Glass, 2014). The issue with these methods is the toxicity of the agents in 
vivo. Newer methods of delivery such as dendrimers and lipids have been in the forefront, 
but to the relatively new nature of these platforms, a more robust and well-studied vehicle is 
required (Vickers and Remaley, 2012; Dzmitruk et al., 2018). 
 
The use of gold nanoparticles (GNPs) for medical research has been well established. From 
treating tumors through thermal ablation to biosensors, the relative safety of GNPs for 
biological use is already established (Dreaden, Alkilany, et al., 2012). Cells have are known 
to easily engulf these GNPs through endocytosis, providing a route to cellular entry. In the 
case of delivering oligonucleotides, the sequences are bonded to the nanoparticle surface 
through the formation of a thiol bond. Therefore, by modifying oligonucleotides (thiolating), 
we can therefore attach them onto GNPs as cargo (Ghosh et al., 2008). In addition, the 
sequences can be protected from intracellular enzymatic degradation by further modifying 
the GNPs using poly-ethylene glycol (PEG) coating which passivates the particle (Manson 
et al., 2011). Once inside the cell, the thiol bond linking the sequences to the GNPs can be 
cleaved by the oxidative agent glutathione in the cell cytoplasm (Kumar, Meenan and Dixon, 
2012). The above-mentioned points highlight the versatility of GNPs and we have taken this 
approach to deliver our sequences to the MSCs. 
 
4.2 Methods and Materials: 
 
4.2.1 Synthesis and functionalization of GNPs: 
All GNP synthesis and characterization was carried out by our collaborators Professor Pedro 
Baptista and his team, based in Caparica, Portugal (Section 2.12). AntagomiRs of miR-205 
and miR-145, along with mimics for miR-143 were purchased from Horizon Discovery Ltd. 
 
4.2.2 Cell Culture: 
All cells used in this section were hMSCs purchased from Promocell GmBH. They were 
cultured in basal DMEM and maintained at 37°C in 5% CO2. At around 80% confluency the 
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cells were passaged, counted and 5,000 (for monolayer) or 200,000 (for micromass) cells 
were seeded on to 24-well plates for the experiments. All details of these processes can be 
found in section 2.1-2.2. Cells were cultured as monolayer for the osteogenesis and 
adipogenesis experiments and as micromasses for the chondrogenesis experiments. 
 
4.2.3 Real Time qPCR Analysis: 
Cells were cultured for 7, 14 and 28 days. At the end of the relevant time points for 
monolayers, the RNA was extracted using a Qiagen RNeasy kit. Micromass RNA was 
extracted using the PARIS kit. RNA concentration was measured using a UV 
spectrophotometer and reverse transcribed using a Quantitect reverse transcription kit. After 
obtaining the cDNA, the samples were plated onto 96-well qPCR plates and using a 
Quantitect SYBR Green PCR kit, the samples were prepared for qPCR. The plates were 
loaded onto the 7500 Sequence Detection System, which provided the Ct values. Using 
standard DDCt algorithm, the expression fold change of the samples was calculated. These 
protocols used can be found in section 2.3 to 2.7. Statistics was done using one-way 
ANOVA. The primers used are listed below. The primer sequences can be found in table 
2.7. 
 
Osteogenesis: Runx2, ALP, OCN 
Adipogenesis: PPARγ, GLUT4, AdipoQ 
Chondrogenesis: Sox9, ACAN, Col10 
Endogenous control: GAPDH 
 
4.2.4 In Cell Western Analysis: 
Cells were plated onto 24-well plates as above, but the required time points, the cells were 
fixed with 4% Formaldehyde solution. Samples were permeabilized and incubated with 
primary antibodies relevant to the study.  
 
Osteogenesis: Runx2, ALP, OCN 
Adipogenesis: PPARγ, GLUT4, AdipoQ 
Stemness: CD90 
 
After incubation, the cells were washed and the secondary antibodies along with Cell tag 
was added and incubated again. Finally, the samples were washed again, dried and visualized 
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using the LICOR Odyssey Sa system. Relative expression of protein was calculated by 
obtaining the ratio of protein fluorescence to Cell tag fluorescence. Protocol can be found in 
section 2.9. Statistics was done using two-way ANOVA. 
 
4.2.5 Histology and Immunofluorescence: 
The cells were cultured as section 4.2.4 until the fixation stage. At this point, the cells were 
processed for histology and immunofluorescence as follows: 
 
Osteogenesis: Von Kossa staining / Osteopontin immunofluorescence 
Adipogenesis: Oil Red O staining / Fatty acid binding protein immunofluorescence 
Chondrogenesis: Safranin O staining / Collagen II immunofluorescence 
 
The protocols were followed as in section 2.10 and 2.11. 
 
4.2.6 Western Blot 
 
The detailed western blot protocol can be found in section 2.15. The primary antibodies used 
were GAPDH, Sox9, Aggrecan and Collagen X. 
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4.3 Results 
 
4.3.1 Effect of GNPs functionalized with miR-205 antagomiRs 
During osteogenesis, miR-205 has been reported to negatively target SATB2 and decrease 
Runx2 expression (Hu et al., 2015). This leads to inhibition of osteogenesis and repression 
of differentiation. An antagomiR against miR-205 was therefore designed and conjugated 
onto GNPs with a view towards delivering to Promocell MSCs to reverse the inhibition of 
osteogenesis and encourage osteoblast formation.   To achieve this, MSCs were cultured on 
24-well plates, two media controls were used; (i) basal DMEM (control) and (ii) osteogenic 
media (positive osteogenesis control). After 24 hours culture the cells were then maintained 
in both media and challenged +/- antagomiR-205 (treatment) and a nonsense strand (negative 
control).  The samples were then cultured for up to 28 days, during and up to which point 
they were assessed for osteogenic differentiation both at the gene and protein level. 
 
 
4.3.1.1 Real time qPCR of MSCs treated with miR-205 antagomiRs 
To assess the impact of the antagomiR-205 at the RNA level, MSCs were cultured for 7, 14 
and 28 days and RT-qPCR was carried out (as section 2.8).  Briefly, at each time point the 
cells were lysed and the RNA was extracted. After the RNA concentration was identified, 
they were reverse-transcribed and the samples were plated for qPCR. Three markers were 
assessed; Runx2 (an early osteogenic marker), alkaline phosphatase (ALP, a general 
osteogenic marker) and osteocalcin (OCN, a later osteogenic marker). 
The MSCs cultured in osteogenic media demonstrated clear increases in all osteogenic 
markers across all three time points, with no difference depending on whether GNPs were 
present or not (orange bars in fig. 4.1).  However, at all three time points the antagomiR-205 
did not indicate any difference when compared to control MSCs (no NPs) or nonsense strand 
GNPs (NS) (blue bars in fig. 4.1). In summary, there was no evidence at the gene level to 
suggest that challenging MSCs with antagomiR-205 promoted osteogenesis. 
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4.3.1.2 In-cell western of MSCs treated with miR-205 antagomiRs 
To assess osteogenesis at the protein level, in-cell western was carried out on MSCs cultured 
for 7, 14 and 28 days (section 2.9). Briefly, cells were seeded in 24 well plates and cultured 
as for the previous PCR study (in DMEM, osteogenic media and +/- antagomiR-205 and 
nonsense strand). At the relevant time points, the samples were fixed with 4% formaldehyde 
solution and stained for the same three osteogenic markers, Runx2, ALP and OCN. In 
addition MSCs were also stained at all time points for the stemness marker CD90.  The 
samples were then analysed to produce plots of relative marker fluorescence. 
Fig. 4.2 indicates the osteogenic marker fluorescence in DMEM on the left panel and 
osteogenic media on the right panel. There are several key points from these graphs: 
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• In the case of Runx2, MSCs cultured without GNPs (no NPs) in osteogenic media 
have significantly higher levels than those cultured in DMEM, however later markers 
of ALP and OCN are similar.  
• Under DMEM conditions (left panel), the addition of antagomiR-205 did not indicate 
any increase in osteogenic markers when compared to no particle control or nonsense 
negative control.  
• Under osteogenic media conditions (right hand panel), the addition of antagomiR-
205 showed a decrease in osteogenic markers when compared to no particle control. 
The nonsense negative control also showed a decrease compared to no particle 
control. 
• Both Runx2 and OCN appear enhanced in MSCs when treated with antagomiR-205 
in osteogenic media compared to DMEM media (i.e. comparing the 205 data in each 
panel). This may suggest a synergistic effect on osteogenesis.   
 
 
 
A 
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Fig. 4. 2 Logged relative fluorescence (RFU) values of osteogenic markers stained in 
Promocell MSCs after treatment with antagomiR-205. Each graph indicates a comparison of an 
osteogenic marker in both basal DMEM and osteogenic media; (A) Runx2 at day 7 day; (B) ALP at 
day 14; (C) OCN at day 28. NP indicates no particles, NS represents the non-sense strand (negative 
control) and 205’ represents the miR-205 antagomiR. (n=4, dots indicate outliers, statistics done 
through two way ANOVA) 
 
In addition to assessing osteogenic markers, CD90 was also verified as a measure of 
stemness (fig. 4.3). Stemness was clearly maintained to a greater extent at days 14 and 21 
and in MSCs cultured in DMEM compared to those cultured in osteogenic media, as shown 
in fig. 4.3 B and C. No difference in stemness was noted when MSCs were challenged with 
B 
C 
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GNPs at any time point in DMEM media (left hand image). However, there was a data trend 
to suggest that addition of GNPs, in particular the antagomiR-205 GNPs, encouraged 
maintenance of stemness when MSCs were cultured in osteogenic media (right hand panel). 
 
 
 
A 
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Fig. 4. 3: Logged relative fluorescence (RFU) values of the stemness marker CD90 stained in 
Promocell MSCs after treatment with antagomiR-205. Each graph indicates a comparison in 
both basal DMEM and osteogenic media; (A) at day 7; (B) at day 14; (C) at day 28. NP indicates 
no particles, NS represents the non-sense strand (negative control) and 205’ represents the miR-205 
antagomiR. (n=4, dots indicate outliers, statistics done through two way ANOVA) 
 
4.3.1.3 Immunofluorescence and Von Kossa staining of MSCs treated with miR-205 
antagomiRs 
To further complement the qPCR and in cell western data, immunofluorescence and 
histology staining was carried out on MSCs cultured for 28 days. The MSCs were cultured 
as for the previous PCR and in cell western studies up to 28 days. At this point the samples 
were fixed with 4% formaldehyde and either underwent Von Kossa staining or standard 
immunofluorescence protocols.  
The black stain in the Von Kossa images indicate silver phosphate that replaced the calcium 
phosphate present within the cells, reflecting a positive stain for osteoblast formation (fig. 
4.4).  MSCs cultured in DMEM media samples did not show any deposits of silver phosphate 
(fig. 4.4 A, C). However, MSCs cultures in osteogenic media clearly indicate positive 
staining (fig. 4.4 B, D). The presence of the antagomiR-205 did not appear to increase 
staining when compared to controls with no GNPs (fig. 4.4 C, D). The change in colour for 
fig. 4.4 D is due to the image being taken at a later date compared to the others. 
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Fig. 4. 4: Von Kossa staining of MSCs after 28 days of culture.  MSCS were (A) cultured in 
DMEM media, (B) cultured in osteogenic media, (C) cultured in basal media supplemented with 
miR-antagomiR-205 and (D) cultured in osteogenic media supplemented with antagomiR-205. 
Arrowheads indicate positive staining. Scale bar – 100 µm 
 
There was no osteopontin (OPN, late stage marker) staining in MSCs cultured in DMEM 
alone (fig. 4.5 A), whilst MSCs cultured in osteogenic media showed strong OPN staining 
(fig. 4.5 B).  Interestingly, OPN staining was visible for MSCs cultured with the antagomiR-
205 in DMEM and in osteogenic media (fig. 4.5 C, D). This suggest that antgomiR-205 may 
have some osteogenic effect at the protein level. Fig. 4.6 corroborates this by measuring the 
fluorescence intensities of the images. 
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Fig. 4. 5: Immunofluorescence staining of osteopontin in MSCs after 28 days of culture.  
MSCs were (A) cultured in DMEM media, (B) cultured in osteogenic media, (C) cultured in 
DMEM media with antagomiR-205 and (D) cultured in osteogenic media with antagomiR-205. 
(Green = osteopontin (OPN), Blue = DAPI (nuclei), Red = actin staining). Arrowheads indicate 
positive staining. 
 
Fig. 4. 6: Semi-quantification of osteopontin staining in MSCs after 28 days of culture. Values 
were calculated using threshold analysis of the FITC channel. (n=3, error bars indicate SD, p<0.05)  
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4.3.2 Effect of GNPs functionalized with miR-143 mimics 
By targeting the ERK pathway, miR-143 has shown to positively regulate adipogenesis. 
By increasing the levels of miR-143 in the cells, it is therefore hypothesised that this will 
lead to an increase in adipogenesis. MiRNA mimics provide the same functionality as its 
original miRNA and so to achieve this, miR-143 mimics were designed and conjugated onto 
GNPs. MSCs were cultured on 24-well plates, two media controls were used; (i) basal 
DMEM (control) and (ii) adipogenic media (positive adipogenic control). After 24 hours 
culture the cells were then maintained in both media, and challenged +/- miR-143 (treatment) 
and a nonsense strand (scrambled original sequence, negative control).  The samples were 
then cultured for up to 28 days, during and up to which point they were assessed for 
adipogenic differentiation both at the gene and protein level. 
 
4.3.2.1 Real time qPCR of MSCs treated with miR-143 mimics 
To assess the impact of the miR-143 mimics at the RNA level, MSCs were cultured in both 
basal DMEM and adipogenic media (AM) for 7, 14 and 28 days. 24 hours after plating, 
GNPs for the non-sense strands (NS) and miR-143 mimics (143’) were added. After the 
RNA concentration was identified, they were reverse transcribed, and the samples were 
plated for qPCR. Three markers were assessed; PPARγ (an early adipogenic marker), 
GLUT4 (a general adipogenic marker) and AdipoQ (a later adipogenic marker). GAPDH 
was used as the endogenous control. 
MSCs cultured in adipogenic media clearly show increased levels of all adipogenic markers, 
with no difference on addition of the GNPs (orange bars in fig. 4.7). No differences were 
noted for MSCs incubated with the miR-143 mimics at any time point when compared to 
control (no GNPs) or the nonsense strand (negative control).  
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4.3.2.2 In-cell western of MSCs treated with miR-143 mimics 
In cell western was conducted to determine whether any changes in adipogenic marker 
protein expression following treatment with miR-143. As for PCR, the cells were plated for 
7, 14 and 28 days. The GNPs were added, and the cells were fixed at the required time points. 
Protein expression of PPARγ, GLUT4 and AdipoQ was assessed at their respective time 
points. The expression of CD90 (stemness marker) was also assessed at all time points. 
Fig. 4.8 indicates the adipogenic marker fluorescence in DMEM on the left panel and 
adipogenic media (AM) on the right panel. There are several key points from these graphs: 
• At all time points, the expression of adipogenic markers was higher in MSCs cultured 
in AM conditions compared to those of samples cultured in basal DMEM, indicating 
that the MSCS are differentiating appropriately.  
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• Under DMEM conditions (left panel), the addition of mimics appeared to increase 
PPARG expression at day 7 compared to no particles (control), with no further 
changes in expression at the later time points.  
• Under osteogenic media conditions (right hand panel), no differences in marker 
expression were noted at any time point following the addition of miR-143 mimics. 
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Fig. 4. 8: Logged relative fluorescence (RFU) values of adipogenic markers stained in 
Promocell MSCs after treatment with miR-143. Each graph indicates a comparison of an 
adipogenic marker in both basal DMEM and adipogenic media; (A) PPARG at day 7 day; (B) 
GLUT4 at day 14; (C) AdipoQ at day 28. NP indicates no particles, NS represents the non-sense 
strand (negative control) and 205’ represents the miR-143 mimic. (n=4, dots indicate outliers, 
statistics done through two-way ANOVA) 
 
In addition to assessing adipogenic markers, CD90 was also verified as a measure of 
stemness (fig. 4.9). Surprisingly, there was very little difference in stemness between MSCs 
cultured in DMEM compared to those cultured in adipogenic media (all time points). There 
was a data trend to suggest that incubation with the GNPs, in particular the miR-143 GNPs, 
encouraged maintenance of stemness when MSCs were cultured in AM compared to DMEM 
(right hand panel compared to left hand panel).  
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Fig. 4. 9: Logged relative fluorescence (RFU) values of the stemness marker CD90 stained in 
Promocell MSCs after treatment with miR-143. Each graph indicates a comparison in both basal 
DMEM and adipogenic media; (A) at day 7; (B) at day 14; (C) at day 28. NP indicates no particles, 
NS represents the non-sense strand (negative control) and 143’ represents the miR-143 mimics. 
(n=4, dots indicate outliers, statistics done through two-way ANOVA) 
 
3.2.3 Oil Red O staining and Immunofluorescence of MSCs treated with miR-143  
To further complement the qPCR and in cell western data, immunofluorescence and 
histology staining was carried out on MSCs cultured for 28 days. The MSCs were cultured 
as for the previous PCR and in cell western studies up to 28 days. At this point the samples 
were fixed with 4% formaldehyde and either underwent Oil Red O staining or standard 
immunofluorescence protocols for adipogenic markers.  
Oil Red O staining highlights the fat deposits present in adipocytes, staining them red, 
providing a great visual indicator of the presence of fatty acids (fig. 4.10).  MSCs cultured 
in DMEM alone did not show any fatty acid deposits (fig. 4.10 A). Meanwhile, MSCs 
cultured in adipogenic media clearly indicate positive staining (fig. 10 B, D). MSCs 
challenged with miR-143 in DMEM indicated several fatty acid deposits in cells, suggesting 
that some cells on starting to differentiate (fig. 4.10 C).  
C
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Fig. 4. 10: Oil Red O staining of MSCs after 28 days of culture. MSCs were (A) cultured in 
basal media, (B) cultured in adipogenic media, (C) cultured in basal media with miR-143 mimics 
and (D) cultured in adipogenic media with antagomiRs. Arrowheads indicate positive staining. 
 
With regard to the immunofluorescence staining, there was no positive fatty acid binding 
protein (FABP) staining in MSCs cultured in DMEM alone (fig. 4.11 A), whilst MSCs 
cultured in adipogenic media showed strong FABP staining, with a clear change in cell 
morphology (fig. 4.11 B, D). The sample cultured in DMEM and treated with antagomiR-
145 did not show any signs of FABP, suggesting that its effect was not strong enough to 
elicit a change. This is corroborated by the fluorescence intensities of the previous figs (fig. 
4.12). 
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Fig. 4. 11: Immunofluorescence staining for fatty acid binding protein in MSCs after 28 days 
of culture.  MSCs were (A) cultured in DMEM media, (B) cultured in adipogenic media, (C) 
cultured in DMEM media with miR-143 and (D) cultured in adipogenic media with miR-143. 
(Green = fatty acid binding protein (FABP), Blue = DAPI (nuclei), Red = actin staining). 
Arrowheads indicate positive staining. 
 
Fig. 4. 12: Semi-quantification of FABP staining in MSCs after 28 days of culture. Values were 
calculated using threshold analysis of the FITC channel. (n=3, error bars indicate SD, p<0.05) 
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4.3.3 Effect of GNPs functionalized with miR-145 antagomiRs 
In MSCs, miR-145 targets Sox9 to inhibit chondrogenesis. By providing antagomiRs 
against miR-145 to MSCs, it is hypothesised that chondrogenesis can be enhanced. To 
achieve this, the MSCs were seeded as micromass cultures (as section 2.3). The high 
concentration of cell-to-cell contact and adhesion promote MSC differentiation towards 
chondrocytes. 
 
4.3.3.1 qPCR of MSCs treated with miR-145 antagomiRs 
To assess the chondrogenic marker gene expression, the cells were cultured as micromass 
cultures for 7, 14 and 28 days and evaluated for early, mid and late stage chondrogenic 
markers. 24 hours after plating, GNPs for the non-sense strands (NS) and antagomiR-145 
(145’) were added. After the RNA concentration was identified, they were reverse 
transcribed and the samples were plated for qPCR. Three markers were assessed; Sox9 (an 
early chondrogenic marker), aggrecan (ACAN, a general chondrogenic marker) and collagen 
10 (Col10, late marker). 
MSCs cultured in chondrogenic media show a trend towards increased levels of 
chondrogenesis, in particular at the later time point of day 28, with a variation observed at 
the early time of day 7 on addition of the antagomiR-145 GNPs (orange bars in fig. 4.13).  
When cultured in DMEM media, at both later time points (days 14 & 28) the addition of 
antagomiR-145 showed a trend for increased expression of chondrogenic markers (blue bars 
in fig. 4.13).  
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4.3.3.2 Western Blot of MSCs treated with miR-145 antagomiRs 
To see whether the gene level changes matches the protein expression, a western blot was 
conducted. Due to the difficult nature of extracting proteins from the micromasses, a very 
low yield of proteins was obtained. Due to this we were not able to properly conduct the 
western blot and as such, were not able to complete our protein study.  
 
4.3.3.3 Safranin O staining and Immunofluorescence of MSCs treated with miR-145 
antagomiRs 
To visualize the impact of miR-145 antagomiRs, Safranin O staining and 
immunofluorescence was conducted. Safranin O stains the proteoglycans and collagen II 
present in cells a deep red colour. Although all cells contain certain amounts of these 
proteins, the intensity of the colour is used as an indicator of chondrogenesis. All images 
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Fig 4. 13: Expression fold change (EFC) of 
Promocell MSCs cultured in DMEM or 
chondrogenic media. (A) Sox9 at day 7, (B) 
ACAN at day 14, and (C) Col10 at day 28. 
(NoP = No particles, NS = Non-sense strands, 
145’= miR-145 antagomiR) (n=4, error bars 
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appeared to show positive staining (fig. 4.14), with the CM and miR-145 treated samples 
giving the strongest staining (fig. 4.14 D) 
 
         
Fig. 4. 14: Safranin O staining of MSCs after 28 days of culture. MSCs were (A) cultured in 
basal media, (B) cultured in chondrogenic media, (C) cultured in basal media with miR-145 
antagomiRs and (D) cultured in chondrogenic media with miR-145 antagomiRs.  
 
The Safranin O stains the proteoglycans within the micromass sections red. The clear/grey 
colouring is that of the cytoplasm. The sample cultured only in DMEM shows light red 
colouring with most of the sample being clear, indicating a minimal or no chondrogenesis. 
In contrast, fig. 4.14 (C) shows a higher intensity of red with few clear spots. This shows 
the influence of the antagomiRs on samples cultured in basal media. The samples cultured 
in CM also showed a deep red colour with few clear spots indicating a shift towards 
chondrogenesis, as expected. 
The immunofluorescence staining allowed us to visualize the presence of collagen II within 
the cells; here, the staining is viewed as green, or yellow due to red/green overlay. Positive 
staining was observed in samples cultured in CM (fig. 4.15 B, D). Positive staining was also 
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observed in MSCs treated with antagomiR-145 and cultured in DMEM, suggesting enhanced 
chondrogenesis (fig. 4.15 C)  
       
 
Fig. 4. 15: Immunofluorescence staining for Collagen II protein in MSCs after 28 days of 
culture.  MSCs were (A) cultured in DMEM media, (B) cultured in chondrogenic media, (C) 
cultured in DMEM media with miR-145 antagomiR and (D) cultured in chondrogenic media with 
miR-145 antagomiR. (Green = collagen II, Blue = DAPI (nuclei), Red = actin staining). 
Arrowheads indicate positive staining. 
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4.4 Discussion 
MicroRNAs have been highlighted as having a role during MSC differentiation, as 
summarised previously in fig. 4.1.  Gold nanoparticles (GNPs) have been used a delivery 
platforms for small RNA sequences, as they protect the sequence from degradation in 
biological systems and can also detach sequences within the cell based on the chemistry of 
the conjugation (Berry, 2013). In our lab we have developed a system of using thiolated 
RNA sequences conjugated onto GNPs, which allows delivery and detachment via 
intracellular glutathione (Conde et al., 2012; McCully et al., 2015). Here, similar principles 
were used, whereby GNPs were used to deliver microRNAs identified as being involved in 
differentiation to MSCs, both control MSCs cultured in DMEM and differentiating MSCs, 
cultured in the appropriate media. 
Therefore, miRNA sequences were conjugated onto GNPs. The GNPs were coated with poly 
ethylene glycol (PEG) to passivate the NPs and to protect the RNA sequences. In vivo, NP 
interaction with serum proteins forming a protein corona can lead to targeted uptake by cells 
such as macrophages (Giner-Casares et al., 2016). PEG is a widely used passivating agent 
that also prevents aggregation of the GNPs in vitro (Manson et al., 2011; Suk et al., 2016). 
 
4.4.1 Mir-205 and Osteogenesis 
Many microRNAs are involved in cancer pathways and as such are used as markers for 
various cancers. Mir-205 has been implicated in breast cancer due to its additional role in 
mammary stem cell maintenance (De Cola et al., 2015). It has also been found to have a role 
in osteogenic differentiation. Early work conducted on vascular smooth muscle cells showed 
that miR-205 may target Runx2 and Smad1 (Qiao, Chen and Zhang, 2014). Runx2 is the 
master regulator of osteogenesis. It targets several osteogenic genes. An important target is 
osteocalcin (OCN) whose levels have been correlated with increased bone mineral density 
(Yang et al., 2003). MiR-205 also targets other osteoblast specific genes such as bone-
sialoprotein (BSP) and osteopontin (OPN) (Hu et al., 2015). Fig. 4.14 summarises the 
potential targets. Runx2 is also involved in the ossification of chondrocytes due to its 
consensus binding site present in collagen type X. This leads to bone formation from 
cartilage (important in bone repair and infantile bone formation) (Qiao, Chen and Zhang, 
2014). As such, any miRNA targeting Runx2 should have an impact on osteogenesis.  
131 
 
 
Fig. 4.16. MiR-205 targets in osteogenesis. MiR-205 has been reported to negatively target 
several osteogenic genes, including runx2, Smad1, osteocalcin (OCN), bone-sialoprotein 
(BSP) and osteopontin (OPN). Therefore, removal of miR-205 may encourage bone 
formation and remodelling, leading to new therapies (adapted from (Narayanan et al., 
2019)). 
 
Another target of miR-205 is SATB2. SATB2 is important in osteoblast differentiation and 
craniofacial patterning (Zhao et al., 2014).  As shown by Zhang et al, SATB2 activates 
Runx2 dependent osteogenesis, therefore it is also essential in the process of bone formation 
(J. Zhang et al., 2011). Here, the authors implanted SATB2 overexpressing cells on to 
mandibular bone defects. The overexpressing cells had an increased activity of BSP and 
underwent faster osteogenic differentiation, indicating SATB2’s role as a potent 
transcription factor. 
The Fluidigm study conducted in chapter 3 correctly identified a decrease in miR-205 
expression in MSCs over time during osteogenesis. The subsequent qPCR in chapter 3 
further supported this, confirming the inhibitory role of miR-205 in osteogenesis. Thus, 
collectively, miR-205 was an attractive candidate for study as it potentially targeted two 
important transcription factors, Runx2 and SATB2. 
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4.4.1.1 Manipulating Mir-205 Levels in MSCs  
As miR-205 reportedly inhibited osteogenesis, it was hypothesised that inhibition of miR-
205 should conversely encourage osteogenesis.  An antagomiR sequence against miR-205 
was therefore conjugated onto the GNPs and incubated with MSCs in both DMEM and 
osteogenic media (OM; positive control). Any potential osteogenic effects were investigated 
at both the RNA and protein levels.  
 
4.4.1.1.1 MiR-205 antagomiR: impact at the RNA level 
Initially, qPCR analysis was carried out to determine any effect of antagomiR-205 on the 
expression of osteogenic markers; Runx2 (early marker), alkaline phosphate (ALP, mid-
phase marker) and osteocalcin (OCN, late stage marker). The MSCs cultured in OM did 
show higher expression of osteo-specific genes at the relevant time points, but the antagomiR 
did not induce a higher expression. 
MiR-205 is known to influence both Runx2 (used as a marker here) and SATB2. The 
function of Runx2 has been extensively studied and its importance in osteogenesis has been 
established (Bruderer et al., 2014). Knockout studies have shown that without Runx2, 
mineralization is absent and leads to severe skeletal abnormalities and high mortality rates 
pre-birth (Takarada et al., 2013). SATB2 is also essential in bone formation as both a Runx2 
enhancer as well as its inhibiting actions on several Hox genes, which are themselves 
inhibitors of osteogenesis (Dobreva et al., 2006). Targeting either or both of these genes 
should theoretically lead to an effect in differentiation. 
The antagomiR-205 treatment did not affect runx2 expression levels. Bearing in mind the 
number of potential targets for mir-205, it may have been more relevant to investigate levels 
of SATB2 expression (as SATB2 influences Runx2 expression). The antagomiR may have 
caused an increase in SATB2 levels, but this might not have translated to an increase in 
Runx2 expression due to post-transcriptional modifications and events. Hu et al. looked at 
SATB2 expression and noticed an increase in its levels when using miR-205 antagomiRs 
(Hu et al., 2015). 
 
4.4.1.1.2 MiR-205 antagomiR: impact at the protein level 
The RNA environment is unstable and can be easily degraded, thus assessing marker protein 
expression is necessary. An in-cell western (ICW) was conducted to understand the changes 
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of the protein environment due to antagomiR-205. ICW uses fluorescently labelled 
antibodies to detect protein levels, compared to the cell number, using a cell tag, such that a 
single cell protein value can be calculated as relative fluorescence units (RFU). Here, the 
osteogenic markers Runx2, ALP and osteocalcin (OCN) were assessed.  
Clear increases in bone markers were noted with MSCs cultures in OM, indicating that the 
MSCs were differentiating appropriately. No differences in markers were recorded for MSCs 
treated with antagomiR-205 in DMEM, however there appeared to be an increase in markers 
at day 14 and 28 for MSCs both cultures in OM and treated with antagomiR-205. This 
suggests that the antagomiR may have a synergistic effect when applied in combination with 
the OM, by enhancing or potentiating osteogenesis. This observation was further supported 
by the immunostaining, where the bone marker osteopontin (OPN) stained for a day 28 
showed increased levels in MSCs treated with antagomiR-205 both in DMEM and also in 
OM.  
As expected, the stemness marker, CD90, was increased in MSCs cultured in DMEM at the 
later time points of days 14 and 28 when compared to MSCs cultured in OM, indicating that 
the MSCs retain their phenotype better in basal media. However, it was also noted that 
treatment with antagomiR-205 also seemed to increase CD90 expression, when compared 
to parallel controls. Another target of miR-205 is phospholipase C beta 1 (PLCβ1). It is an 
important enzyme in nuclear lipid transduction as well as cell cycle progression (Fiume et 
al., 2012). Zhao and his group showed that PLCβ1 was a target of miR-205 and by 
downregulating the expression of miR-205 using vectors, they discovered that the stemness 
of hepatocellular carcinoma cells increased (Zhao et al., 2015). It can be said that this role 
of miR-205 may be present in MSCs too, recorded as an increase in CD90 expression levels. 
CD90 was chosen as the marker for stemness due to its prevalence in MSCs and 
recommendation by the ISCT as one of the criteria for defining MSCs (Samsonraj et al., 
2015). It may be pertinent to use other MSC markers such as CD105 or even Stro-1 and 
compare the fluctuations in its levels at different time points. Due to various factors such as 
time to reach confluency, the cells lose stemness overtime. This can lead to issues with 
expression of certain factors and using cells at an earlier passage point may provide more 
stable results. 
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4.4.1.1.3 Manipulating Mir-205 Levels in MSCs: Conclusion 
In summary, whilst treatment with antagomiR-205 does not show a strong impact on 
osteogenesis, the protein expression evidence suggests that reduction of miR-205 during 
osteogenesis can potentiate differentiation.  
 
 
4.4.2 Mir-143 and Adipogenesis 
The impact of obesity on our lifestyles cannot be understated. This leads to multiple issues 
such as type 2 diabetes mellitus and cardiovascular diseases. Adipose tissue stores fat 
deposits within adipocytes. It is therefore crucial to understand the underlying mechanisms 
involved in this process. MiRNAs are able to indirectly regulate adipogenic differentiation 
of MSCs by targeting various genes that may be involved in balancing self-renewal and stem 
cell differentiation. Our study focused on using miR-143 mimics with a view towards 
shifting the lineage of MSCs to adipocytes. This may provide a better understanding of the 
process of adipogenesis and also potentially look towards using antagomiRs against 
adipogenesis as a clinical treatment.   
Using a combination of expression data and functional assay results, Esau and co-workers 
first identified miR-143 as one of the regulators of adipocyte differentiation (Esau et al., 
2004). MiR-143 was identified as targeting extracellular signal-regulated kinase 5 (ERK5), 
also known as mitogen-activated protein kinase 7 (MAPK7) gene, which is involved in 
promoting growth and proliferation in response to tyrosine kinase signalling, boosting 
adipocyte differentiation (Nithianandarajah-Jones et al., 2012). ERK5 mediates 
phosphorylation of PPARγ, the master regulator of adipogenesis and promotes adipogenesis, 
thus miR-143 indirectly enhances adipogenesis as seen in fig. 4.17 (Zhu et al., 2014). 
In chapter 3, the Fluidigm study correctly identified an increase in miR-143 expression in 
MSCs over time during adipogenesis. The subsequent qPCR in chapter 3 further supported 
this, with large significant increase in miR-143 recorded in both Promocell and Stro-1 MSC 
populations over time in adipogenic media (AM), confirming the positive role of miR-143 
in adipogenesis. Thus, miR-143 was used in this study with a view towards enhancing 
adipogenesis. 
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4.4.2.1 Manipulating Mir-143 Levels in MSCs  
As miR-143 reportedly enhanced adipogenesis, it was hypothesised that increasing miR-143 
levels in MSCs should further encourage adipogenesis.  A miR-143 mimic sequence was 
therefore conjugated onto the GNPs and incubated with MSCs in both DMEM and 
adipogenic media (AM; positive control). Any potential adipogenic effects were investigated 
at both the RNA and protein levels.  
 
4.4.2.1.1 MiR-143 mimics: impact at the RNA level 
To assess the effect of the miR-143 mimics on the RNA environment, qPCR was carried 
out.  The expression of adipogenic markers; PPARγ (early stage marker), GLUT4 (mid-
stage) and adiponectin (AdipoQ, late stage) were assessed.  
The markers were all increased for MSCs cultured in AM, indicating that the cells are 
differentiating appropriately. However, there were no changes in marker expression for 
MSCs treated with the miR-143 mimics, either in basal DMEM or AM. Esau’s study showed 
that by transfecting miR-143, they obtained higher levels of ERK5, and thus increased 
adipogenesis, but also by providing antagomiRs to miR-143, there was a decreased 
expression of PPARγ and GLUT4 expression. The use of a transfection agent may have led 
to a more pronounced localization of miR-143 within the cells (Esau et al., 2004). 
 
4.4.2.1.2 MiR-143 mimics: impact at the protein level 
Protein expression of PPARγ, GLUT4 and AdipoQ were assessed at their respective time 
points to identify changes in protein adipogenic markers. Clear increases in marker 
expression were noted with MSCs cultured in AM over all time points, indicating that the 
MSCs were differentiating appropriately. The miR-143 mimics showed an increase in 
PPARG for MSCs cultured in DMEM, with no changes noted at later time points. The 
histology staining reflected this, with a small number of MSCs exhibiting fat droplets 
following miR-143 treatment.  Whilst the evidence was not strong, it does suggest that miR-
143 has a potential influence on adipogenesis  
The CD90 expression was generally similar across MSCs cultured in either DMEM or AM, 
indicating no clear changes in retention of expression. Interestingly, there was an increase in 
CD90 expression following treatment of miR-143 at days 7 and 28 in both DMEM and AM, 
suggesting that MSC phenotype is preserved in MSCs treated with miR-143 mimics. The 
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opposite was identified on previous studies on cancer stem cells. For example miR-143 
(along with miR-145) was shown to supress cancer stem cell markers/’stemness’ factors 
including CD133, CD44, Oct4, c-Myc and Klf4 in cells from prostate cancer bone metastasis 
(Huang et al., 2012). In addition, a further study demonstrated that increasing levels of miR-
143 reduced cancer stem stemness, potentially signifying a greater role in stemness (Zhang 
et al., 2015).  Collectively, this evidence, along with our study, suggests a role for miRNAs 
in regulating stem cell characteristics.  
 
4.4.1.1.3 Manipulating Mir-143 Levels in MSCs: conclusion 
In summary, from the evidence presented here, the addition of miR-143 mimics to MSCs 
may slightly enhance adipogenesis, but also maintain MSC phenotype.  
MiR-143 has been shown to be relevant during adipogenesis. It influences the MAPK 
pathway by possibly targeting ERK5 (Clapé et al., 2009). ERK5 is vital in vascular 
development as target deletion of ERK5 in mice led to severe issues with cardiovascular 
development and vascular integrity. It was difficult initially to understand its effects in 
adipogenesis due to foetal lethality upon deletion of ERK5 (Nithianandarajah-Jones et al., 
2012).  
Here, we see a slight increase in early stage adipogenesis following treatment of miR-143. 
Conversely, Chen et al. conducted a study to investigate the role of miR-143 in adipocyte 
derived stem cells (ADSCs) and found that miR-143 halted the progression of adipogenesis, 
along with cell proliferation during early stages of clonal expansion, but when introduced 
during the growth arrest/terminal differentiation phase, it promoted adipogenesis. In Chen’s 
study, miR-143 was delivered using a lentivirus after 48 hours of culture, resulting in 
increased levels of PPARγ and larger amounts of fat deposits. Further study discovered that 
miR-143 also targets MAP2K5, another member of the MAPK family (Chen et al., 2014). 
But by targeting MAP2K5, miR-143 inhibits adipogenesis. During the clonal expansion 
stage, DNA synthesis and cell division require the activation of the MAPK pathway. One of 
the factors controlling this is MAP2K5. By targeting this pathway, miR-143 may in fact be 
stunting the clonal expansion. This in turn cascades to suppression of C/EBPα (another 
important adipogenic transcription factor) leading to the decrease of adipogenesis, as shown 
in fig. 4.17 (Chen et al., 2014). However, when introduced at the later stages, miR-143 did 
in fact block the MAPK pathway leading to lower phosphorylation of PPARγ. This is 
important as phosphorylation of PPARγ prevents differentiation of the cells. By preventing 
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this, more non-phosphorylated PPARγ remains, promoting adipogenesis. Therefore, the 
influence of miR-143 appears to be related to the timeline of adipogenesis.  
 
 
 
 
Fig. 4. 17: Schematic of the proposed miR-143 and MAP2K5 regulation during ADSC 
adipogenesis. ERK as a substrate of MAP2K5 trigger clonal expansion and activates C/EBP-a, thus 
overexpression of miR-143 in this phase blocks clonal expansion and subsequent differentiation (by 
inhibiting MAP2K5). However blocking MAP2K5 during the terminal differentiation stage reduces 
phosphorylation of PPAR-g and thus promotes adipogenic differentiation (taken from (Chen et al., 
2014)). 
 
In our study, the miR-143 mimics were added 24 hours after seeding cells. As such, we were 
in fact introducing miR-143 during the early cell growth phase, which may have led to the 
prevention of clonal expansion, stunting differentiation during time in culture. It would be 
interesting to identify whether adding the mimics at a later time point, after cell growth was 
established, would better influence adipogenesis.  
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4.4.3 Mir-145 and Chondrogenesis 
Cartilage degradation can be caused by either physical injury or osteoarthritis (Caplan et al., 
1997). As cartilage does not regenerate, techniques to promote cartilage production in clinic 
are a common aim in regenerative medicine. The main issue comes with maintaining the 
nature of chondrocytes. Chondrocytes, over time, become ossified and become part of the 
skeletal structure. This is essential is foetal development, but as one progresses with age, this 
becomes an issue (Mackie et al., 2008).  
As with the other differentiation pathways, miRNAs are involved in the regulation of 
chondro-specific genes (Crowe et al., no date). The main regulator of chondrogenesis is 
Sox9, which controls the secretion of cartilage matrix proteins, leading to chondrocyte 
formation (Akiyama et al., 2002). Sox9 knockout studies showed that loss prevented 
cartilage development and also repressed the expression of other cartilage specific genes 
such as Collagen II (Col2a1) and aggrecan (ACAN), both being part of the cartilage matrix 
(Lefebvre and de Crombrugghe, 1998). MiR-145 had been shown to target Sox9, by binding 
to it and causing repression. Thus, by introducing antagomiRs against miR-145, the aim is 
to prevent this action and thereby promote chondrogenesis. 
 
4.4.3.1 Manipulating Mir-145 Levels in MSCs  
As miR-145 reportedly inhibited chondrogenesis, it was hypothesised that inhibition of miR-
145 should conversely encourage chondrogenesis (B. Yang et al., 2011; Kenyon et al., 
2019).  An antagomiR sequence against miR-145 was therefore conjugated onto the GNPs 
and incubated with MSCs in both DMEM and chondrogenic media (CM; positive control). 
Any potential chondrogenic effects were investigated at both the RNA and protein levels.  
 
4.4.3.1.1 MiR-145 antagomiR: impact at the RNA level 
To determine the effect of antagomiR-145 on chondrogenic gene expression qPCR was 
carried out. MSCs were expanded as micromass cultures and Sox9 (an early adipogenic 
marker), aggrecan (ACAN, a general adipogenic marker) and collagen 10 (Col10) 
expression was assessed at days 7, 14 and 28 days respectively. 
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The gene expression for all chondrogenic makers was increased in MSCs cultured in CM 
when compared to DMEM, indicating that the cells were differentiating appropriately. The 
antagomiR-145 GNPs were designed to target Sox9, but no changes in Sox9 expression were 
noted following treatment.  Instead, there was an increase in gene expression at the later time 
points, supporting chondrogenesis (days 14 and 28). For example, collagen X (Col10) 
showed increased expression for the treated samples. This is an important matrix protein 
providing the network linkage present in chondrocytes (Shen, 2005). Although this is mainly 
expressed in hypertrophic chondrocytes, its increased expression in samples treated with 
antagomiRs is promising. 
To date, all research conducted on the role of miR-145 in MSCs have demonstrated an 
inhibitory effect on chondrogenesis. In one such study, Yang et al. showed that introduction 
of miR-145 through overexpression did not cause any changes in the levels of Sox9 mRNA 
expression. However, subsequent protein analysis identified that protein levels of Sox9 were 
decreased (B. Yang et al., 2011). It was hypothesized that miR-145 may be binding through 
imperfect complementation, thus not affecting the mRNA levels. Instead, it affected the 
translational process, leading to the eventual decrease in Sox9 protein levels. This might 
have led to the low purity of the RNA samples due to the presence of the antagomiRs. The 
antagomiRs would prevent the post-transcriptional silencing of the Sox9 proteins, leading to 
an increase in the expression of ACAN and Col10 at later stages.   
 
 
4.4.3.1.2 MiR-145 antagomiR: impact at the protein level 
Due to the nature of micromass culture, in cell western cannot be used, therefore a standard 
western blot was scheduled. Unfortunately, due to the low level of proteins obtained from 
the sample, we were not able to obtain a result from the western blotting. This was most 
likely due to the lysis step of the micromass culture. The RIPA buffer used for lysis was 
probably not able to lyse all the cells causing a low yield. As such, the protein concentration 
was compromised and the blot that was run did not provide any information. 
As yet, there are no studies using antagomiRs of miR-145 to study the effect on late stage 
chondrogenesis. Instead, most research has been carried out to show the role of miR-145 in 
downregulating chondrogenesis. In these studies, authors showed that there was a decrease 
in the levels of chondro-specific proteins and also the their impact on cartilage formation 
(Lee et al., 2011; Martinez-Sanchez, Dudek and Murphy, 2012). It would be interesting to 
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see if Sox9 expression is indeed decreased at the early stages and also if the production of 
collagen and proteoglycans are affected. 
4.4.3.1.3 miR-145 antagomiR: Histology and Immunofluorescence: 
Although we were not able to conduct a protein study, the Safranin O and 
immunofluorescence staining did show the presence of essential components of cartilage 
formation, i.e., proteoglycans and collagen II. The results were promising, as MSCs treated 
with antagomiR-145 demonstrated much higher levels of these proteins when compared to 
MSCs cultured without the antagomiRs.  
 
4.4.3.1.4 miR-145 antagomiR: Conclusion 
If research can regenerate cartilage without allowing a shift towards hypertrophy, treatments 
may be able to move away from arthroplasty (implanting a ‘fake cartilage’) or cartilage 
replacement from other parts of the body. Due to the common nature of injuries such as 
anterior cruciate ligament (ACL) tears and diseases including osteoarthritis, a consistent and 
safer option is in high demand. 
Here, by targeting miR-145, the aim was to enhance chondrogenesis. As discussed, miR-145 
targets Sox9, an important regulator of chondrogenesis. Our gene expression studies were 
consistent with Yang’s study, which showed no changes for Sox9 expression. The specific 
binding of miR-145 to a unique 3’-UTR region of the Sox9 mRNA has been suggested to be 
the cause of this. The eventual increase in downstream protein expression of other chondro-
specific genes in histology and immunofluorescence staining, such as ACAN and Col10, 
leads us to believe that there is in fact a change caused by the antagomiRs. This is promising, 
but it is essential to confirm whether the chondrocytes remain at this stage or become 
hypertrophic. The high Col10 expression is a potential sign of possible hypertrophy, but only 
after further protein expression studies in addition to identifying runx2 levels can this be 
determined. 
 
4.4.4 The use of miRNA sequences to manipulate differentiation 
Previous studies have shown that altering miRNA sequences can influence MSC 
differentiation, for example inhibiting miR-205 can cause an increase in the expression of 
osteo-specific genes (Baglìo et al., 2013; Zhuang et al., 2019). Often, transfection agents are 
used deliver the miRNA sequences, such as Lipofectamine 2000, which boasts a high 
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delivery rate, but is toxic to cells/tissues, thus cannot be used therapeutically.  Here we used 
gold nanoparticles (GNPs) as a delivery platform, a method that is non-invasive and has been 
shown to cause minimal toxicity. 
However, as we do not observe strong gene or protein expression changes when delivering 
the miRNA/antagomiR sequences to MSCs, it may be that the sequences are not reaching 
their target, for example they may be degraded in the cell after release. An established 
glutathione mediated response is used here to release the sequences following cellular uptake 
(McCully et al., 2015). The thiol bond attaching the miRNA sequence to the GNP is cleaved 
by glutathione present within the cell cytoplasm. Whilst release should occur without any 
issues, perhaps the miRNA/antagomiR sequence may not be able to reach its target within 
the cell as it is degraded by the various RNases present. To adapt out protocols, we could 
potentially further modify the sequences to allow protection, without changing its activity or 
target selection. 
Another factor that may affect the efficacy of these treatments may be the fact that the 
antagomiRs are not binding to the miRNAs, affecting the mRNA function. To understand 
this, ribosome profiling may be useful. It is based on next generation sequencing of ribosome 
protected mRNA fragments (Guo et al., 2010). This provides data on whether the mRNA is 
being repressed or degraded due to the activity of our sequences. If we can identify the 
efficacy of the repression of target genes, we may indirectly understand if the sequences are 
affecting the population of miRNAs in the first place. 
It is also highly likely that a single type of miRNA/antagomiR sequence may not be 
sufficient to cause a response. For example, miR-205 is one of many miRNAs that are 
involved in osteogenesis. The effect of single miRNA may be offset by other factors such as 
additional miRNAs and general autocrine/paracrine signals. This is supported by the 
evidence suggesting that antagomiR-205 enhanced osteogenesis when used in combination 
with OM. In future work it may be useful to combine treatments, using a miRNA/antagomiR 
sequence as an adjunct with another established differentiation technique.  
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4.5 Appendix 
 
To confirm the uptake of nanoparticles within cells, Transmission Electron Microscopy 
images of MSCs were taken at 1 hour and 48 hours after incubation with GNPs.  
 
 
Fig. 4. 18: TEM images of MSCs cultured in DMEM for 24 hours. (A) shows GNPs after 1 
hour of incubation with MSCs and (B) shows GNPs after 48 hours of incubation. Localization of 
GNPs at these multiple time points can be seen. (Scale bar - 0.2 µm) 
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Chapter 5: Using a combination of miR-31 
antagomiR with nanovibrational 
stimulation to induce osteogenesis   
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5.1 Introduction 
 
5.1.1 Osteogenesis via Physical Cues 
 
The role of mesenchymal stem cells (MSCs) in regenerative therapeutics has been 
highlighted in previous chapters. In particular, the need for bone regeneration is paramount, 
both for skeletal issues such as non-union fractures and diseases including osteoporosis. 
Therefore, there has been much research into manipulating MSC differentiation towards 
bone.  
As detailed in chapter 1, there are several techniques employed to encourage osteogenesis 
(1.1.3). The most established approach entails the use of chemical supplements, in the case 
of osteogenesis, a phosphate source (β-glycerophosphate) and a pathway (Runx2) trigger 
such as dexamethasone (Langenbach and Handschel, 2013). Growth factors can also be used 
to enhance bone formation, either directly to the media, or supplanting it onto implanted 
surfaces to promote growth or differentiation. This has shown to be a potent stimulant for 
osteogenic differentiation and has seen wide use in research, namely bone morphogenetic 
protein (BMP-2) (Noël et al., 2004). 
There are also physical means of inducing osteogenesis Cell-cell interaction can be 
mimicked by topography using nanopillars and nanopits. The topography can be presented 
to the cells using biomaterials (Li et al., 2011). This technology is based on the importance 
that cell tension and adhesion play in cell function, due to the mechanotransductive 
mechanisms in the cell cytoskeleton caused by physical cues present in the environment 
(Dalby et al., 2007; Guilak et al., 2009).With MSCs, certain nanotopographies have shown 
to stimulate osteogenesis (Dalby et al., 2007; Tsimbouri et al., 2014; Yang et al., 2014). 
Further to topography, manipulating MSC differentiation through substrate stiffness, for 
example by matching the stiffness of bone, triggers osteogenesis (Engler et al., 2006; Parekh 
et al., 2011).  This technique of controlling the environment can be taken a step through the 
use of vibrations to induce changes within the cell. 
5.1.2 Nanokicking and Osteogenesis 
A more novel method of inducing osteogenesis through physical cues is using a technology 
termed ‘nanokicking’. Nanokicking uses nanovibrations, created by passing electric current 
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through piezoelectric actuators, to induce mechanical stresses to cells (Pemberton et al., 
2015). The amplitude of these vibrations are around 30 nm and this triggers the Rho-kinase 
(ROCK) pathway, which directs MSC lineage towards osteogenesis (McBeath et al., 2004). 
By using specially made bioreactors (fig. 5.1), we can induce nanovibrations that cause 
actin-myosin contractions due to the ROCK pathway. Studies conducted using this technique 
have shown an increase in the levels of alkaline phosphatase (ALP) and Osterix (Pemberton 
et al., 2015; Tsimbouri et al., 2017). ALP is a robust indicator of bone formation and Osterix 
is an important transcription factor for osteogenesis (Marie, 2008). At the structural level, 
an increase in nucleus size and vinculin for ‘nanokicked’ cells evidence the phenotypic 
changes. Being a cytoskeletal protein, an increase in vinculin shows that the vibrations do in 
fact target the adhesion networks, causing stresses that trigger certain processes (Robertson 
et al., 2018).  
Further study demonstrated that the ROCK pathway was active during nanokicking 
(Robertson et al., 2018). Inhibition of the ROCK pathway using inhibitors affected SMAD 
function within cells by preventing dimerization of SMAD1 with SMAD4 and also its 
translocation to the nucleus (Ji et al., 2014). The importance of SMAD proteins in skeletal 
development is well established, as deletion of SMAD1 led to foetal lethality due to 
chondrodysplasia (Retting et al., 2009). They are essential in triggering the BMP/TGFβ 
pathways, and as such, all the downstream processes involved with them. By promoting the 
ROCK pathway and in turn, SMAD mediated BMP/TGFβ pathway, nanokicking physically 
causes a response from the cells, which leads to osteogenesis (Retting et al., 2009).  
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Fig. 5.1: The nanokicking bioreactor setup. The nano-vibrational bioreactor consists of a piezo-
driven vibrational plate set on top of a heavy base block to direct vibration upwards. The culture-
ware is magnetically attached to the top plate and vibrated at the nanoscale according to the input 
voltage signal. Adapted from (Tsimbouri et al., 2017) 
 
Although much work on vibrational studies in conjunction with nanoparticles have been to 
understand the physical properties of such a combination (changes in optical properties, 
plasmon resonance), Curtis and group tried to see whether using nanovibrations can 
stimulate uptake of nanoparticles in cells. They saw that by modulating the frequency, there 
was an increase in uptake of nanoparticles. Although the conditions of the experiment vary 
greatly with this study (they used a frequency between 2-10 Hz and magnetic particles of 
500 nm), they showed that the combination did not affect particle uptake negatively 
(Vaidyanathan, Curtis and Mullin, 2011). Smaller nanoparticles will not be pulled physically 
when compared to larger sizes, but as it does not negate the uptake mechanisms of the cell, 
this study should have no issues (Smith et al., 2010). No studies have been conducted on 
particle uptake using gold nanoparticles and nanovibrations, but there should be a 
comparatively lower effect of nanovibrations on gold particles compared to magnetic 
particles. 
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5.1.4 Chapter Aims 
In the previous chapter, results suggested that whilst the application of miRNA sequences to 
MSCs was not sufficient to induce differentiation, there was evidence that the sequences 
could potentiate differentiation. This was investigated in this chapter by combining the 
nanokicking approach with miRNA-based therapeutics, to determine whether osteogenesis 
can be enhanced.  
Previous work in our lab demonstrated that antagomiR-31 stimulated osteogenesis (McCully 
et al., 2018).  The literature reports that miR-31 targets the AT-rich sequence-binding protein 
2 (SATB2), which is a positive influencer of Runx2 (Xie et al., 2014). By acting on SATB2, 
Runx2 functionality is lowered, leading to a decrease in osteogenesis (J. Zhang et al., 2011). 
In addition, Manochantr reported an increase in the expression of alkaline phosphatase 
(ALP) in the MSCs treated with miR-31 inhibitors (Manochantr et al., 2017). Similarly, 
McCully et al. also noticed an increase of osteocalcin protein (McCully et al., 2018). These 
studies showed that using miR-31 antagomiRs leads to an increase in osteogenesis through 
functional repression of miR-31. We therefore employed the application of antagomiR-31 
along with nanokicking to determine investigate whether this provided a synergistic effect 
on MSC osteogenesis. 
 
5.2 Materials and methods 
5.2.1 Synthesis and functionalization of GNPs 
All GNP synthesis and characterization was carried out by our collaborators Professor Pedro 
Baptista and his team, based in Caparica, Portugal (Section 2.12). AntagomiRs of miR-31 
were purchased from Horizon Discovery Ltd. 
 
5.2.2 Cell culture 
HMSCs were cultured as the cell culture protocol in section 4.2.2 and section 2.1. All 
samples were cultured as monolayers. 
 
5.2.3 Nanokicking bioreactor 
The bottom of the plates of samples to be nanokicked were stuck to magnetic sheets to allow 
magnetic attachment to the bioreactor. After seeding of the cells, the plate was placed on top 
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of the bioreactor and incubated at 37°C with 5% CO2. The nanovibrations were set at a 
frequency of 1,000 Hz with a displacement amplitude of 30 nm. The set-up of the reactor 
can be found in section 2.13. 
 
5.2.4 Real Time qPCR Analysis: 
RT-qPCR was followed as in section 4.2.3 and from 2.3 to 2.7. GAPDH was used as the 
endogenous control, while gene expression of Runx2, ALP and OCN was calculated at early, 
mid and late time points. 
 
5.2.5 In Cell Western Analysis 
Protocol was followed as in section 4.2.4 and section 2.9. Protein expression of Runx2, ALP 
and OCN was confirmed for early, mid and late time points, while CD90 was used as a 
stemness marker. 
 
5.2.6 Histology and Immunofluorescence 
Von Kossa staining was followed as section 2.10 and immunofluorescence protocol can be 
found in 2.11. OPN antibody was used as a visual indicator of OPN protein within cells. 
 
5.3 Results 
5.3.1 Effect of GNPs functionalized with miR-31 antagomiRs on MSCs 
with/without nanokicking 
 
MiR-31 has been reported to repress osteogenesis by targeting SATB2 and thus affecting 
Runx2 expression. An antagomiR against miR-31 was generated and conjugated onto GNPs 
with an aim to delivering to Promocell MSCs to reverse the inhibition of osteogenesis and 
encourage osteoblast formation. Nanokicking is a novel technique of using nanovibrational 
stimulation to enhance osteogenesis. We aimed to use a combination of nanokicking along 
with miR-31 antagomiRs to determine the effect on MSC osteogenesis.  
To achieve this, MSCs were cultured on 24-well plates, two media controls were used; (i) 
basal DMEM (control) and (ii) osteogenic media (positive osteogenesis control). After 24 
hours culture the cells were then maintained in both media, and challenged with +/- 
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antagomiR-31 (treatment).  The samples were then cultured for up to 28 days, during and up 
to which point they were assessed for osteogenic differentiation both at the gene and protein 
level at multiple time points. 
 
5.3.2 Real time qPCR of MSCs treated with miR-31 antagomiRs 
Initially the gene expression of osteogenic markers was investigated at early (7 days), mid 
(14 days) and late (28 days) time points for MSCs that were (i) cultured in DMEM or 
osteogenic media, (ii) treated with antagomiR-31 and (iii) nanokicked or not nanokicked.  
At the relevant time points, the cells were lysed and after cDNA synthesis, real time PCR 
was conducted. The osteogenic markers examined were Runx2, ALP and OCN expression 
at the respective time points. For nanokicked cells, the plates were placed on the bioreactor 
4 hours after seeding to allow attachment of the cells to the plate. GAPDH was used as the 
endogenous control.  The data was graphed to allow observation of whether any of the 
individual three approaches to stimulating osteogenesis were successful, as well as 
identifying any synergistic effects.  
The Runx2 gene expression levels at day 7 are shown in fig. 5.2. Neither the osteogenic 
media nor the antagomiR-31 treatment enhanced Runx2 expression, however nanokicking 
significantly increased Runx2 expression. There was no synergistic increased observed for 
antagomiR-31 with either osteogenic media or nanokicking. 
 
Fig. 5.2 Promocell MSC expression fold change (EFC) of Runx2 cultured in DMEM/osteogenic 
media +/- antagomiR-31, with and without nanokicking for 7 days. (Blue= DMEM, Orange= 
OM, NoP = No particles, 31’= miR-31 antagomiR, NK= Non-Kicked, K= Kicked) (n=3, error bars 
indicate SD, p<0.05) * is significance between kicked and non-kicked samples. 
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The ALP gene expression levels are shown in fig. 5.3. The results mirrored the Runx2 
expression levels, neither osteogenic media nor antagomiR-31 influenced ALP expression, 
whereas nanokicking significantly increased expression. There was a potential data trend for 
further enhanced expression when nanokicking was applied in combination with antagomiR-
31, however this was not significant. 
 
 
Fig. 5.3 Promocell MSC expression fold change (EFC) of Runx2 cultured in DMEM/osteogenic 
media +/- antagomiR-31, with and without nanokicking for 14 days. (Blue= DMEM, Orange= 
OM, NoP = No particles, 31’= miR-31 antagomiR, NK= Non-Kicked, K= Kicked) (n=3, error bars 
indicate SD, p<0.05). * is significance between kicked and non-kicked samples. 
 
 
The osteocalcin gene expression levels are shown in fig. 5.4. Again, niether osteogenic 
media nor antagomiR-31 influenced expression levels, but nanokicking significant increased 
osteocalcin expression. There was no evidence for any synergistic effects.  
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Fig. 5.4 Promocell MSC expression fold change (EFC) of OCN cultured in DMEM/osteogenic 
media +/- antagomiR-31, with and without nanokicking for 28 days. (Blue= DMEM, Orange= 
OM, NoP = No particles, 31’= miR-31 antagomiR, NK= Non-Kicked, K= Kicked) (n=3, error bars 
indicate SD, p<0.05). * is significance between kicked and non-kicked samples. 
 
5.3.3 In-cell western of MSCs treated with miR-31 antagomiRs 
After analysing the gene expression, an in-cell western (ICW) was conducted to determine 
any changes in protein expression of osteogenic makers. As previously, the cells were 
cultured in 24-well plates and the antagomiRs and appropriate media were added 24 hours 
after seeding. Samples to be nanokicked were placed on bioreactors 4 hours after initial 
seeding. After 7, 14 and 28 days, the samples were fixed and processed for in cell western, 
assessing Runx2, ALP and OCN protein expression after 7, 14 and 28 days respectively. 
CD90 antibody was used as a stemness marker.  
MSCs which were not nanokicked are shown in fig. 5.3A, with kicked cells in fig. 5.3B. The 
cells cultured in osteogenic media indicated a general increase for Runx2 expression when 
compared to equivalent cells in DMEM culture. The addition of antagomiR-31 did not 
provide any increase in Runx2 expression in DMEM culture for non-nanokicked cells (fig. 
5.5A, left panel), however there was a trend for increased Runx2 with antagomiR-31 treated 
cells in osteogenic media (fig. 5.5A, right panel). For nanokicked cells, antagomR-31 
showed an increasing trend for Runx2 in DMEM and in osteogenic media.  This suggests 
that the combination of antagomiR-31 with osteogenic media encouraged Runx2 epression, 
with is further increased in nanokicked cells. 
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Fig. 5.5 Logged relative fluorescence (RFU) values of Runx2 expression in Promocell MSCs 
after treatment with antagomiR-31 +/- nanokicking. Each graph indicates a comparison of Runx2 
in both basal DMEM and osteogenic media; (A) in control, non-nanokicked cells (B) in nanokicked 
cells. NP indicates no particles, NS represents the non-sense strand (negative control) and 31 
represents the miR-31 antagomiR. (n=4, dots indicate outliers, statistics done through two-way 
ANOVA) 
 
At day 14, there was no increase in ALP expression noted with any condition; osteogenic 
media, antagomiR-31 or nanokicking cells (fig. 5.6 A, B).  
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Fig. 5.6 Logged relative fluorescence (RFU) values of ALP expression in Promocell MSCs after 
treatment with antagomiR-31 +/- nanokicking. Each graph indicates a comparison of Runx2 in 
both basal DMEM and osteogenic media; (A) in control, non-nanokicked cells (B) in nanokicked 
cells. NP indicates no particles, NS represents the non-sense strand (negative control) and 31 
represents the miR-31 antagomiR. (n=4, dots indicate outliers, statistics done through two-way 
ANOVA) 
 
The expression of osteocalcin mirrored the ALP expression at day 14, with no increases in 
OCN identified under any treatment condition; osteogenic media, antagomiR-31 or 
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nanokicking (fig. 5.4 A, B). In fact, the osteogenic media actually caused a decrease in OCN 
expression in non-kicked cells (fig. 5.7 A, right panel). 
  
 
 
Fig. 5. 7 Logged relative fluorescence (RFU) values of OCN expression in Promocell MSCs 
after treatment with antagomiR-31 +/- nanokicking. Each graph indicates a comparison of Runx2 
in both basal DMEM and osteogenic media; (A) in control, non-nanokicked cells (B) in nanokicked 
cells.NP indicates no particles, NS represents the non-sense strand (negative control) and 31 
represents the miR-31 antagomiR. (n=4, dots indicate outliers, statistics done through two-way 
ANOVA) 
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The stemness marker, CD90, was assessed to determine maintenance of MSC phenotype. At 
day 7, CD90 expression was higher in non-nanokicked cells treated with antagomiR-31, in 
both DMEM and osteogenic media (fig. 5.8A). Conversely, a decrease in CD90 expression 
was noted with nanokicked MSCs treated with antagomiR-31 in DMEM and osteogenic 
media (fig. 5.4B). 
 
 
Fig. 5. 8: Logged relative fluorescence (RFU) values of the stemness marker CD90 stained in 
Promocell MSCs at day 7 after treatment with antagomiR-31. Each graph indicates a comparison 
in both basal DMEM and osteogenic media; (A) in control, non-nanokicked cells (B) in nanokicked 
cells. NP indicates no particles, NS represents the non-sense strand (negative control) and 31 
represents the miR-31 antagomiR. (n=4, dots indicate outliers, statistics done through two-way 
ANOVA) 
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At day 14, CD90 expression in non-nanokicked cells was decreased in both DMEM and 
osteogenic media (Fig. 5.9A). Nanokicked MSCs again demonstrated a decrease CD90 
expression in DMEM, with no change in osteogenic media (fig. 5.5B).  
 
 
Fig. 5.9: Logged relative fluorescence (RFU) values of the stemness marker CD90 stained in 
Promocell MSCs at day 14 after treatment with antagomiR-31. Each graph indicates a 
comparison in both basal DMEM and osteogenic media; (A) in control, non-nanokicked cells (B) in 
nanokicked cells. NP indicates no particles, NS represents the non-sense strand (negative control) 
and 31 represents the miR-31 antagomiR. (n=4, dots indicate outliers, statistics done through two-
way ANOVA) 
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By day 28, CD90 expression levels were being maintained in both non-kicked and 
nanokicked MSCs regardless of media or antagomiR-31 treatment (fig. 5.10).  
 
 
Fig. 5.10: Logged relative fluorescence (RFU) values of the stemness marker CD90 stained in 
Promocell MSCs at day 28 after treatment with antagomiR-31. Each graph indicates a 
comparison in both basal DMEM and osteogenic media; (A) in control, non-nanokicked cells (B) in 
nanokicked cells. NP indicates no particles, NS represents the non-sense strand (negative control) 
and 31 represents the miR-31 antagomiR. (n=4, dots indicate outliers, statistics done through two-
way ANOVA) 
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5.3.4 Immunofluorescence and Von Kossa staining of MSCs treated with miR-31 
antagomiRs 
In addition to the gene and protein expression studies, Von Kossa staining and 
immunofluorescence were conducted on both non-kicked and nanokicked MSCs cultured 
for 28 days.   
 
5.3.4.1 Von Kossa staining for non-kicked and nanokicked MSCs 
In the control, non-nanokicked MSCs, positive Von Kossa staining was only detected in 
cells cultured in osteogenic media, indicating a shift towards osteogenesis (fig. 5.11 B, D). 
The cells treated with antagomiR-31 cultured in DMEM did not show any indication of 
staining.  
   
    
Fig. 5.11: Von Kossa staining of MSCs after 28 days of culture with antagomiR-31.  MSCs were 
cultured in (A) DMEM media, (B) osteogenic media, (C) DMEM supplemented with antagomiR-31 
and (D) osteogenic media supplemented with antagomiR-31. Arrowheads indicate positive staining. 
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Conversely, MSCs that were cultured on top of nanokick bioreactors, we see the presence of 
silver phosphate deposits on all samples (fig. 5.12). This indicates a shift of cell lineage 
towards osteogenesis in response to nanokicking. 
    
    
Fig. 5. 12. Von Kossa staining of MSCs after 28 days of culture with antagomiR-31 after 
nanokicking.  MSCS were cultured in (A) DMEM media, (B) osteogenic media, (C) DMEM 
supplemented with antagomiR-31 and (D) osteogenic media supplemented with antagomiR-31. 
Arrowheads indicate positive staining. 
 
5.3.4.2 Immunofluorescence staining for non-kicked and nanokicked MSCs 
To visualize the cell protein, immunofluorescence was conducted on MSCs after 28 days of 
culture using both DMEM and osteogenic media, treated with antagomiR-31 and either non-
nanokicked or nanokicked.  At 28 days the cells were fixed with 4% formaldehyde, 
processed for immunofluorescence and osteopontin (OPN) was visualised as an indicator of 
osteogenesis. 
The immunofluorescence for non-kicked samples mirrored the Von Kossa results, where 
OPN was indicated for MSCs cultures in osteogenic media (fig. 5.13 B, D), but no positive 
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staining was observed with the antagomiRs (fig. 5.13 C). This can lso be seen in the 
fluorescence intensities as in fig. 5.14. 
 
      
 
 
Fig. 5.13: Immunofluorescence staining of osteopontin in MSCs after 28 days of culture.  MSCs 
were cultured in (A) DMEM media, (B) osteogenic media, (C) DMEM with antagomiR-31 and (D) 
osteogenic media with antagomiR-31. (Green = osteopontin (OPN), Blue = DAPI (nuclei), Red = 
actin staining). Arrowheads indicate positive staining. 
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Fig. 5. 14: Semi-quantification of osteopontin staining in MSCs after 28 days of culture without 
nanoicking. Values were calculated using threshold analysis of the FITC channel. (n=3, error bars 
indicate SD, p<0.05) 
 
Again, as with the Von Kossa staining, positive OPN staining was demonstrated for all 
nanokicked samples (fig. 5.15). As the antagomiR treated non-kicked sample did not show 
any presence of OPN in non-kicked samples, the positive staining is due to nanokicking. 
This is corroborated in fig. 5.16. 
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Fig. 5.15: Immunofluorescence staining of osteopontin in MSCs after 28 days of culture after 
nanokicking.  MSCs were cultured in (A) DMEM media, (B) osteogenic media, (C) DMEM with 
antagomiR-31 and (D) osteogenic media with antagomiR-31. (Green = osteopontin (OPN), Blue = 
DAPI (nuclei), Red = actin staining). Arrowheads indicate positive staining. 
 
Fig. 5. 16: Semi-quantification of osteopontin staining in MSCs after 28 days of culture with 
nanokicking. Values were calculated using threshold analysis of the FITC channel. (n=3, error bars 
indicate SD, p<0.05) 
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5.4 Discussion: 
In chapter 4, it was shown that whilst delivering miRNA sequences alone to MSCs did not 
strongly influence differentiation, a combination approach (i.e. delivery of miRNA 
sequences in combination with differentiation media) did appear to enhance the effect of 
either cue on its own. Therefore, this chapter aimed to use a positive method of stimulating 
differentiation, in this case, osteogenesis, in combination with delivery of miRNA sequences 
to determine whether a synergistic effect is produced.  
MicroRNAs have been shown to impact important cell processes including differentiation. 
MiR-31 is a highly studied miRNA that is touted to repress osteogenesis by targeting 
SATB2. Studies using both miR-31 mimics and antagomiRs demonstrate its role in 
osteogenesis via targeting of SATB2 (Xie et al., 2014; McCully et al., 2018). In chapter 3, 
both Fluidigm and qPCR studies verified the expression of miR-31 in both Promocell and 
Stro-1 MSC populations. Here, miR-31 gene expression was shown to decrease during 
osteogenesis (figs 3.9 and 3.12 for Promocells; fig. 3.11 and 3.14 for Stro-1). These results, 
taken collectively with a previous publication from our group showing the delivery of 
antagomiR-31 to MSCs increased bone marker expression (McCully et al., 2018), supported 
the use of miR-31 as a target for osteogenesis. Therefore, miR-31 antagomiRs were designed 
and conjugated on to PEGylated gold nanoparticles (GNPs) for delivery to MSCs. 
Nanokicking is a novel technique that uses nanovibrations to exploit the physical properties 
of the cell to stimulate osteogenesis. By causing stresses and strains on the cell cytoskeleton, 
the cell responds by enhancing osteoblast formation. We aim to exploit this 
mechanotransduction response in combination with the delivery of antagomiR-31 to 
determine any synergistic effects on osteogenesis. 
 
5.4.1 AntagomiR-31 +/- nanokicking: Impact at the RNA level 
The gene expression levels for three different osteogenic markers were assessed at three time 
points (days 7, 14 and 28). With regards to the data, any increases in expression levels 
indicate an increase in the MSC osteogenic response.  
Surprisingly, the osteogenic media did not give a positive response for any of the markers, 
this was unusual, as typically chemical induction works well (as shown in previous chapters). 
The antagomiR-31 application did not increase marker expression either. If the experiment 
had not included nanokicking, it may have been assumed that the MSC phenotype was 
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compromised and the cells were unable to differentiate. However, the nanokicked MSCs 
clearly demonstrated an increase for all three marker expression levels at all time points, 
supporting the ability of the MSC population to differentiate. A slight increase in expression 
is seen for DMEM samples when compared to OM samples. The reason behind this is not 
understood as we expect a higher increase for the differentiation media. Possible 
contamination during qPCR for either DMEM or OM samples may have contributed to this. 
A repeat experiment in a more sterilized environment may provide the expected result. The 
OM may have degraded in its function, but there would still be either an equal or higher 
expression. As such, this can be ruled out. 
In terms of synergistic effects, there was no strong evidence to support that using two 
different osteogenic cues simultaneously enhanced osteogenesis. The hypothesis behind the 
theory of multiple cues acting synergistically is logical. The co-regulation of stem cell 
function by multi-variant stimuli occurs in vivo and the replication of this, using different 
approaches in vitro, may provide interesting information regarding the main stimulus that 
cells respond to (e.g. chemical or physical) (Kshitiz et al., 2012). Cells interpret multiple 
signals from their microenvironment and it is most likely that a combination of stimuli drive 
MSc self-renewal and differentiation (Kumar, Placone and Engler, 2017). A lack of evidence 
to support this occurring in vitro in this chapter does not disprove the theory, but perhaps 
suggests that experiments can be further planned and expanded to gather as much 
information as possible at various timelines during differentiation.   
 
5.4.2 AntagomiR-31 +/- nanokicking: Impact at the protein level 
Following on from the gene study, the protein expression changes for three osteogenic 
markers were assessed over time in culture. Each approach used to stimulate osteogenesis 
was presented individually, with a combined graph for antagomiR-31 +/- osteogenic media 
and antagomiR-31 +/- nanokicking.  
The only results which demonstrated positive changes in bone marker expression in response 
to osteogenic media, antagomiR-31 and nanokicking were at day 7 with Runx2; no changes 
were observed at days 14 and 28 with ALP or osteocalcin respectively.  Whilst Runx2 
protein expression at day 7 was not influenced by the addition of antagomiR-31 alone, there 
was a trend for increased expression when MSCs were treated with both osteogenic media 
and antagomiR-31 (fig. 5.3A). This potentially could support the notion of a synergistic 
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effect of the antagomiR and the osteogenic media. However, when comparing the 
nanokicked cells +/- antagomiR-31, there was no difference (fig. 5.3B). 
The increase of Runx2 at the early time points does suggest an effect of miR-31, but since 
the antagomiRs are only added 24 hours after seeding, it may not be sufficient to cause a 
response at later stages. Refreshing the amount of miR-31 antagomiRs at regular intervals 
may potentially provide a stronger and more consistent response. 
Interestingly, alongside a trend for increasing Runx2 expression, there was a clear increase 
in stemness marker CD90 for MSCs treated with antagomiR-31 and with osteogenic media. 
Whilst this only happened at the early time points of day 7, this is surprisingly, as in theory 
if cells are committing to differentiate towards the osteoblastic lineage, a decrease in 
stemness may be expected. However, it may just reflect that within the cultured MSCs there 
may be different populations of cells responding to treatments. 
As quoted by the Genevier group in York, who specialise in MSC heterogeneity, biological 
processes are dynamic, adaptive and variable. Heterogeneity will always exist or emerge 
within even the most rigorously sorted clonal cell populations (Wilson et al., 2019). This is 
especially true for MSCs, where the term is used to describe a heterogeneous population of 
stromal cells. Many studies have shown that MSCs are largely tissue-committed progenitors 
and may display varied tissue antigen that categorise the cells into subpopulations (Liu et 
al., 2019). This heterogeneity can be demonstrated during chemical induction of 
differentiation, where only a population of the cells will actually differentiate as shown in 
chapter 3 (i.e. 100% of the cells are not differentiating).  Therefore, perhaps for subtle 
changes in expression profiles, in this work in particular where small concentration of 
miRNAs are used in a single application, only small subsets of the entire population are 
responding. 
The histology (Von Kossa) and immunofluorescence staining demonstrated positive 
osteogenesis for both osteogenic media and nanokicking, both alone and in combination. 
Unfortunately, the antagomiR treated DMEM samples did not show any signs of 
osteogenesis. Adding antagomiRs at multiple time points may provide an increased response 
for treated samples. Deng and co. used transfection reagents to deliver miR-31 antagomiRs 
(Deng et al., 2014). Every 3 days the antagomiRs were added again and they showed the 
importance of miR-31 in osteogenesis up to the 21st day of culture. Other studies used 
plasmids to deliver changes to osteogenic genes (Runx2, OCN, etc.) to silence the effect of 
miR-31 (Deng et al., 2013; Xie et al., 2014). The study in this chapter can be compared to 
Deng’s work, with the key difference being the delivery method and number of applications. 
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The use of transfection agents has been well studied and although they have high rates of 
successful delivery, they cannot be used as therapeutics, as these reagents cannot be used in 
the human body, due to their toxicity and possible off target effects. 
 
5.4.3 Manipulating miR-31 levels in MSCs alongside nanokicking: Conclusion 
This chapter showed that antagomiR-31 had an effect at the early time point during 
differentiation, but perhaps due to the exhaustion of antagomiRs on the GNPs and eventual 
release of GNPs from the cells, the addition of miR-31 antagomiRs at the early time point 
may not be enough. Introducing the antagomiRs at multiple time points may potentially 
increase osteogenesis. In addition, the use of GNPs as delivery platforms should be 
addressed. The benefits of GNPs, such as low toxicity and release rates, make them a good 
potential candidate for use in regenerative medicine.  
MiR-31 has been studied mainly in cancer relate research and its pleiotropy in tumour 
progression in pancreatic cancer (among others) and tumour apoptosis in ovarian cancer (and 
others) is not understood (Yu et al., 2018). As such it may not be the ideal candidate for 
therapeutic use, but due to their relevance in osteogenesis, studies can be conducted to see 
whether we can induce differentiation and carry over the methodology with better 
candidates. 
The protein studies showed that nanokicked samples produced a higher expression of osteo-
specific proteins such as Runx2, ALP, OCN and OPN. The Von Kossa staining also showed 
the increased response due to nanokicking. The cell’s ability to react to changes in the 
environment, whether chemical or physical is vital for developing new forms of therapy. 
Dalby et al. has previously shown that nanoscale change to the environment using 
nanopatterning techniques led to changes in differentiation and proliferation of MSCs 
(Dalby, Gadegaard and Oreffo, 2014). The cell motor proteins, such as filopodia or blebs 
react to the patterning and the stresses caused by this led to changes in the cell to achieve 
homeostasis.  
This ability of the cell can be exploited using nanovibrations. By using piezoelectric 
conductors, nanoscale vibrations can be produced, affecting the Rho-kinase (ROCK) 
pathways due to the tension created from actin-myosin contractions, leading to activation of 
SMAD proteins (Attisano and Wrana, 2002). These proteins are essential for triggering the 
BMP/TGFβ pathway. The ROCK pathway promotes dimerization of these SMAD proteins 
and their eventual translocation the nucleus. This leads to a cascade of events promoting 
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osteogenesis. Nanokick bioreactors are able to provide these nanovibrations and studies have 
shown their role in osteogenesis (Nikukar et al., 2013). We also showed that using this 
technique increases the expression of osteogenic proteins and confirmed their importance as 
a new form of inducing bone formation. A representation of the proposed processes involved 
is shown in fig. 5.17. 
 
Fig. 5.17: The proposed processes involved in stimulating osteogenesis through 
nanokicking (Robertson et al., 2018). 
 
As mentioned in the previous chapter, ribosome profiling can also be conducted to see the 
mRNA changes brought upon by preventing miR-31 function. Any variations from the 
nanovibrations to mRNA translation can also be studied. 
Whilst some results may support a potential theory, clear evidence for a synergistic approach 
enhancing osteogenesis was not demonstrated. By introducing the antagomiRs at regular 
intervals, we may see an increase in the expression of other osteogenic proteins. The use of 
nanokicking at this juncture may provide an even larger effect and this avenue of research 
may be promising for regenerative therapy. 
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Chapter 6: Final Discussion 
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6.1 Gold nanoparticles 
With the advent of biological and medical research, new and complex forms of therapy have 
been in the forefront. Gold is one of the oldest forms of medicine in the world, with Chinese 
texts suggesting its use as a curative for measles, small pox and removal of mercury from 
the skin (Huaizhi and Yuantao, 2001). Although these ‘cures’ were not based on scientific 
research, the properties of gold lent itself to these situations.  
Being a noble metal, the main property of gold is its inertness. Being mostly unaffected by 
its surroundings, this property also lends itself to the reverse; it has minimal impact on the 
biological environment. As such, research was conducted to potentially exploit this property 
for medical applications. Biodistribution studies of GNPs have shown that very small sizes 
tend to be equally distributed within the body, but larger sizes accumulate within the liver 
and spleen (Park et al., 2010). It can take up to 6 months to completely drain the system of 
GNPs so accounting for biodistribution and dosage is of paramount importance. 
Gold nanoparticles (GNPs) were first formed as colloidal particles by Michael Faraday. He 
also noticed that this solution was red in colour. This was due to the absorption and scattering 
properties of the GNPs, which are different from its natural state. Depending on the size 
structure and aggregation state, they can absorb and scatter light of different wavelengths 
(Dreaden, Austin, et al., 2012). This has been capitalized for use in imaging techniques as 
dark field microscopy illuminates GNPs without the use of fluorescent tags. The 
photothermal properties of GNPs have found use as a potential for tumour apoptosis through 
ablation (Dreaden et al., 2011). The GNPs themselves could exhibit anti-angiogenic 
properties in studies (Arvizo et al., 2011). Further research discovered that GNPs could be 
functionalized, and this would lend itself for use as a delivery vehicle for drugs and small 
sequences. 
The sequences we used in our study were delivered by poly-ethylene glycol (PEG) coated 
GNPs. This is necessary to passivate the GNPs against the bodies natural defences and also 
protect its cargo (Berry, 2013). Thiolated sequences can be loaded on to gold surfaces due 
to formation of an Au-S bond. This bond is essential as a means of release. We aimed to 
utilize a glutathione mediated release to release these sequences. Glutathione is an 
antioxidant present within the cytoplasm that cleaves the Au-S bond releasing its cargo into 
the cell cytoplasm (McCully et al., 2015). 
Our work consisted of using these antagomiR/mimic functionalized GNPs to trigger 
differentiation of MSCs. Most research involving miRNAs use transfection agents such as 
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Lipofectamine 2000 to deliver their sequences. Although powerful, their toxicity to cells and 
tissue make translating their work in vivo difficult. By using gold nanoparticles as a delivery 
platform, we aimed to circumvent this problem. Xue et al. used miR-375 functionalized 
GNPs in mice to suppress tumour growth (Xue et al., 2016). They found that miR-375 
succeeded in this function and showed that the GNPs was cleared from the system after 7 
days. There was no damage to the organ systems or adverse effects. Another group used 
miR-20a functionalized GNPs to promote cell survival in human prostate cancer cells (Hao 
et al., 2011). Although not as popular as transfection agents, the need to be biologically 
compatible has led researches away from transfection agents and towards GNPs and 
biological compounds such as dendrimers. 
Our work showed the possible use of functionalized GNPs in MSC differentiation. By 
enhancing the body’s natural recovery processes through miRNAs, a new therapeutic agent 
can be brought to the forefront. Out of all our results, miR-143, miR-145 and miR-31 seem 
promising for further research. By using multiple treatments at the correct time point, we 
might be able to circumvent some of the issues we faced. Newer delivery methods such as 
dendrimers or hydrogel-based delivery platforms may provide a more efficient system, but 
the imaging properties, inertness and relative cost of production may help to bring GNPs 
into the spotlight. 
 
6.2 MiRNA as potential candidates 
MicroRNAs (miRNA) are small (around 22nt) single stranded RNAs that are involved in 
the regulatory mechanisms of nearly 60% of all genes in the human body. They function by 
binding to mRNAs, and either through perfect or imperfect complementarity, degrade or 
silence their function respectively. They were initially studied due to their involvement in 
cancer, but as more and more functions were discovered, their potential in medical therapies 
has increased.  
Their role in MSC differentiation is an ongoing research field with profiling studies picking 
up several miRNAs that have important targets. All differentiation pathways of MSCs have 
a few miRNAs that either positively or negatively influence the process (fig. 3.1). By 
manipulating the levels of these miRNAs, we aimed to direct the lineage of MSCs to certain 
fates. 
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The manipulation of miRNAs for MSC differentiation is a burgeoning field due to their 
important role as regulators (Jonas and Izaurralde, 2015). Several studies have shown the 
importance of miRNAs in MSC pathways by targeting the various transcription factors 
involved in these processes (Clark et al., 2014). Table 1.1 shows a small list of completed 
studies for MSC differentiation. Through the use of either transfection agents, delivery 
vehicles or gene constructs, the levels of miRNAs are altered leading to changes in the cell 
system (Wang et al., 2015).  
One main issue in miRNA therapeutics is that miRNAs have multiple targets of action. As 
their emergence due to involvement in cancer progression has been established, it is essential 
to confirm their impact on other systems through in vivo studies. Even if the delivery system 
is perfect, the miRNAs may still trigger oncogenic pathways. Increase in miR-21 levels has 
been linked to transformation of normal fibroblasts to cancer-associated fibroblasts (Pan, 
Wang and Wang, 2010). It has also been shown that it positively influences osteogenesis (Li 
et al., 2017). This can lead to potential issues in therapy if taken to that step. A large number 
of miRNAs have functions that have yet to be documented. As such, it is imperative to 
recognize the threats posed by this area and steps must be taken to ensure utmost safety of 
the patients. 
 
6.3 MiRNA for chondrogenesis and adipogenesis 
Cartilage repair is an important area of research due to the difficulty of reaching and 
maintaining the chondrocyte phenotype. Current research includes using hydrogels or 
scaffolds with chondrogenesis promoting growth factors to stimulate cartilage growth 
(Ahmed et al., 2015; Kubosch et al., 2016; Legendre et al., 2017). Novel techniques such as 
using lipid coated bubbles and even genetically enhanced fruits have shown promising 
results (Aliabouzar, Zhang and Sarkar, 2016; Choudhary et al., 2016). The use of miRNAs 
in this field is just emerging and most research focuses on finding ideal targets for 
manipulation. 
MiR-145 and miR-140 are play an essential role in chondrogenesis by targeting Sox9 and 
Wnt pathway respectively (Miyaki et al., 2010; B. Yang et al., 2011). Our Fluidigm study 
showed that miR-145 was downregulated with chondrogenesis. We functionalized the 
antagomiR-145 to GNPs to potentially prevent the downregulation of Sox9. Our results 
showed an increase in late stage gene expression of Aggrecan and Collagen X. Histology 
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and immunofluorescence also provided a further insight into the function of the antagomiR. 
The increase in the presence of proteoglycans and Collagen II, essential in cartilage matrix, 
indicated the success of the antagomiR. Although the levels of Collagen X were high, 
indicating possible hypertrophy, we were able to stimulate chondrogenesis and by 
potentially manipulating other miRNAs, we may be able to stunt the ossification of these 
chondrocytes. Further protein study is essential to confirm these results, but the initial 
outlook is positive. 
Although promoting adipogenesis is not essential for therapy, any insight into controlling 
this process can be used for further research. By understanding the mechanisms involved in 
adipogenesis, alternate methods of bone-related therapy may open up.  
Most studies consisted of discovering the upregulation or downregulation of miRNAs during 
adipocyte formation. One such miRNA, miR-27, was found to be downregulated in 
adipocytes. Through computational target prediction, it was shown to target PPARγ, the 
master regulator of adipogenesis (Takanabe et al., 2008). Other miRNAs that were found to 
be significant in promoting adipogenesis were in fact miRNAs that targeted the osteogenic 
pathways. MiR-375, a repressor of osteogenesis, was shown to suppress the ERK pathway 
and miR-30a and miR-30d functioned by targeting Runx2 (Ling et al., 2011; Zaragosi et al., 
2011). 
The most studied miRNA for adipogenesis is miR-143. Several studies showed the role of 
miR-143 as a promoter of adipogenesis (Esau et al., 2004; T. Sun et al., 2009; Xie, Lim and 
Lodish, 2009). After our initial verification, we used miR-143 mimics with an aim to 
increase adipogenesis of MSCs. Our results did not work as expected, as we did not see any 
increases in adipogenic specific proteins after treatment with mimics, but this was due to the 
introduction of the mimics during the clonal expansion stage. Chen et al. showed that by 
introducing miR-143 during the terminal differentiation phase, ERK5 targeting helped to 
improve adipogenesis (Chen et al., 2014). We might discover new findings by changing the 
time of addition. Although this may not be ideal in our study, as the MSCs require a push to 
shift towards adipogenesis, the introduction of miR-143 antagomiRs during the growth arrest 
stage of osteogenesis may help in directing the differentiation towards osteogenesis. We 
could also use the mimics in tandem with other approaches towards adipogenesis as a 
‘promoter’. 
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6.4 MiRNA for osteogenesis 
Osteoporosis and other low-bone density causing diseases are difficult ailments to live with. 
The quality of life becomes very arduous and most forms of treatment involves prevention 
of bone-density loss. As such, a therapy that can increase the density is very attractive and 
research is still ongoing to find a definite form of cure. Promoting osteogenesis of MSCs is 
viewed as a potential method of treatment. By using scaffolding to harbour growth factors 
or special nanopatterns, there seems to be a lot of promise in this field (Kilian et al., 2010; 
Tsimbouri et al., 2014). A way of non-invasive form is treatment is even more attractive. 
MiRNAs have been shown to be involved in the differentiation of MSCs to osteoblasts. They 
are involved in all stages from the mesenchyme to osteoclast differentiation. Targets of 
Runx2 are especially attractive as being the master regulator of osteogenesis, any 
interference with its function could have profound impact down the line. Some of these 
miRNAs are miR-23a, miR-133, miR-205 (Hassan et al., 2010; Liao et al., 2013; Hu et al., 
2015). Other miRNAs that target important osteogenic factors are miR-31 (SATB2) and 
miR-214 (Osterix) (Shi et al., 2013; Xie et al., 2014). 
Through our candidate identification study, we showed the downregulation of both miR-31 
and miR-205 during osteogenesis. As important regulators of bone formation, repressing 
their function through antagomiRs may provide an insight into new forms of therapy. 
MiR-205 did not show any promising results. It has been reported to target both Runx2 and 
SATB2. By targeting either, we should see an increase in the rate of osteogenesis, but our 
results could not match other conducted studies in strength. This may be due to the inefficacy 
of miR-205 as a target or the damage to the sequence by the cytoplasmic RNases. Although 
we do see evidences of osteopontin in the immunofluorescence studies, we are not able to 
show similar changes in other proteins. By possibly protecting miR-205 better, or by using 
a transfection agent, we may see an improved reaction from the MSCs. 
Our final study conducted used miR-31 antagomiRs to again influence osteogenesis. This 
was done in tandem with another novel technique that uses nanovibrations, called 
‘nanokicking’. Our results showed an increase at the early stages, wherein both Runx2 gene 
and protein expression was increased when the MSCs were treated with the antagomiRs 
across all samples. This was not reflected later on as there was no significant changes 
between the treated samples and controls. Studies by Deng’s and Xie’s group showed an 
increase in osteogenesis by using miR-31 antagomiRs. The main difference between their 
studies and our studies was the repeated addition of antagomiRs every 3 days. Although the 
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delivery platform was different (transfection agents), the refreshing of levels of miR-31 
antagomiRs may have a significant impact on osteogenesis. By modifying our protocol, we 
may be able to carry on the progress of the early stages through to the final time point.  
 
6.5 Nanokicking and combinational approaches 
As mentioned previously, the need for new forms of treatments for osteoporosis is vital. By 
exploring new avenues of research, we may be able to discover exciting and innovative 
forms of therapy. A recently developing field is the use of the physical environment to trigger 
changes in the cell. By manipulating the stresses the cell undergoes, we may be able to 
initiate certain important pathways that can open the way for new areas of cell research. The 
use of patterning and scaffolding to act on the cytoskeleton proteins have shown to stimulate 
osteogenesis of MSCs. This has been carried on to other types of cells, again showing 
promising results. Through the use of nanovibrations, Dalby et al. has shown that 
manipulating the actin-myosin contractions of MSCs can direct the lineage of MSCs towards 
osteoblasts (Pemberton et al., 2015). 
We used a combination of nanokicking and antagomiRs to enhance the expression of osteo-
specific genes and proteins, potentially leading to osteogenesis. Although our antagomiRs 
were not effective at a later stage, as mentioned previously, the use of nanokicking did show 
strong results. The expression of osteogenic proteins were higher for nanokicked samples, 
compared to non-kicked samples. The Von Kossa assay and immunofluorescence also 
showed deposits of silver phosphate and the presence of osteopontin respectively. Without 
the use of any osteogenic stimulants, we saw the signs of osteogenesis in the basal samples 
(MSCs cultured in DMEM). This confirms the already established impact of nanokicking on 
osteogenesis. By adding miR-31 antagomiRs at regular intervals and using the nanokicking 
bioreactor, we may see a synergistic effect that could be a new form of treatment or possible 
method to obtain osteoblasts for research. 
Due to their targeted nature of action and size, antagomiR functionalized GNPs could be 
used with other techniques such as nanopatterning, scaffolding and growth factors to 
possibly see an increased rate and strength of osteogenesis. 
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6.6 Future Work 
The research conducted in this study was able to exploit the function of miRNAs to induce 
differentiation of MSCs through functionalized GNPs. The potential for the use of GNPs in 
therapeutics is large and by using miRNAs to illicit changes in the cell system can be carried 
forward to other cell processes such as cancer. As such it is necessary to understand the 
mechanisms involved in cellular uptake and efficacy in the action of the functionalized 
sequences. 
The cells used in the experiment were passage 3. This was done to obtain a large number of 
cells for multiple experiments. This can lead to loss of stemness and differentiation potential. 
It will be useful to conduct the experiments again for cells at the earlier passages to see if 
there is any improvement in the differentiation. Many studies are being conducted to see the 
role of miRNAs in cell function, but due to their varied role, it is difficult to pinpoint all their 
effects in cell processes. This can lead to potential side effects such as tumour growth. To 
circumvent this, in vivo studies are required to confirm off-target effects. Omic-based 
technologies (proteomics, metabolomics, etc.) can provide a deeper understanding of the 
processes involved, allowing a clear insight into the pathways being activated and also 
highlighting any unintended consequences. Ribosome profiling can also show if the 
sequences introduced are functioning accordingly and can show whether betterment in the 
sequences (such as improving targeting or protection) are required. The toxicity of GNPs 
have already been conducted and has shown its relatively low impact on body functions, it 
is still important to check for toxicity, biodistribution and dosage for further work. 
 
6.7 Concluding Remarks 
Our studies showed the promising nature of three out of four of our chosen targets: 
• MiR-143 mimics decreased adipogenesis due to introduction at the early stage 
• MiR-145 antagomiRs showed promising results as a promoter of chondrogenesis 
• MiR-31 antagomiRs showed increased expression of the early stage marker 
These results show the capabilities of miRNA therapeutics and the potential of using GNPs 
for therapy. This can be taken further by using miRNA mimics and antagomiRs to target 
other processes such an oncogenesis to prevent or treat tumours and cancerous cells. Other 
forms of differentiation and cell processes can also be viable targets of action. 
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Nanokicking has also lent its powerful use as an osteogenesis stimulator, with ongoing 
research being conducted to see its effect on other cell types and pathways. 
Although these methods seem novel with great potential, it is necessary to look at 
improvements that could be made. GNPs have great use as a delivery platform, but it is 
essential to confirm the delivery of cargo and also confirm its biodistribution for in vivo 
studies. Although non-toxic, high amounts of GNPs in the liver or spleen can lead to 
complications. New forms of delivery such as dendrimers and liposomes are also potential 
delivery platforms that could prove viable and more effective than GNPs. The ease of 
production and functionalization are big pros for the use of GNPs, but efficiency is key for 
medicine. As such, we must look at the new vehicles being introduced and compare their 
efficacy. 
With respect to the miRNAs, we must look at all possible targets for chosen miRNAs. MiR-
31 has been implicated in oncogenesis and as such may prove to be a deterrent in its use as 
a therapeutic. Due to the short nature of miRNA sequences, there are multiple target sites 
that have not been identified for miRNAs. This can lead to off-target effects producing 
unintended consequences. Through tissue or animal studies, we may be able to confirm the 
effects of conserved miRNAs. Another point to note is the protection of miRNAs. By 
changing or adding certain sequences to the oligonucleotides, we may be better able to 
protect the sequence from its environment and even potentially allow specific targeting. 
The ever-increasing list of miRNAs and their functions will provide novel forms of therapies 
for a multitude of ailments. By understanding its role, we can use multiple miRNA 
therapeutics in tandem, even with other forms of therapy, to reach new frontiers in medicine 
and therapy. 
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